INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26001, 25389, 'Sodium iodide', 'Kidney Diseases', 'Sodium iodide is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.', '2', '"Product Information. Iodopen (sodium iodide)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26002, 19984, 'Sodium glycerophosphate', 'Dehydration', 'Sodium glycerophosphate is contraindicated in patients in a state of dehydration or with hypernatremia, or shock.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26003, 19984, 'Sodium glycerophosphate', 'Hyperphosphatemia', 'Sodium glycerophosphate is contraindicated in patients with hyperphosphatemia.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26004, 19984, 'Sodium glycerophosphate', 'Renal Insufficiency', 'Sodium glycerophosphate is contraindicated in patients with severe renal insufficiency.  This agent should be used with caution in patients with impaired renal function.  It is recommended to monitor the phosphate status of all patients regularly.', '3', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26005, 6705, 'Sodium citrate', 'Water-Electrolyte Imbalance', 'Alkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure.  Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.', '3', '"Product Information. Sodium Bicarbonate (sodium bicarbonate)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26006, 6961, 'Sodium citrate', 'Water-Electrolyte Imbalance', 'Alkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure.  Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.', '3', '"Product Information. Sodium Bicarbonate (sodium bicarbonate)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26007, 16429, 'Sodium citrate', 'Water-Electrolyte Imbalance', 'Alkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure.  Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.', '3', '"Product Information. Sodium Bicarbonate (sodium bicarbonate)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26008, 6705, 'Sodium citrate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26009, 6961, 'Sodium citrate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26010, 16429, 'Sodium citrate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26011, 6705, 'Sodium citrate', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26012, 6961, 'Sodium citrate', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26013, 16429, 'Sodium citrate', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26014, 6705, 'Sodium citrate', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Tham (tromethamine)." Abbott Pharmaceutical  (2001):|"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26015, 6961, 'Sodium citrate', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Tham (tromethamine)." Abbott Pharmaceutical  (2001):|"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26016, 16429, 'Sodium citrate', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '"Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company|"Product Information. Tham (tromethamine)." Abbott Pharmaceutical  (2001):|"Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26017, 1342, 'Beclomethasone dipropionate (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26018, 14964, 'Beclomethasone dipropionate (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26019, 14965, 'Beclomethasone dipropionate (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26020, 14967, 'Beclomethasone dipropionate (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26021, 16499, 'Beclomethasone dipropionate (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26022, 29230, 'Beclomethasone dipropionate (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26023, 1342, 'Beclomethasone dipropionate (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26024, 14964, 'Beclomethasone dipropionate (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26025, 14965, 'Beclomethasone dipropionate (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26026, 14967, 'Beclomethasone dipropionate (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26027, 16499, 'Beclomethasone dipropionate (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26028, 29230, 'Beclomethasone dipropionate (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26029, 1342, 'Beclomethasone dipropionate (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26030, 14964, 'Beclomethasone dipropionate (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26031, 14965, 'Beclomethasone dipropionate (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26032, 14967, 'Beclomethasone dipropionate (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26033, 16499, 'Beclomethasone dipropionate (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26034, 29230, 'Beclomethasone dipropionate (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26035, 1342, 'Beclomethasone dipropionate (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26036, 14964, 'Beclomethasone dipropionate (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26037, 14965, 'Beclomethasone dipropionate (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26038, 14967, 'Beclomethasone dipropionate (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26039, 16499, 'Beclomethasone dipropionate (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26040, 29230, 'Beclomethasone dipropionate (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26041, 1342, 'Beclomethasone dipropionate (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26042, 14964, 'Beclomethasone dipropionate (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26043, 14965, 'Beclomethasone dipropionate (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26044, 14967, 'Beclomethasone dipropionate (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26045, 16499, 'Beclomethasone dipropionate (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26046, 29230, 'Beclomethasone dipropionate (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26047, 0, 'Sodium oxybate', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26048, 0, 'Sodium oxybate', 'Alcoholism', 'Sodium oxybate should not be used with alcohol.  This drug should be used with caution in patients with history of drug or alcohol abuse.  The inappropriate use of this drug alone or in combination with other CNS depressants is associated with CNS adverse reaction including seizures, respiratory depression, decreases in the levels of consciousness, coma and death.  Because illicit use and abuse has been reported, physicians should evaluate carefully their patients for history of drug or alcohol abuse and should follow such patients closely, observing them for signs of misuse.', '3', '"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26049, 0, 'Sodium oxybate', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26050, 0, 'Sodium oxybate', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26051, 0, 'Sodium oxybate', 'Cardiovascular disease', 'Sodium oxybate has a high content of salt, and it should be used with caution in patients sensitive to salt intake such as patients with heart failure, hypertension, or renal impairment.', '2', '"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26052, 0, 'Sodium oxybate', 'Sleep Apnea, Obstructive', 'The use of sodium oxybate may impair the respiratory drive especially in patients with compromised respiratory function.  Sodium oxybate should be used cautiously in patients with sleep apnea and sleep-related breathing disorders as there have been reports of increased central apneas and clinically relevant desaturation.  Prescribers should be aware that sleep-related disorders tend to be more prevalent in obese patients, postmenopausal women not receiving hormone replacement therapy and also among patients with narcolepsy.', '2', '"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26053, 0, 'Sodium ferric gluconate complex', 'Hypotension', 'Sodium ferric gluconate complex injection may cause clinically significant hypotension.  Hypotension associated with lightheadedness, malaise, fatigue, weakness or severe pain in the chest, back, flanks, or groin has been reported.  These hypotensive reactions may or may not be associated with signs and symptoms of hypersensitivity reactions and usually resolve within one to two hours.  Transient hypotension may occur during dialysis and sodium ferric gluconate complex injection may augment hypotension caused by dialysis.  Patients with hypotension and patients undergoing dialysis should be monitored for signs and symptoms of hypotension during and following sodium ferric gluconate complex injection administration.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26054, 0, 'Bedaquiline', 'Arrhythmias, Cardiac', 'Bedaquiline causes QT prolongation.  Use with drugs that prolong the QT interval may cause additive QT prolongation.  Monitor ECG before initiation of treatment, and at least 2, 12, and 24 weeks after starting treatment and obtain serum potassium, calcium, and magnesium at baseline and correct if abnormal.  Discontinue bedaquiline if significant ventricular arrhythmia or if QTcF interval prolongation of greater than 500 ms.  develops.  If syncope occurs, obtain an ECG to detect QT prolongation.', '3', '"Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26055, 0, 'Bedaquiline', 'Long QT Syndrome', 'Bedaquiline can cause QT prolongation, which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  Use of bedaquiline should be avoided in patients with congenital long QT syndrome, known prolongation of the QTc interval, uncompensated heart failure, or severe left ventricular hypertrophy, hypothyroidism, and in patients with electrolytes abnormalities.  It is recommended to obtain an ECG before initiation of treatment, and at least 2, 12, and 24 weeks after starting treatment and to discontinue treatment if significant ventricular arrhythmia or if QTcF interval prolongation of greater than 500 ms develops.', '3', '"Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26056, 0, 'Bedaquiline', 'Alcoholism', 'The use of bedaquiline might increase hepatic-related adverse events and lead to hepatotoxicity.  It is recommended to avoid alcohol and other hepatotoxic drugs while on bedaquiline.  Close monitoring is recommended in alcoholic patients as they are at a greater risk of hepatic toxicity.  Liver function tests should be done at baseline, monthly while on treatment, and as needed thereafter and discontinuance of therapy if evidence of new or worsening liver dysfunction occurs as indicated by the manufacturer.', '2', '"Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26057, 0, 'Bedaquiline', 'Liver Diseases', 'Bedaquiline population pharmacokinetic analysis indicated that mild to moderate hepatic impairment had no significant influence on bedaquiline pharmacokinetics.  Close monitoring of liver function is recommended in patients with severe hepatic impairment as the pharmacokinetics of bedaquiline is unknown in these patients.', '2', '"Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26058, 0, 'Bedaquiline', 'Kidney Diseases', 'No dose adjustment is required for patients with mild or moderate renal impairment.  Care should be exercised when using bedaquiline in patients with severe renal impairment or end-stage renal disease requiring hemodialysis or peritoneal dialysis.  It is recommended to monitor patients closely for adverse events.', '2', '"Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26059, 30844, 'Sodium zirconium cyclosilicate', 'Intestinal Obstruction', 'The use of sodium zirconium cyclosilicate should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal postoperative bowel motility disorders.  This medication has not been studied in patients with these conditions and may be ineffective and it may worsen gastrointestinal conditions.', '3', '"Product Information. Lokelma (sodium zirconium cyclosilicate)." Astra-Zeneca Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26060, 30845, 'Sodium zirconium cyclosilicate', 'Intestinal Obstruction', 'The use of sodium zirconium cyclosilicate should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal postoperative bowel motility disorders.  This medication has not been studied in patients with these conditions and may be ineffective and it may worsen gastrointestinal conditions.', '3', '"Product Information. Lokelma (sodium zirconium cyclosilicate)." Astra-Zeneca Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26061, 30844, 'Sodium zirconium cyclosilicate', 'Edema', 'Each 5 g dose of sodium zirconium cyclosilicate contains approximately 400 mg of sodium, and can cause edema, which was generally mild to moderate in severity in clinical trials.  Patients should be monitored for signs of edema, particularly those who should restrict their sodium intake or are prone to fluid overload (e.g., heart failure or renal disease).  Advise patients to adjust dietary sodium, and if appropriate, increase the dose of diuretics as needed.', '2', '"Product Information. Lokelma (sodium zirconium cyclosilicate)." Astra-Zeneca Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26062, 30845, 'Sodium zirconium cyclosilicate', 'Edema', 'Each 5 g dose of sodium zirconium cyclosilicate contains approximately 400 mg of sodium, and can cause edema, which was generally mild to moderate in severity in clinical trials.  Patients should be monitored for signs of edema, particularly those who should restrict their sodium intake or are prone to fluid overload (e.g., heart failure or renal disease).  Advise patients to adjust dietary sodium, and if appropriate, increase the dose of diuretics as needed.', '2', '"Product Information. Lokelma (sodium zirconium cyclosilicate)." Astra-Zeneca Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26063, 0, 'Somatotropin', 'Neoplasms', 'Somatropin is contraindicated in the presence of any active malignancy.  Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy.  This includes the presence of any intracranial tumor.  Somatropin should be discontinued if there is any evidence of recurrence.', '3', '"Product Information. Serostim (somatropin)." Serono Laboratories Inc  (2004):|"Product Information. Zorbtive (somatropin)." Serono Laboratories Inc  (2004):|"Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26064, 0, 'Somatotropin', 'Acute Critical Illness', 'Treatment with somatropin is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure.  Patients with these conditions have an increased risk of mortality.', '3', '"Product Information. Serostim (somatropin)." Serono Laboratories Inc  (2004):|"Product Information. Zorbtive (somatropin)." Serono Laboratories Inc  (2004):|"Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26065, 0, 'Somatotropin', 'Diabetic Retinopathy', 'Somatropin is contraindicated in patients with active proliferative or severe non- proliferative diabetic retinopathy.', '3', '"Product Information. Serostim (somatropin)." Serono Laboratories Inc  (2004):|"Product Information. Zorbtive (somatropin)." Serono Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26066, 0, 'Somatotropin', 'Prader-Willi Syndrome', 'Somatropin is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment.  There have been reports of sudden death when somatropin was used in such patients.', '3', '"Product Information. Serostim (somatropin)." Serono Laboratories Inc  (2004):|"Product Information. Zorbtive (somatropin)." Serono Laboratories Inc  (2004):|"Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26067, 0, 'Somatotropin', 'Diabetes Mellitus', 'The use of growth hormone has been associated with resistance to insulin.  Patients with diabetes mellitus or impaired glucose tolerance should be observed closely during therapy.  The dose of antihyperglycemic drugs (insulin or oral/injectable agents) may require adjustment.', '2', '"Product Information. Nutropin (somatropin)." Genentech  (2001):|"Product Information. Protropin (somatrem)." Genentech  (2001):|"Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26068, 0, 'Somatotropin', 'Hypothyroidism', 'The use of growth hormone has been associated with the development of hypothyroidism.  Patients should be monitored baseline and periodically for adequate thyroid function.  Inadequate treatment of hypothyroidism may inhibit the optimal response to growth hormone.', '2', '"Product Information. Nutropin (somatropin)." Genentech  (2001):|"Product Information. Protropin (somatrem)." Genentech  (2001):|"Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26069, 0, 'Somatotropin', 'Intracranial Hypertension', 'Intracranial hypertension with papilledema, visual changes, nausea and/or vomiting has been reported in a small number of patients treated with somatropin.  Fundoscopic examination should be performed before treatment initiation to exclude preexisting papilledema, and should be continued periodically during treatment.  If papilledema is observed during treatment, therapy should be stopped.  Treatment could be restarted at a lower dose once intracranial hypertension has been resolved.  Patients with Turner Syndrome might be at increased risk of developing intracranial hypertension.', '2', '"Product Information. Serostim (somatropin)." Serono Laboratories Inc  (2004):|"Product Information. Zorbtive (somatropin)." Serono Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26070, 0, 'Somatotropin', 'Scoliosis', 'Progression of scoliosis can occur in patients who experience rapid growth.  Since somatropin increases growth rate, children with a history of scoliosis should be monitored for progression of this condition.  Physicians should be alert for this skeletal abnormality which can be commonly seen in patients with Turner and Prader-Willi syndromes, and can manifest during somatropin treatment.', '2', '"Product Information. Serostim (somatropin)." Serono Laboratories Inc  (2004):|"Product Information. Zorbtive (somatropin)." Serono Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26071, 0, 'Somatotropin', 'Turner Syndrome', 'Somatropin may increase the risk of otitis media in patients with Turner syndrome.  These patients should be evaluated carefully for otitis media and other ear disorders as they have an increased risk of ear and hearing disorders.', '2', '"Product Information. Serostim (somatropin)." Serono Laboratories Inc  (2004):|"Product Information. Zorbtive (somatropin)." Serono Laboratories Inc  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26072, 1426, 'Sotalol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26073, 27312, 'Sotalol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26074, 1426, 'Sotalol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Acupress (carteolol ophthalmic)." Otsuka American Pharmaceuticals Inc, Rockville, MD.|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26075, 27312, 'Sotalol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Acupress (carteolol ophthalmic)." Otsuka American Pharmaceuticals Inc, Rockville, MD.|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26076, 1426, 'Sotalol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Lechat P, Jaillon P, Fontaine ML, Chanton E, Mesenge C, Gagey S, Guillardeau A, Dussous V "A randomized trial of beta-blockade in heart failure - the cardiac insufficiency bisoprolol study (CIBIS)." Circulation 90 (1994):  1765-73|Maisel AS "Beneficial effects of metoprolol treatment in congestive heart failure - reversal of sympathetic-induced alterations of immunologic function." Circulation 90 (1994):  1774-80|Persson H, Rythenalder E, Melcher A, Erhardt L "Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol." Br Heart J 74 (1995):  140-8|Kelly DT "Carvedilol in heart failure." Cardiology 82 Suppl 3 (1993):  45-9|Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR "Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study." J Am Coll Cardiol 25 (1995):  1225-31|Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. "Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure." Circulation 92 (1995):  1499-506|Australia-New Zealand Heart Failure Research Collaborative Group. "Effects of carvedilol, a vasodilator-B-blocker, in patients with congestive heart failure due to ischemic heart disease." Circulation 92 (1995):  212-8|Kalman J, Buchholz C, Steinmetz M, Courtney M, Gass A, Lansman S, Kukin ML "Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting transplantation." J Heart Lung Transplant 14 (1995):  1212-7|Adams KF Jr "Current perspectives on B-receptor antagonists in the treatment of symptomatic ventricular dysfunction." Pharmacotherapy 16(2 Pt 2) (1996):  69-77|Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure." N Engl J Med 334 (1996):  1349-55|Persson SV, Erhardt L "Effects of beta receptor antagonists on left ventricular function in patients with clinical evidence of heart failure after myocardial infarction. A double-blind comparison of metoprolol and xamoterol: echocardiographic results from the Metoprolol and..." Eur Heart J 17 (1996):  741-9|Cleland JGF, Swedberg K "Carvedilol for heart failure, with care." Lancet 347 (1996):  1199-201|Moye LA, Abernethy D "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318|Von Olshausen K, Pop T, Berger J "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318-20|Packer M, Cohn JN, Colucci WS "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1310-20|Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackne "Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure." Circulation 94 (1996):  2800-6|Macmahon S, Sharpe N, Doughty R, Krum H, Tonkin A, Trotter A, Burton R, Garrett J, Lane G, Owensby D, Ryan J, Shepherd J, Sing "Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease." Lancet 349 (1997):  375-80|Bristow MR, Gilbert EM, Abraham WT, et al. "Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators." Circulation 94 (1996):  2807-16|Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D "Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial Prospective Randomized Evaluation of Carvedilol on Symptoms an Exercise." Circulation 94 (1996):  2793-9|Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N "Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-Ne Zealand Heart Failure Research Collaborative Group." J Am Coll Cardiol 29 (1997):  1060-6|Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP "Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials." Circulation 98 (1998):  1184-91|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|CIBIS-II Investigators and Committees. "The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial." Lancet 353 (1999):  9-13|Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ "Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure." J Am Coll Cardiol 33 (1999):  924-31|Hjalmarson A, Goldstein S, Fagerberg B, et al. "Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)." JAMA 283 (2000):  1295-302|Phillips KA, Shlipak MG, Coxson P, et al. "Health and economic benefits of increased B-blocker use following myocardial infarction." JAMA 284 (2000):  2748-54|Hart SM "Influence of B-blockers on mortality in chronic heart failure." Ann Pharmacother 34 (2000):  1440-51|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26077, 27312, 'Sotalol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Lechat P, Jaillon P, Fontaine ML, Chanton E, Mesenge C, Gagey S, Guillardeau A, Dussous V "A randomized trial of beta-blockade in heart failure - the cardiac insufficiency bisoprolol study (CIBIS)." Circulation 90 (1994):  1765-73|Maisel AS "Beneficial effects of metoprolol treatment in congestive heart failure - reversal of sympathetic-induced alterations of immunologic function." Circulation 90 (1994):  1774-80|Persson H, Rythenalder E, Melcher A, Erhardt L "Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol." Br Heart J 74 (1995):  140-8|Kelly DT "Carvedilol in heart failure." Cardiology 82 Suppl 3 (1993):  45-9|Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR "Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study." J Am Coll Cardiol 25 (1995):  1225-31|Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. "Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure." Circulation 92 (1995):  1499-506|Australia-New Zealand Heart Failure Research Collaborative Group. "Effects of carvedilol, a vasodilator-B-blocker, in patients with congestive heart failure due to ischemic heart disease." Circulation 92 (1995):  212-8|Kalman J, Buchholz C, Steinmetz M, Courtney M, Gass A, Lansman S, Kukin ML "Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting transplantation." J Heart Lung Transplant 14 (1995):  1212-7|Adams KF Jr "Current perspectives on B-receptor antagonists in the treatment of symptomatic ventricular dysfunction." Pharmacotherapy 16(2 Pt 2) (1996):  69-77|Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure." N Engl J Med 334 (1996):  1349-55|Persson SV, Erhardt L "Effects of beta receptor antagonists on left ventricular function in patients with clinical evidence of heart failure after myocardial infarction. A double-blind comparison of metoprolol and xamoterol: echocardiographic results from the Metoprolol and..." Eur Heart J 17 (1996):  741-9|Cleland JGF, Swedberg K "Carvedilol for heart failure, with care." Lancet 347 (1996):  1199-201|Moye LA, Abernethy D "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318|Von Olshausen K, Pop T, Berger J "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1318-20|Packer M, Cohn JN, Colucci WS "Carvedilol in patients with chronic heart failure." N Engl J Med 335 (1996):  1310-20|Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackne "Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure." Circulation 94 (1996):  2800-6|Macmahon S, Sharpe N, Doughty R, Krum H, Tonkin A, Trotter A, Burton R, Garrett J, Lane G, Owensby D, Ryan J, Shepherd J, Sing "Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease." Lancet 349 (1997):  375-80|Bristow MR, Gilbert EM, Abraham WT, et al. "Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators." Circulation 94 (1996):  2807-16|Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D "Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial Prospective Randomized Evaluation of Carvedilol on Symptoms an Exercise." Circulation 94 (1996):  2793-9|Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N "Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-Ne Zealand Heart Failure Research Collaborative Group." J Am Coll Cardiol 29 (1997):  1060-6|Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP "Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials." Circulation 98 (1998):  1184-91|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|CIBIS-II Investigators and Committees. "The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial." Lancet 353 (1999):  9-13|Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ "Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure." J Am Coll Cardiol 33 (1999):  924-31|Hjalmarson A, Goldstein S, Fagerberg B, et al. "Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)." JAMA 283 (2000):  1295-302|Phillips KA, Shlipak MG, Coxson P, et al. "Health and economic benefits of increased B-blocker use following myocardial infarction." JAMA 284 (2000):  2748-54|Hart SM "Influence of B-blockers on mortality in chronic heart failure." Ann Pharmacother 34 (2000):  1440-51|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26078, 1426, 'Sotalol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26079, 27312, 'Sotalol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26080, 1426, 'Sotalol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26081, 27312, 'Sotalol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26082, 1426, 'Sotalol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'Miller RR, Olson HG, Amsterdam EA, Mason DT "Propranolol-withdrawal rebound phenomenon: exacerbation of coronary events after abrupt cessation of antianginal therapy." N Engl J Med 293 (1975):  416-8|Rangno RE, Langlois S "Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol." Am Heart J 104 (1982):  473-8|Szecsi E, Kohlschutter S, Schiess W, Lang E "Abrupt withdrawal of pindolol or metoprolol after chronic therapy." Br J Clin Pharmacol 13 (1982):  s353-7|Walden RJ, Hernandez J, Yu Y, et al. "Withdrawal of beta-blocking drugs." Am Heart J 104 (1982):  515-20|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26083, 27312, 'Sotalol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'Miller RR, Olson HG, Amsterdam EA, Mason DT "Propranolol-withdrawal rebound phenomenon: exacerbation of coronary events after abrupt cessation of antianginal therapy." N Engl J Med 293 (1975):  416-8|Rangno RE, Langlois S "Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol." Am Heart J 104 (1982):  473-8|Szecsi E, Kohlschutter S, Schiess W, Lang E "Abrupt withdrawal of pindolol or metoprolol after chronic therapy." Br J Clin Pharmacol 13 (1982):  s353-7|Walden RJ, Hernandez J, Yu Y, et al. "Withdrawal of beta-blocking drugs." Am Heart J 104 (1982):  515-20|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26084, 1426, 'Sotalol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26085, 27312, 'Sotalol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Michelson EL, Frishman WH, Lewis JE, et al. "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983):  68-80|Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Myers J, Morgan T, Waga S, et al. "Long-term experiences with labetalol." Med J Aust 1 (1980):  665-6|Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983):  342-8|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26086, 1426, 'Sotalol', 'Asthma', 'Some beta-adrenergic receptor blocking agents (i.e., non-cardioselective beta-blockers) are contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease.  In general, beta-adrenergic receptor blocking agents should not be used in patients with bronchospastic diseases.  Beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  If beta-blocker therapy is necessary in these patients, an agent with beta-1 selectivity (e.g., atenolol, metoprolol, betaxolol) is considered safer, but should be used with caution nonetheless.  Cardioselectivity is not absolute and can be lost with larger doses.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26087, 27312, 'Sotalol', 'Asthma', 'Some beta-adrenergic receptor blocking agents (i.e., non-cardioselective beta-blockers) are contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease.  In general, beta-adrenergic receptor blocking agents should not be used in patients with bronchospastic diseases.  Beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  If beta-blocker therapy is necessary in these patients, an agent with beta-1 selectivity (e.g., atenolol, metoprolol, betaxolol) is considered safer, but should be used with caution nonetheless.  Cardioselectivity is not absolute and can be lost with larger doses.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26088, 1426, 'Sotalol', 'Diseases requiring hemodialysis', 'Therapy with sotalol should be administered cautiously in patients with renal failure undergoing hemodialysis.  The half-life of sotalol is prolonged (up to 69 hours) in anuric patients.  Although sotalol is partially removed by hemodialysis, a rebound in drug concentration often occurs after dialysis is complete.  Sotalol should preferably be administered after dialysis and after hemodynamic stability has been established.  Heart rate and ECG, particularly the QTc interval, must be closely monitored.', '3', 'Tjandramaga TB, Verbeeck R, Thomas J, Verbesselt R, Verberckmoes R, Schepper PJD "The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol." Br J Clin Pharmacol 3 (1976):  259-65|Forsyth R P, Tjandramaga TB, Verberckmoes R, Verbeeck R, De Schepper PJ. Influence of chronic renal failure and haemodialysis on the elimination of the beta-adrenoceptor blocking drugs practolol and sotalol.  In: Saxena PR, eds., Verbesselt R "Beta-adrenoceptor Blocking Agents." Amsterdam, North-Holland,   :  (1976):  323-33|Singh SN, Lazin A, Cohen A, Johnson M, Fletcher RD "Sotalol-induced torsades de pointes successfully treated with hemodialysis after failure of conventional therapy." Am Heart J 121 (1991):  601-2|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26089, 27312, 'Sotalol', 'Diseases requiring hemodialysis', 'Therapy with sotalol should be administered cautiously in patients with renal failure undergoing hemodialysis.  The half-life of sotalol is prolonged (up to 69 hours) in anuric patients.  Although sotalol is partially removed by hemodialysis, a rebound in drug concentration often occurs after dialysis is complete.  Sotalol should preferably be administered after dialysis and after hemodynamic stability has been established.  Heart rate and ECG, particularly the QTc interval, must be closely monitored.', '3', 'Tjandramaga TB, Verbeeck R, Thomas J, Verbesselt R, Verberckmoes R, Schepper PJD "The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol." Br J Clin Pharmacol 3 (1976):  259-65|Forsyth R P, Tjandramaga TB, Verberckmoes R, Verbeeck R, De Schepper PJ. Influence of chronic renal failure and haemodialysis on the elimination of the beta-adrenoceptor blocking drugs practolol and sotalol.  In: Saxena PR, eds., Verbesselt R "Beta-adrenoceptor Blocking Agents." Amsterdam, North-Holland,   :  (1976):  323-33|Singh SN, Lazin A, Cohen A, Johnson M, Fletcher RD "Sotalol-induced torsades de pointes successfully treated with hemodialysis after failure of conventional therapy." Am Heart J 121 (1991):  601-2|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26090, 1426, 'Sotalol', 'Long QT Syndrome', 'The use of sotalol is contraindicated in patients with congenital or acquired QT interval prolongation syndromes.  Sotalol has dose-dependent proarrhythmic effects related to prolongation of the QT interval.  The risk of torsades de pointes is progressively increased as the degree of prolongation becomes greater.  The manufacturer states that sotalol should be used with particular caution in patients whose QTc is greater than 500 msec on- therapy.  Serious consideration should be given to reducing the dosage or discontinuing therapy when the QTc exceeds 550 msec.The use of sotalol is contraindicated in patients with hypokalemia (< 4 meq/L).  Electrolyte disturbances such as hypokalemia and hypomagnesemia may augment the prolongation effect of sotalol on the QT interval and should be corrected prior to institution of sotalol therapy.  In addition, patients who experience frequent, severe, or prolonged diarrhea may be subject to electrolyte losses and should be followed closely and managed accordingly during therapy with sotalol.', '3', 'Kuck KH, Kunze KP, Roewer N, Bleifeld W "Sotalol-induced torsade de pointes." Am Heart J 107 (1984):  179-80|Jordaens L, Gorgels A, Stroobandt R, Temmerman J "Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. The Sotalol Versus Placebo Multicenter Study Group." Am J Cardiol 68 (1991):  35-40|Soyka LF, Wirtz C, Spangenberg RB "Clinical safety profile of sotalol in patients with arrhythmias." Am J Cardiol 65 (1990):  a74-81;|Allberry RA "Torsade de pointes." Anaesthesia 38 (1983):  910|Antonaccio MJ, Lessem JN, Soyka LF "Sotalol, hypokalaemia, syncope, and torsade de pointes." Br Heart J 52 (1984):  358-9|McKibbin JK, Pocock WA, Barlow JB, Millar RN, Obel IW "Sotalol, hypokalaemia, syncope, and torsade de pointes." Br Heart J 51 (1984):  157-62|Krapf R, Gertsch M "Torsade de pointes induced by sotalol despite therapeutic plasma sotalol concentrations." Br Med J (Clin Res Ed) 290 (1985):  1784-5|Neuvonen PJ, Elonen E, Tanskanen A, Tuomilehto J "Sotalol prolongation of the QTc interval in hypertensive patients." Clin Pharmacol Ther 32 (1982):  25-32|Suttorp MJ, Kingma JH, Tjon Joe Gin RM, van Hemel NM, Koomen EM, Defauw JA, Adan AJ, Ernst SM "Efficacy and safety of low- and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations." J Thorac Cardiovasc Surg 100 (1990):  921-6|Griffith MJ, Linker NJ, Garratt CJ, Ward DE, Camm AJ "Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia." Lancet 336 (1990):  670-3|Arstall MA, Hii JT, Lehman RG, Horowitz JD "Sotalol-induced torsade de pointes: management with magnesium infusion." Postgrad Med J 68 (1992):  289-90|Rakovec P, Cercek B, Rode P, Brucan A, Horvat M "Sotalol-induced torsade de pointes." Cathet Cardiovasc Diagn 10 (1984):  167-70|Gossinger HD, Siostrzonek P, Schmoliner R, Grimm G, Jager U, Mosslacher H "Sotalol-induced torsades de pointes in a patient with pre-existent normal response to programmed ventricular stimulation." Eur Heart J 8 (1987):  1351-3|Hohnloser SH, Zabel M, van de Loo A, Klingenheben T, Just H "Efficacy and safety of sotalol in patients with complex ventricular arrhythmias." Int J Cardiol 37 (1992):  283-91|Laakso M, Pentikainen PJ, Rehnberg S "Sotalol-induced prolongation of the Q-T interval and attacks of unconsciousness." Int J Clin Pharmacol Ther Toxicol 22 (1984):  487-90|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|Cui GG, Sen LY, Sager P, Uppal P, Singh BN "Effects of amiodarone, sematilide, and sotalol on QT dispersion." Am J Cardiol 74 (1994):  896-900|Lehmann MH, Hardy S, Archibald D, Quart B, Macneil DJ "Sex difference in risk of torsade de pointes with d,l-sotalol." Circulation 94 (1996):  2535-41', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26091, 27312, 'Sotalol', 'Long QT Syndrome', 'The use of sotalol is contraindicated in patients with congenital or acquired QT interval prolongation syndromes.  Sotalol has dose-dependent proarrhythmic effects related to prolongation of the QT interval.  The risk of torsades de pointes is progressively increased as the degree of prolongation becomes greater.  The manufacturer states that sotalol should be used with particular caution in patients whose QTc is greater than 500 msec on- therapy.  Serious consideration should be given to reducing the dosage or discontinuing therapy when the QTc exceeds 550 msec.The use of sotalol is contraindicated in patients with hypokalemia (< 4 meq/L).  Electrolyte disturbances such as hypokalemia and hypomagnesemia may augment the prolongation effect of sotalol on the QT interval and should be corrected prior to institution of sotalol therapy.  In addition, patients who experience frequent, severe, or prolonged diarrhea may be subject to electrolyte losses and should be followed closely and managed accordingly during therapy with sotalol.', '3', 'Kuck KH, Kunze KP, Roewer N, Bleifeld W "Sotalol-induced torsade de pointes." Am Heart J 107 (1984):  179-80|Jordaens L, Gorgels A, Stroobandt R, Temmerman J "Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. The Sotalol Versus Placebo Multicenter Study Group." Am J Cardiol 68 (1991):  35-40|Soyka LF, Wirtz C, Spangenberg RB "Clinical safety profile of sotalol in patients with arrhythmias." Am J Cardiol 65 (1990):  a74-81;|Allberry RA "Torsade de pointes." Anaesthesia 38 (1983):  910|Antonaccio MJ, Lessem JN, Soyka LF "Sotalol, hypokalaemia, syncope, and torsade de pointes." Br Heart J 52 (1984):  358-9|McKibbin JK, Pocock WA, Barlow JB, Millar RN, Obel IW "Sotalol, hypokalaemia, syncope, and torsade de pointes." Br Heart J 51 (1984):  157-62|Krapf R, Gertsch M "Torsade de pointes induced by sotalol despite therapeutic plasma sotalol concentrations." Br Med J (Clin Res Ed) 290 (1985):  1784-5|Neuvonen PJ, Elonen E, Tanskanen A, Tuomilehto J "Sotalol prolongation of the QTc interval in hypertensive patients." Clin Pharmacol Ther 32 (1982):  25-32|Suttorp MJ, Kingma JH, Tjon Joe Gin RM, van Hemel NM, Koomen EM, Defauw JA, Adan AJ, Ernst SM "Efficacy and safety of low- and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations." J Thorac Cardiovasc Surg 100 (1990):  921-6|Griffith MJ, Linker NJ, Garratt CJ, Ward DE, Camm AJ "Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia." Lancet 336 (1990):  670-3|Arstall MA, Hii JT, Lehman RG, Horowitz JD "Sotalol-induced torsade de pointes: management with magnesium infusion." Postgrad Med J 68 (1992):  289-90|Rakovec P, Cercek B, Rode P, Brucan A, Horvat M "Sotalol-induced torsade de pointes." Cathet Cardiovasc Diagn 10 (1984):  167-70|Gossinger HD, Siostrzonek P, Schmoliner R, Grimm G, Jager U, Mosslacher H "Sotalol-induced torsades de pointes in a patient with pre-existent normal response to programmed ventricular stimulation." Eur Heart J 8 (1987):  1351-3|Hohnloser SH, Zabel M, van de Loo A, Klingenheben T, Just H "Efficacy and safety of sotalol in patients with complex ventricular arrhythmias." Int J Cardiol 37 (1992):  283-91|Laakso M, Pentikainen PJ, Rehnberg S "Sotalol-induced prolongation of the Q-T interval and attacks of unconsciousness." Int J Clin Pharmacol Ther Toxicol 22 (1984):  487-90|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|Cui GG, Sen LY, Sager P, Uppal P, Singh BN "Effects of amiodarone, sematilide, and sotalol on QT dispersion." Am J Cardiol 74 (1994):  896-900|Lehmann MH, Hardy S, Archibald D, Quart B, Macneil DJ "Sex difference in risk of torsade de pointes with d,l-sotalol." Circulation 94 (1996):  2535-41', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26092, 1426, 'Sotalol', 'Kidney Diseases', 'Sotalol is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sotalol, including torsade de pointes and worsened ventricular tachycardia, due to decreased drug clearance.  Therapy with sotalol should be administered cautiously in patients with renal impairment.  Dosage adjustments (i.e. prolongation of dosing interval) are recommended in patients with moderate to severe renal dysfunction (CrCl <= 60 mL/min), and dosage escalations should occur not more often than after administration of every 5 to 6 doses.  Heart rate and ECG, particularly the QTc interval, should be closely monitored.', '3', 'Blair AD, Burgess ED, Maxwell BM, Cutler RE "Sotalol kinetics in renal insufficiency." Clin Pharmacol Ther 29 (1981):  457-63|Tjandramaga TB, Verbeeck R, Thomas J, Verbesselt R, Verberckmoes R, Schepper PJD "The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol." Br J Clin Pharmacol 3 (1976):  259-65|Berglund G, Descamps R, Thomis JA "Pharmacokinetics of sotalol after chronic administration to patients with renal insufficiency." Eur J Clin Pharmacol 18 (1980):  321-6|Dumas M, d''Athis P, Besancenot JF, Chadoint-Noudeau V, Chalopin JM, Rifle G, Escousse A "Variations of sotalol kinetics in renal insufficiency." Int J Clin Pharmacol Ther Toxicol 27 (1989):  486-9|Forsyth R P, Tjandramaga TB, Verberckmoes R, Verbeeck R, De Schepper PJ. Influence of chronic renal failure and haemodialysis on the elimination of the beta-adrenoceptor blocking drugs practolol and sotalol.  In: Saxena PR, eds., Verbesselt R "Beta-adrenoceptor Blocking Agents." Amsterdam, North-Holland,   :  (1976):  323-33|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|Patrick GM, Pollock CA, Ibels LS, Caterson RJ "Sotalol and end-stage renal failure." Aust N Z J Med 24 (1994):  319-20', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26093, 27312, 'Sotalol', 'Kidney Diseases', 'Sotalol is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sotalol, including torsade de pointes and worsened ventricular tachycardia, due to decreased drug clearance.  Therapy with sotalol should be administered cautiously in patients with renal impairment.  Dosage adjustments (i.e. prolongation of dosing interval) are recommended in patients with moderate to severe renal dysfunction (CrCl <= 60 mL/min), and dosage escalations should occur not more often than after administration of every 5 to 6 doses.  Heart rate and ECG, particularly the QTc interval, should be closely monitored.', '3', 'Blair AD, Burgess ED, Maxwell BM, Cutler RE "Sotalol kinetics in renal insufficiency." Clin Pharmacol Ther 29 (1981):  457-63|Tjandramaga TB, Verbeeck R, Thomas J, Verbesselt R, Verberckmoes R, Schepper PJD "The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol." Br J Clin Pharmacol 3 (1976):  259-65|Berglund G, Descamps R, Thomis JA "Pharmacokinetics of sotalol after chronic administration to patients with renal insufficiency." Eur J Clin Pharmacol 18 (1980):  321-6|Dumas M, d''Athis P, Besancenot JF, Chadoint-Noudeau V, Chalopin JM, Rifle G, Escousse A "Variations of sotalol kinetics in renal insufficiency." Int J Clin Pharmacol Ther Toxicol 27 (1989):  486-9|Forsyth R P, Tjandramaga TB, Verberckmoes R, Verbeeck R, De Schepper PJ. Influence of chronic renal failure and haemodialysis on the elimination of the beta-adrenoceptor blocking drugs practolol and sotalol.  In: Saxena PR, eds., Verbesselt R "Beta-adrenoceptor Blocking Agents." Amsterdam, North-Holland,   :  (1976):  323-33|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|Patrick GM, Pollock CA, Ibels LS, Caterson RJ "Sotalol and end-stage renal failure." Aust N Z J Med 24 (1994):  319-20', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26094, 1426, 'Sotalol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26095, 27312, 'Sotalol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26096, 1426, 'Sotalol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26097, 27312, 'Sotalol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26098, 1426, 'Sotalol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26099, 27312, 'Sotalol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Valimaki M, Maass L, Harno K, Nikkila EA "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol 30 (1986):  17-20|Disler LJ, Joffe BI, Seftel HC "Massive hypertriglyceridemia associated with atenolol." Am J Med 85 (1988):  586-7|Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol 27 (1987):  475-80|Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Rossner S, Weiner L "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol 24 (1983):  573-7|Weiner L, Rossner S "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand 677 (1983):  153-7|Ferrara LA, Marotta T, Scilla A, et al. "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol 26 (1984):  331-4|Pasotti C, Capra A, Fiorella G, et al. "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol 13 (1982):  s435-9|Carlson LA, Ribacke M, Terent A "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol 24 (1987):  s61-2|Samuel P, Chin B, Schoenfeld BH, et al. "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol 24 (1987):  s63-4|Terent A, Ribacke M, Carlson LA "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol 36 (1989):  347-50|Sasaki J, Saku K, Ideishi M, et al. "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther 11 (1989):  219-24|Szollar LG, Meszaros I, Tornoci L, et al. "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol 15 (1990):  911-7|Leren P, Foss PO, Nordvik B, Fossbakk B "The effect of enalapril and timolol on blood lipids." Acta Med Scand 223 (1988):  321-6|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Northcote RJ, Packard CJ, Ballantyne D "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta 158 (1986):  187-91|Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol 21 (1983):  73-6|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|Safran AB, Simona F, Sansonetti A, Pometta D, James R "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol 117 (1994):  683|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|Clucas A, Miller N "Effects of acebutolol on the serum lipid profile." Drugs 36 Suppl 2 (1988):  41-50|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Lind L, Pollare T, Berne C, Lithell H "Long-term metabolic effects of antihypertensive drugs." Am Heart J 128 (1994):  1177-83|Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther 32 (1994):  660-4|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Lithell H, Andersson PE "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol 52 (1997):  13-7|Gordon NF, Scott CB, Duncan JJ "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol 79 (1997):  1065-9|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26100, 1426, 'Sotalol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26101, 27312, 'Sotalol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26102, 1426, 'Sotalol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26103, 27312, 'Sotalol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26104, 1426, 'Sotalol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26105, 27312, 'Sotalol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26106, 1426, 'Sotalol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26107, 27312, 'Sotalol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26108, 1426, 'Sotalol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26109, 27312, 'Sotalol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26110, 1426, 'Sotalol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26111, 27312, 'Sotalol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26112, 0, 'Solriamfetol', 'Cardiotoxicity', 'Solriamfetol increases systolic blood pressure, diastolic blood pressure, and heart rate in a dose-dependent fashion.  It is recommended to exercise caution when treating patients at higher risk of cardiovascular toxicities, particularly patients with known cardiovascular and cerebrovascular disease, preexisting hypertension, and patients with advanced age.  Assess blood pressure and control hypertension before initiating treatment and monitor blood pressure regularly during treatment.  Periodically reassess the need for continued therapy with solriamfetol and treat new-onset hypertension and exacerbations of preexisting hypertension according to clinical guidelines.  If a patient experiences increases in blood pressure or heart rate that cannot be managed with dose reduction or other appropriate medical intervention, consider treatment discontinuation.', '2', '"Product Information. Sunosi (solriamfetol)." Jazz Pharmaceuticals  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26113, 0, 'Solriamfetol', 'Psychotic Disorders', 'The use of solriamfetol may cause adverse psychiatric reactions, including anxiety, insomnia, and irritability.  It is recommended to exercise caution when treating patients who have a history of psychosis or bipolar disorders.  Observe patients treated with solriamfetol for the possible emergence or exacerbation of psychiatric symptoms and consider dose reduction or discontinuation of treatment.', '2', '"Product Information. Sunosi (solriamfetol)." Jazz Pharmaceuticals  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26114, 0, 'Solriamfetol', 'Kidney Diseases', 'The primary route of solriamfetol elimination is via urinary excretion.  Dosage adjustment is not required for patients with mild renal impairment.  Dosage adjustment is recommended for patients with moderate to severe renal impairment.  Solriamfetol is not recommended for patients with end-stage renal disease.  An average of 21% of solriamfetol is removed by hemodialysis.  Patients with moderate or severe renal impairment may be at a higher risk of increases in cardiovascular adverse events and psychiatric symptoms because of the prolonged half-life.', '2', '"Product Information. Sunosi (solriamfetol)." Jazz Pharmaceuticals  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26115, 14126, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26116, 14620, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26117, 18462, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26118, 20055, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26119, 20056, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26120, 20434, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26121, 20538, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26122, 23043, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26123, 23168, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26124, 23831, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26125, 26834, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26126, 27217, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26127, 27218, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26128, 27220, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26129, 27221, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26130, 27222, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26131, 27223, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26132, 28182, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):|"Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):|"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):|"Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):|"Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):|"Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):|"Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26133, 14126, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26134, 14620, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26135, 18462, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26136, 20055, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26137, 20056, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26138, 20434, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26139, 20538, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26140, 23043, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26141, 23168, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26142, 23831, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26143, 26834, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26144, 27217, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26145, 27218, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26146, 27220, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26147, 27221, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26148, 27222, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26149, 27223, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26150, 28182, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26151, 14126, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26152, 14620, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26153, 18462, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26154, 20055, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26155, 20056, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26156, 20434, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26157, 20538, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26158, 23043, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26159, 23168, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26160, 23831, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26161, 26834, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26162, 27217, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26163, 27218, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26164, 27220, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26165, 27221, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26166, 27222, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26167, 27223, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26168, 28182, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '"Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26169, 27304, 'Sorafenib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26170, 27305, 'Sorafenib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26171, 10718, 'Sorbitol', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26172, 23526, 'Sorbitol', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26173, 27308, 'Sorbitol', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26174, 10718, 'Sorbitol', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26175, 23526, 'Sorbitol', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26176, 27308, 'Sorbitol', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet  (2001):|"Product Information. Citrucel (methylcellulose)." SmithKline Beecham  (2001):|"Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26177, 10718, 'Sorbitol', 'Renal Insufficiency', 'The use of sorbitol solution for urologic irrigation is contraindicated in patients with anuria.  In addition, sorbitol irrigation should be administered cautiously in patients with cardiopulmonary or renal dysfunction.  Irrigating fluids may enter the systemic circulation, and absorption of large quantities of fluids containing sorbitol may significantly alter cardiopulmonary and renal dynamics.  Before and during the urologic procedure, cardiovascular and renal status should be monitored, particularly if the volume absorbed is expected to produce a substantial expansion of the intravascular fluid (e.g., via opened prostatic veins in transurethral prostatectomies).', '3', '"Product Information. Sorbitol (sorbitol)." B. Braun/McGaw Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26178, 23526, 'Sorbitol', 'Renal Insufficiency', 'The use of sorbitol solution for urologic irrigation is contraindicated in patients with anuria.  In addition, sorbitol irrigation should be administered cautiously in patients with cardiopulmonary or renal dysfunction.  Irrigating fluids may enter the systemic circulation, and absorption of large quantities of fluids containing sorbitol may significantly alter cardiopulmonary and renal dynamics.  Before and during the urologic procedure, cardiovascular and renal status should be monitored, particularly if the volume absorbed is expected to produce a substantial expansion of the intravascular fluid (e.g., via opened prostatic veins in transurethral prostatectomies).', '3', '"Product Information. Sorbitol (sorbitol)." B. Braun/McGaw Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26179, 27308, 'Sorbitol', 'Renal Insufficiency', 'The use of sorbitol solution for urologic irrigation is contraindicated in patients with anuria.  In addition, sorbitol irrigation should be administered cautiously in patients with cardiopulmonary or renal dysfunction.  Irrigating fluids may enter the systemic circulation, and absorption of large quantities of fluids containing sorbitol may significantly alter cardiopulmonary and renal dynamics.  Before and during the urologic procedure, cardiovascular and renal status should be monitored, particularly if the volume absorbed is expected to produce a substantial expansion of the intravascular fluid (e.g., via opened prostatic veins in transurethral prostatectomies).', '3', '"Product Information. Sorbitol (sorbitol)." B. Braun/McGaw Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26180, 10718, 'Sorbitol', 'Diabetes Mellitus', 'Sorbitol is converted to glucose in the body.  The use of sorbitol is not recommended as an alternative sweetener in patients with diabetes.  Sorbitol is one of the end products of glucose metabolism that results in some of the late complications of diabetes.', '2', '"Product Information. Sorbitol (sorbitol)." B. Braun/McGaw Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26181, 23526, 'Sorbitol', 'Diabetes Mellitus', 'Sorbitol is converted to glucose in the body.  The use of sorbitol is not recommended as an alternative sweetener in patients with diabetes.  Sorbitol is one of the end products of glucose metabolism that results in some of the late complications of diabetes.', '2', '"Product Information. Sorbitol (sorbitol)." B. Braun/McGaw Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26182, 27308, 'Sorbitol', 'Diabetes Mellitus', 'Sorbitol is converted to glucose in the body.  The use of sorbitol is not recommended as an alternative sweetener in patients with diabetes.  Sorbitol is one of the end products of glucose metabolism that results in some of the late complications of diabetes.', '2', '"Product Information. Sorbitol (sorbitol)." B. Braun/McGaw Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26183, 10718, 'Sorbitol', 'Water-Electrolyte Imbalance', 'Shift of sodium-free intracellular fluid into the extracellular compartment following systemic absorption of sorbitol irrigation may lower serum sodium concentration and aggravate preexisting-existing hyponatremia.  Excessive loss of water and electrolytes may may also cause hypernatremia.  Sustained diuresis from transurethral irrigation with sorbitol irrigation may obscure and intensify inadequate hydration or hypovolemia.  Patients with sodium imbalances or dehydration should be closely monitored.', '2', '"Product Information. Sorbitol (sorbitol)." B. Braun/McGaw Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26184, 23526, 'Sorbitol', 'Water-Electrolyte Imbalance', 'Shift of sodium-free intracellular fluid into the extracellular compartment following systemic absorption of sorbitol irrigation may lower serum sodium concentration and aggravate preexisting-existing hyponatremia.  Excessive loss of water and electrolytes may may also cause hypernatremia.  Sustained diuresis from transurethral irrigation with sorbitol irrigation may obscure and intensify inadequate hydration or hypovolemia.  Patients with sodium imbalances or dehydration should be closely monitored.', '2', '"Product Information. Sorbitol (sorbitol)." B. Braun/McGaw Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26185, 27308, 'Sorbitol', 'Water-Electrolyte Imbalance', 'Shift of sodium-free intracellular fluid into the extracellular compartment following systemic absorption of sorbitol irrigation may lower serum sodium concentration and aggravate preexisting-existing hyponatremia.  Excessive loss of water and electrolytes may may also cause hypernatremia.  Sustained diuresis from transurethral irrigation with sorbitol irrigation may obscure and intensify inadequate hydration or hypovolemia.  Patients with sodium imbalances or dehydration should be closely monitored.', '2', '"Product Information. Sorbitol (sorbitol)." B. Braun/McGaw Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26186, 2944, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26187, 4825, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26188, 4995, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26189, 9310, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26190, 10632, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26191, 10633, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26192, 13015, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26193, 13016, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26194, 20758, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26195, 20759, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26196, 23243, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26197, 23244, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26198, 27094, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26199, 27214, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26200, 27249, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26201, 27250, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26202, 28356, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26203, 28357, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26204, 28823, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26205, 29195, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26206, 29196, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26207, 2944, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26208, 4825, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26209, 4995, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26210, 9310, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26211, 10632, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26212, 10633, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26213, 13015, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26214, 13016, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26215, 20758, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26216, 20759, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26217, 23243, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26218, 23244, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26219, 27094, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26220, 27214, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26221, 27249, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26222, 27250, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26223, 28356, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26224, 28357, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26225, 28823, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26226, 29195, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26227, 29196, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26228, 2944, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26229, 4825, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26230, 4995, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26231, 9310, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26232, 10632, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26233, 10633, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26234, 13015, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26235, 13016, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26236, 20758, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26237, 20759, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26238, 23243, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26239, 23244, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26240, 27094, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26241, 27214, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26242, 27249, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26243, 27250, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26244, 28356, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26245, 28357, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26246, 28823, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26247, 29195, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26248, 29196, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26249, 2944, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26250, 4825, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26251, 4995, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26252, 9310, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26253, 10632, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26254, 10633, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26255, 13015, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26256, 13016, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26257, 20758, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26258, 20759, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26259, 23243, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26260, 23244, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26261, 27094, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26262, 27214, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26263, 27249, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26264, 27250, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26265, 28356, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26266, 28357, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26267, 28823, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26268, 29195, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26269, 29196, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26270, 2944, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26271, 4825, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26272, 4995, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26273, 9310, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26274, 10632, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26275, 10633, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26276, 13015, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26277, 13016, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26278, 20758, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26279, 20759, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26280, 23243, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26281, 23244, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26282, 27094, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26283, 27214, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26284, 27249, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26285, 27250, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26286, 28356, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26287, 28357, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26288, 28823, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26289, 29195, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26290, 29196, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26291, 2944, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26292, 4825, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26293, 4995, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26294, 9310, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26295, 10632, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26296, 10633, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26297, 13015, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26298, 13016, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26299, 20758, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26300, 20759, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26301, 23243, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26302, 23244, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26303, 27094, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26304, 27214, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26305, 27249, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26306, 27250, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26307, 28356, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26308, 28357, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26309, 28823, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26310, 29195, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26311, 29196, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26312, 2944, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26313, 4825, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26314, 4995, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26315, 9310, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26316, 10632, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26317, 10633, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26318, 13015, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26319, 13016, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26320, 20758, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26321, 20759, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26322, 23243, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26323, 23244, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26324, 27094, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26325, 27214, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26326, 27249, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26327, 27250, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26328, 28356, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26329, 28357, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26330, 28823, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26331, 29195, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26332, 29196, 'Solifenacin', 'Long QT Syndrome', 'Dose dependent prolongation in QT interval has been observed with the use of solifenacin.  This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.', '2', '"Product Information. VESIcare (solifenacin)." GlaxoSmithKline  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26333, 24890, 'Acetohydroxamic acid', 'Kidney Diseases', 'Acetohydroxamic acid is primarily eliminated by the kidney and it is contraindicated in patients whose renal function is poor (serum creatinine more than 2.5 mg/dl and/or creatinine clearance less than 20 mL/min).  Patients with less marked renal impairment may be at increased risk of toxicity associated with administration of acetohydroxamic acid and therapy should be administered cautiously and reduced dosage may be necessary.', '3', '"Product Information. Lithostat (acetohydroxamic acid)." Mission Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26334, 24890, 'Acetohydroxamic acid', 'Bone Marrow Failure Disorders', 'The use of acetohydroxamic acid is a known inhibitor of DNA synthesis and also chelates metals - notably iron.  Its bone marrow suppressant effect is probably related to its ability to inhibit DNA synthesis, but anemia could also be related to depletion of iron stores.  Clinical monitoring of the platelet and white cell count is recommended in patients with bone marrow depression.', '2', '"Product Information. Lithostat (acetohydroxamic acid)." Mission Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26335, 24890, 'Acetohydroxamic acid', 'Liver Failure', 'Abnormalities of liver function have not been reported to date.  However, a chloro-benzene derivative of acetohydroxamic acid caused significant liver dysfunction in an unrelated study.  Therefore, close monitoring of liver function is highly recommended in patients receiving AHA, especially in those with liver impairment.', '2', '"Product Information. Lithostat (acetohydroxamic acid)." Mission Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26336, 266, 'Spironolactone', 'Acidosis', 'Acidosis alters the ratio of extracellular to intracellular potassium and may commonly lead to rapid increases in serum potassium levels.  Conversely, high serum potassium concentrations may potentiate acidosis.  Because of their hyperkalemic effects, therapy with potassium-sparing diuretics should be avoided in patients with metabolic or respiratory acidosis.  These agents should be used cautiously in patients in whom acidosis may occur, such as patients with cardiopulmonary disease, severe respiratory disease, or poorly controlled diabetes.  Acid-base balance and serum potassium levels should be monitored at regular intervals.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Gabow PA, Moore S, Schrier RW "Spironolactone-induced hyperchloremic acidosis in cirrhosis." Ann Intern Med 90 (1979):  338-40|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26337, 268, 'Spironolactone', 'Acidosis', 'Acidosis alters the ratio of extracellular to intracellular potassium and may commonly lead to rapid increases in serum potassium levels.  Conversely, high serum potassium concentrations may potentiate acidosis.  Because of their hyperkalemic effects, therapy with potassium-sparing diuretics should be avoided in patients with metabolic or respiratory acidosis.  These agents should be used cautiously in patients in whom acidosis may occur, such as patients with cardiopulmonary disease, severe respiratory disease, or poorly controlled diabetes.  Acid-base balance and serum potassium levels should be monitored at regular intervals.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Gabow PA, Moore S, Schrier RW "Spironolactone-induced hyperchloremic acidosis in cirrhosis." Ann Intern Med 90 (1979):  338-40|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26338, 10788, 'Spironolactone', 'Acidosis', 'Acidosis alters the ratio of extracellular to intracellular potassium and may commonly lead to rapid increases in serum potassium levels.  Conversely, high serum potassium concentrations may potentiate acidosis.  Because of their hyperkalemic effects, therapy with potassium-sparing diuretics should be avoided in patients with metabolic or respiratory acidosis.  These agents should be used cautiously in patients in whom acidosis may occur, such as patients with cardiopulmonary disease, severe respiratory disease, or poorly controlled diabetes.  Acid-base balance and serum potassium levels should be monitored at regular intervals.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Gabow PA, Moore S, Schrier RW "Spironolactone-induced hyperchloremic acidosis in cirrhosis." Ann Intern Med 90 (1979):  338-40|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26339, 10789, 'Spironolactone', 'Acidosis', 'Acidosis alters the ratio of extracellular to intracellular potassium and may commonly lead to rapid increases in serum potassium levels.  Conversely, high serum potassium concentrations may potentiate acidosis.  Because of their hyperkalemic effects, therapy with potassium-sparing diuretics should be avoided in patients with metabolic or respiratory acidosis.  These agents should be used cautiously in patients in whom acidosis may occur, such as patients with cardiopulmonary disease, severe respiratory disease, or poorly controlled diabetes.  Acid-base balance and serum potassium levels should be monitored at regular intervals.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Gabow PA, Moore S, Schrier RW "Spironolactone-induced hyperchloremic acidosis in cirrhosis." Ann Intern Med 90 (1979):  338-40|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26340, 10816, 'Spironolactone', 'Acidosis', 'Acidosis alters the ratio of extracellular to intracellular potassium and may commonly lead to rapid increases in serum potassium levels.  Conversely, high serum potassium concentrations may potentiate acidosis.  Because of their hyperkalemic effects, therapy with potassium-sparing diuretics should be avoided in patients with metabolic or respiratory acidosis.  These agents should be used cautiously in patients in whom acidosis may occur, such as patients with cardiopulmonary disease, severe respiratory disease, or poorly controlled diabetes.  Acid-base balance and serum potassium levels should be monitored at regular intervals.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Gabow PA, Moore S, Schrier RW "Spironolactone-induced hyperchloremic acidosis in cirrhosis." Ann Intern Med 90 (1979):  338-40|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26341, 10817, 'Spironolactone', 'Acidosis', 'Acidosis alters the ratio of extracellular to intracellular potassium and may commonly lead to rapid increases in serum potassium levels.  Conversely, high serum potassium concentrations may potentiate acidosis.  Because of their hyperkalemic effects, therapy with potassium-sparing diuretics should be avoided in patients with metabolic or respiratory acidosis.  These agents should be used cautiously in patients in whom acidosis may occur, such as patients with cardiopulmonary disease, severe respiratory disease, or poorly controlled diabetes.  Acid-base balance and serum potassium levels should be monitored at regular intervals.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Gabow PA, Moore S, Schrier RW "Spironolactone-induced hyperchloremic acidosis in cirrhosis." Ann Intern Med 90 (1979):  338-40|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26342, 10818, 'Spironolactone', 'Acidosis', 'Acidosis alters the ratio of extracellular to intracellular potassium and may commonly lead to rapid increases in serum potassium levels.  Conversely, high serum potassium concentrations may potentiate acidosis.  Because of their hyperkalemic effects, therapy with potassium-sparing diuretics should be avoided in patients with metabolic or respiratory acidosis.  These agents should be used cautiously in patients in whom acidosis may occur, such as patients with cardiopulmonary disease, severe respiratory disease, or poorly controlled diabetes.  Acid-base balance and serum potassium levels should be monitored at regular intervals.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Gabow PA, Moore S, Schrier RW "Spironolactone-induced hyperchloremic acidosis in cirrhosis." Ann Intern Med 90 (1979):  338-40|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26343, 25078, 'Spironolactone', 'Acidosis', 'Acidosis alters the ratio of extracellular to intracellular potassium and may commonly lead to rapid increases in serum potassium levels.  Conversely, high serum potassium concentrations may potentiate acidosis.  Because of their hyperkalemic effects, therapy with potassium-sparing diuretics should be avoided in patients with metabolic or respiratory acidosis.  These agents should be used cautiously in patients in whom acidosis may occur, such as patients with cardiopulmonary disease, severe respiratory disease, or poorly controlled diabetes.  Acid-base balance and serum potassium levels should be monitored at regular intervals.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Gabow PA, Moore S, Schrier RW "Spironolactone-induced hyperchloremic acidosis in cirrhosis." Ann Intern Med 90 (1979):  338-40|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26344, 25079, 'Spironolactone', 'Acidosis', 'Acidosis alters the ratio of extracellular to intracellular potassium and may commonly lead to rapid increases in serum potassium levels.  Conversely, high serum potassium concentrations may potentiate acidosis.  Because of their hyperkalemic effects, therapy with potassium-sparing diuretics should be avoided in patients with metabolic or respiratory acidosis.  These agents should be used cautiously in patients in whom acidosis may occur, such as patients with cardiopulmonary disease, severe respiratory disease, or poorly controlled diabetes.  Acid-base balance and serum potassium levels should be monitored at regular intervals.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Gabow PA, Moore S, Schrier RW "Spironolactone-induced hyperchloremic acidosis in cirrhosis." Ann Intern Med 90 (1979):  338-40|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26345, 25080, 'Spironolactone', 'Acidosis', 'Acidosis alters the ratio of extracellular to intracellular potassium and may commonly lead to rapid increases in serum potassium levels.  Conversely, high serum potassium concentrations may potentiate acidosis.  Because of their hyperkalemic effects, therapy with potassium-sparing diuretics should be avoided in patients with metabolic or respiratory acidosis.  These agents should be used cautiously in patients in whom acidosis may occur, such as patients with cardiopulmonary disease, severe respiratory disease, or poorly controlled diabetes.  Acid-base balance and serum potassium levels should be monitored at regular intervals.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Gabow PA, Moore S, Schrier RW "Spironolactone-induced hyperchloremic acidosis in cirrhosis." Ann Intern Med 90 (1979):  338-40|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26346, 25081, 'Spironolactone', 'Acidosis', 'Acidosis alters the ratio of extracellular to intracellular potassium and may commonly lead to rapid increases in serum potassium levels.  Conversely, high serum potassium concentrations may potentiate acidosis.  Because of their hyperkalemic effects, therapy with potassium-sparing diuretics should be avoided in patients with metabolic or respiratory acidosis.  These agents should be used cautiously in patients in whom acidosis may occur, such as patients with cardiopulmonary disease, severe respiratory disease, or poorly controlled diabetes.  Acid-base balance and serum potassium levels should be monitored at regular intervals.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Gabow PA, Moore S, Schrier RW "Spironolactone-induced hyperchloremic acidosis in cirrhosis." Ann Intern Med 90 (1979):  338-40|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26347, 266, 'Spironolactone', 'Diabetes Mellitus', 'Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with diabetes mellitus, with or without nephropathy, may be particularly susceptible to the hyperkalemic effect of these drugs due to a defect in the renin-angiotensin-aldosterone axis.  Therapy with potassium-sparing diuretics should be avoided, if possible, in patients with diabetes, especially uncontrolled or insulin-dependent diabetes mellitus.  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Amery A, Berthaux P, Bulpitt C, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F, Hellemans J, Lund-Johansen PMutsers A, Tuomilehto J "Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly." Lancet 1 (1978):  681-3|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26348, 268, 'Spironolactone', 'Diabetes Mellitus', 'Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with diabetes mellitus, with or without nephropathy, may be particularly susceptible to the hyperkalemic effect of these drugs due to a defect in the renin-angiotensin-aldosterone axis.  Therapy with potassium-sparing diuretics should be avoided, if possible, in patients with diabetes, especially uncontrolled or insulin-dependent diabetes mellitus.  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Amery A, Berthaux P, Bulpitt C, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F, Hellemans J, Lund-Johansen PMutsers A, Tuomilehto J "Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly." Lancet 1 (1978):  681-3|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26349, 10788, 'Spironolactone', 'Diabetes Mellitus', 'Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with diabetes mellitus, with or without nephropathy, may be particularly susceptible to the hyperkalemic effect of these drugs due to a defect in the renin-angiotensin-aldosterone axis.  Therapy with potassium-sparing diuretics should be avoided, if possible, in patients with diabetes, especially uncontrolled or insulin-dependent diabetes mellitus.  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Amery A, Berthaux P, Bulpitt C, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F, Hellemans J, Lund-Johansen PMutsers A, Tuomilehto J "Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly." Lancet 1 (1978):  681-3|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26350, 10789, 'Spironolactone', 'Diabetes Mellitus', 'Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with diabetes mellitus, with or without nephropathy, may be particularly susceptible to the hyperkalemic effect of these drugs due to a defect in the renin-angiotensin-aldosterone axis.  Therapy with potassium-sparing diuretics should be avoided, if possible, in patients with diabetes, especially uncontrolled or insulin-dependent diabetes mellitus.  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Amery A, Berthaux P, Bulpitt C, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F, Hellemans J, Lund-Johansen PMutsers A, Tuomilehto J "Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly." Lancet 1 (1978):  681-3|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26351, 10816, 'Spironolactone', 'Diabetes Mellitus', 'Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with diabetes mellitus, with or without nephropathy, may be particularly susceptible to the hyperkalemic effect of these drugs due to a defect in the renin-angiotensin-aldosterone axis.  Therapy with potassium-sparing diuretics should be avoided, if possible, in patients with diabetes, especially uncontrolled or insulin-dependent diabetes mellitus.  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Amery A, Berthaux P, Bulpitt C, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F, Hellemans J, Lund-Johansen PMutsers A, Tuomilehto J "Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly." Lancet 1 (1978):  681-3|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26352, 10817, 'Spironolactone', 'Diabetes Mellitus', 'Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with diabetes mellitus, with or without nephropathy, may be particularly susceptible to the hyperkalemic effect of these drugs due to a defect in the renin-angiotensin-aldosterone axis.  Therapy with potassium-sparing diuretics should be avoided, if possible, in patients with diabetes, especially uncontrolled or insulin-dependent diabetes mellitus.  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Amery A, Berthaux P, Bulpitt C, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F, Hellemans J, Lund-Johansen PMutsers A, Tuomilehto J "Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly." Lancet 1 (1978):  681-3|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26353, 10818, 'Spironolactone', 'Diabetes Mellitus', 'Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with diabetes mellitus, with or without nephropathy, may be particularly susceptible to the hyperkalemic effect of these drugs due to a defect in the renin-angiotensin-aldosterone axis.  Therapy with potassium-sparing diuretics should be avoided, if possible, in patients with diabetes, especially uncontrolled or insulin-dependent diabetes mellitus.  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Amery A, Berthaux P, Bulpitt C, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F, Hellemans J, Lund-Johansen PMutsers A, Tuomilehto J "Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly." Lancet 1 (1978):  681-3|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26354, 25078, 'Spironolactone', 'Diabetes Mellitus', 'Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with diabetes mellitus, with or without nephropathy, may be particularly susceptible to the hyperkalemic effect of these drugs due to a defect in the renin-angiotensin-aldosterone axis.  Therapy with potassium-sparing diuretics should be avoided, if possible, in patients with diabetes, especially uncontrolled or insulin-dependent diabetes mellitus.  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Amery A, Berthaux P, Bulpitt C, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F, Hellemans J, Lund-Johansen PMutsers A, Tuomilehto J "Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly." Lancet 1 (1978):  681-3|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26355, 25079, 'Spironolactone', 'Diabetes Mellitus', 'Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with diabetes mellitus, with or without nephropathy, may be particularly susceptible to the hyperkalemic effect of these drugs due to a defect in the renin-angiotensin-aldosterone axis.  Therapy with potassium-sparing diuretics should be avoided, if possible, in patients with diabetes, especially uncontrolled or insulin-dependent diabetes mellitus.  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Amery A, Berthaux P, Bulpitt C, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F, Hellemans J, Lund-Johansen PMutsers A, Tuomilehto J "Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly." Lancet 1 (1978):  681-3|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26356, 25080, 'Spironolactone', 'Diabetes Mellitus', 'Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with diabetes mellitus, with or without nephropathy, may be particularly susceptible to the hyperkalemic effect of these drugs due to a defect in the renin-angiotensin-aldosterone axis.  Therapy with potassium-sparing diuretics should be avoided, if possible, in patients with diabetes, especially uncontrolled or insulin-dependent diabetes mellitus.  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Amery A, Berthaux P, Bulpitt C, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F, Hellemans J, Lund-Johansen PMutsers A, Tuomilehto J "Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly." Lancet 1 (1978):  681-3|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26357, 25081, 'Spironolactone', 'Diabetes Mellitus', 'Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with diabetes mellitus, with or without nephropathy, may be particularly susceptible to the hyperkalemic effect of these drugs due to a defect in the renin-angiotensin-aldosterone axis.  Therapy with potassium-sparing diuretics should be avoided, if possible, in patients with diabetes, especially uncontrolled or insulin-dependent diabetes mellitus.  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Amery A, Berthaux P, Bulpitt C, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F, Hellemans J, Lund-Johansen PMutsers A, Tuomilehto J "Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly." Lancet 1 (1978):  681-3|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26358, 266, 'Spironolactone', 'Water-Electrolyte Imbalance', 'All diuretics may cause or aggravate fluid and electrolyte disturbances.  Potassium-sparing diuretics may cause hyperkalemia and, infrequently, hyponatremia.  The latter generally occurs when these agents are combined with other diuretics such as thiazides or used in markedly edematous patients with restricted sodium intake.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with or predisposed to electrolyte abnormalities.  Electrolyte imbalances should be corrected prior to initiating therapy, and serum electrolyte concentrations should be monitored periodically and maintained at normal ranges during therapy.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Tarssanen L, Huikko M, Rossi M "Amiloride-induced hyponatremia." Acta Med Scand 208 (1980):  491-4|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Roberts CJ, Channer KS, Bungay D "Hyponatraemia induced by a combination of hydrochlorothiazide and triamterene." Br Med J (Clin Res Ed) 288 (1984):  1962|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Hirschl MM, Seidler D, Laggner AN "Spironolactone-associated hyponatremic coma." Nephron 67 (1994):  503', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26359, 268, 'Spironolactone', 'Water-Electrolyte Imbalance', 'All diuretics may cause or aggravate fluid and electrolyte disturbances.  Potassium-sparing diuretics may cause hyperkalemia and, infrequently, hyponatremia.  The latter generally occurs when these agents are combined with other diuretics such as thiazides or used in markedly edematous patients with restricted sodium intake.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with or predisposed to electrolyte abnormalities.  Electrolyte imbalances should be corrected prior to initiating therapy, and serum electrolyte concentrations should be monitored periodically and maintained at normal ranges during therapy.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Tarssanen L, Huikko M, Rossi M "Amiloride-induced hyponatremia." Acta Med Scand 208 (1980):  491-4|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Roberts CJ, Channer KS, Bungay D "Hyponatraemia induced by a combination of hydrochlorothiazide and triamterene." Br Med J (Clin Res Ed) 288 (1984):  1962|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Hirschl MM, Seidler D, Laggner AN "Spironolactone-associated hyponatremic coma." Nephron 67 (1994):  503', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26360, 10788, 'Spironolactone', 'Water-Electrolyte Imbalance', 'All diuretics may cause or aggravate fluid and electrolyte disturbances.  Potassium-sparing diuretics may cause hyperkalemia and, infrequently, hyponatremia.  The latter generally occurs when these agents are combined with other diuretics such as thiazides or used in markedly edematous patients with restricted sodium intake.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with or predisposed to electrolyte abnormalities.  Electrolyte imbalances should be corrected prior to initiating therapy, and serum electrolyte concentrations should be monitored periodically and maintained at normal ranges during therapy.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Tarssanen L, Huikko M, Rossi M "Amiloride-induced hyponatremia." Acta Med Scand 208 (1980):  491-4|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Roberts CJ, Channer KS, Bungay D "Hyponatraemia induced by a combination of hydrochlorothiazide and triamterene." Br Med J (Clin Res Ed) 288 (1984):  1962|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Hirschl MM, Seidler D, Laggner AN "Spironolactone-associated hyponatremic coma." Nephron 67 (1994):  503', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26361, 10789, 'Spironolactone', 'Water-Electrolyte Imbalance', 'All diuretics may cause or aggravate fluid and electrolyte disturbances.  Potassium-sparing diuretics may cause hyperkalemia and, infrequently, hyponatremia.  The latter generally occurs when these agents are combined with other diuretics such as thiazides or used in markedly edematous patients with restricted sodium intake.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with or predisposed to electrolyte abnormalities.  Electrolyte imbalances should be corrected prior to initiating therapy, and serum electrolyte concentrations should be monitored periodically and maintained at normal ranges during therapy.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Tarssanen L, Huikko M, Rossi M "Amiloride-induced hyponatremia." Acta Med Scand 208 (1980):  491-4|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Roberts CJ, Channer KS, Bungay D "Hyponatraemia induced by a combination of hydrochlorothiazide and triamterene." Br Med J (Clin Res Ed) 288 (1984):  1962|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Hirschl MM, Seidler D, Laggner AN "Spironolactone-associated hyponatremic coma." Nephron 67 (1994):  503', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26362, 10816, 'Spironolactone', 'Water-Electrolyte Imbalance', 'All diuretics may cause or aggravate fluid and electrolyte disturbances.  Potassium-sparing diuretics may cause hyperkalemia and, infrequently, hyponatremia.  The latter generally occurs when these agents are combined with other diuretics such as thiazides or used in markedly edematous patients with restricted sodium intake.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with or predisposed to electrolyte abnormalities.  Electrolyte imbalances should be corrected prior to initiating therapy, and serum electrolyte concentrations should be monitored periodically and maintained at normal ranges during therapy.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Tarssanen L, Huikko M, Rossi M "Amiloride-induced hyponatremia." Acta Med Scand 208 (1980):  491-4|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Roberts CJ, Channer KS, Bungay D "Hyponatraemia induced by a combination of hydrochlorothiazide and triamterene." Br Med J (Clin Res Ed) 288 (1984):  1962|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Hirschl MM, Seidler D, Laggner AN "Spironolactone-associated hyponatremic coma." Nephron 67 (1994):  503', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26363, 10817, 'Spironolactone', 'Water-Electrolyte Imbalance', 'All diuretics may cause or aggravate fluid and electrolyte disturbances.  Potassium-sparing diuretics may cause hyperkalemia and, infrequently, hyponatremia.  The latter generally occurs when these agents are combined with other diuretics such as thiazides or used in markedly edematous patients with restricted sodium intake.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with or predisposed to electrolyte abnormalities.  Electrolyte imbalances should be corrected prior to initiating therapy, and serum electrolyte concentrations should be monitored periodically and maintained at normal ranges during therapy.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Tarssanen L, Huikko M, Rossi M "Amiloride-induced hyponatremia." Acta Med Scand 208 (1980):  491-4|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Roberts CJ, Channer KS, Bungay D "Hyponatraemia induced by a combination of hydrochlorothiazide and triamterene." Br Med J (Clin Res Ed) 288 (1984):  1962|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Hirschl MM, Seidler D, Laggner AN "Spironolactone-associated hyponatremic coma." Nephron 67 (1994):  503', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26364, 10818, 'Spironolactone', 'Water-Electrolyte Imbalance', 'All diuretics may cause or aggravate fluid and electrolyte disturbances.  Potassium-sparing diuretics may cause hyperkalemia and, infrequently, hyponatremia.  The latter generally occurs when these agents are combined with other diuretics such as thiazides or used in markedly edematous patients with restricted sodium intake.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with or predisposed to electrolyte abnormalities.  Electrolyte imbalances should be corrected prior to initiating therapy, and serum electrolyte concentrations should be monitored periodically and maintained at normal ranges during therapy.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Tarssanen L, Huikko M, Rossi M "Amiloride-induced hyponatremia." Acta Med Scand 208 (1980):  491-4|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Roberts CJ, Channer KS, Bungay D "Hyponatraemia induced by a combination of hydrochlorothiazide and triamterene." Br Med J (Clin Res Ed) 288 (1984):  1962|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Hirschl MM, Seidler D, Laggner AN "Spironolactone-associated hyponatremic coma." Nephron 67 (1994):  503', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26365, 25078, 'Spironolactone', 'Water-Electrolyte Imbalance', 'All diuretics may cause or aggravate fluid and electrolyte disturbances.  Potassium-sparing diuretics may cause hyperkalemia and, infrequently, hyponatremia.  The latter generally occurs when these agents are combined with other diuretics such as thiazides or used in markedly edematous patients with restricted sodium intake.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with or predisposed to electrolyte abnormalities.  Electrolyte imbalances should be corrected prior to initiating therapy, and serum electrolyte concentrations should be monitored periodically and maintained at normal ranges during therapy.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Tarssanen L, Huikko M, Rossi M "Amiloride-induced hyponatremia." Acta Med Scand 208 (1980):  491-4|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Roberts CJ, Channer KS, Bungay D "Hyponatraemia induced by a combination of hydrochlorothiazide and triamterene." Br Med J (Clin Res Ed) 288 (1984):  1962|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Hirschl MM, Seidler D, Laggner AN "Spironolactone-associated hyponatremic coma." Nephron 67 (1994):  503', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26366, 25079, 'Spironolactone', 'Water-Electrolyte Imbalance', 'All diuretics may cause or aggravate fluid and electrolyte disturbances.  Potassium-sparing diuretics may cause hyperkalemia and, infrequently, hyponatremia.  The latter generally occurs when these agents are combined with other diuretics such as thiazides or used in markedly edematous patients with restricted sodium intake.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with or predisposed to electrolyte abnormalities.  Electrolyte imbalances should be corrected prior to initiating therapy, and serum electrolyte concentrations should be monitored periodically and maintained at normal ranges during therapy.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Tarssanen L, Huikko M, Rossi M "Amiloride-induced hyponatremia." Acta Med Scand 208 (1980):  491-4|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Roberts CJ, Channer KS, Bungay D "Hyponatraemia induced by a combination of hydrochlorothiazide and triamterene." Br Med J (Clin Res Ed) 288 (1984):  1962|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Hirschl MM, Seidler D, Laggner AN "Spironolactone-associated hyponatremic coma." Nephron 67 (1994):  503', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26367, 25080, 'Spironolactone', 'Water-Electrolyte Imbalance', 'All diuretics may cause or aggravate fluid and electrolyte disturbances.  Potassium-sparing diuretics may cause hyperkalemia and, infrequently, hyponatremia.  The latter generally occurs when these agents are combined with other diuretics such as thiazides or used in markedly edematous patients with restricted sodium intake.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with or predisposed to electrolyte abnormalities.  Electrolyte imbalances should be corrected prior to initiating therapy, and serum electrolyte concentrations should be monitored periodically and maintained at normal ranges during therapy.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Tarssanen L, Huikko M, Rossi M "Amiloride-induced hyponatremia." Acta Med Scand 208 (1980):  491-4|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Roberts CJ, Channer KS, Bungay D "Hyponatraemia induced by a combination of hydrochlorothiazide and triamterene." Br Med J (Clin Res Ed) 288 (1984):  1962|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Hirschl MM, Seidler D, Laggner AN "Spironolactone-associated hyponatremic coma." Nephron 67 (1994):  503', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26368, 25081, 'Spironolactone', 'Water-Electrolyte Imbalance', 'All diuretics may cause or aggravate fluid and electrolyte disturbances.  Potassium-sparing diuretics may cause hyperkalemia and, infrequently, hyponatremia.  The latter generally occurs when these agents are combined with other diuretics such as thiazides or used in markedly edematous patients with restricted sodium intake.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with or predisposed to electrolyte abnormalities.  Electrolyte imbalances should be corrected prior to initiating therapy, and serum electrolyte concentrations should be monitored periodically and maintained at normal ranges during therapy.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Tarssanen L, Huikko M, Rossi M "Amiloride-induced hyponatremia." Acta Med Scand 208 (1980):  491-4|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Roberts CJ, Channer KS, Bungay D "Hyponatraemia induced by a combination of hydrochlorothiazide and triamterene." Br Med J (Clin Res Ed) 288 (1984):  1962|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Hirschl MM, Seidler D, Laggner AN "Spironolactone-associated hyponatremic coma." Nephron 67 (1994):  503', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26369, 266, 'Spironolactone', 'Hyperkalemia', 'The use of potassium-sparing diuretics is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in all patients treated with potassium-sparing diuretics, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  The diuretic should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.  The combined use of a potassium-sparing diuretic with a kaliuretic diuretic (e.g., thiazides) may decrease the risk of hyperkalemia.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006):  49-58', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26370, 268, 'Spironolactone', 'Hyperkalemia', 'The use of potassium-sparing diuretics is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in all patients treated with potassium-sparing diuretics, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  The diuretic should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.  The combined use of a potassium-sparing diuretic with a kaliuretic diuretic (e.g., thiazides) may decrease the risk of hyperkalemia.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006):  49-58', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26371, 10788, 'Spironolactone', 'Hyperkalemia', 'The use of potassium-sparing diuretics is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in all patients treated with potassium-sparing diuretics, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  The diuretic should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.  The combined use of a potassium-sparing diuretic with a kaliuretic diuretic (e.g., thiazides) may decrease the risk of hyperkalemia.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006):  49-58', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26372, 10789, 'Spironolactone', 'Hyperkalemia', 'The use of potassium-sparing diuretics is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in all patients treated with potassium-sparing diuretics, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  The diuretic should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.  The combined use of a potassium-sparing diuretic with a kaliuretic diuretic (e.g., thiazides) may decrease the risk of hyperkalemia.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006):  49-58', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26373, 10816, 'Spironolactone', 'Hyperkalemia', 'The use of potassium-sparing diuretics is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in all patients treated with potassium-sparing diuretics, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  The diuretic should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.  The combined use of a potassium-sparing diuretic with a kaliuretic diuretic (e.g., thiazides) may decrease the risk of hyperkalemia.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006):  49-58', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26374, 10817, 'Spironolactone', 'Hyperkalemia', 'The use of potassium-sparing diuretics is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in all patients treated with potassium-sparing diuretics, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  The diuretic should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.  The combined use of a potassium-sparing diuretic with a kaliuretic diuretic (e.g., thiazides) may decrease the risk of hyperkalemia.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006):  49-58', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26375, 10818, 'Spironolactone', 'Hyperkalemia', 'The use of potassium-sparing diuretics is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in all patients treated with potassium-sparing diuretics, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  The diuretic should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.  The combined use of a potassium-sparing diuretic with a kaliuretic diuretic (e.g., thiazides) may decrease the risk of hyperkalemia.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006):  49-58', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26376, 25078, 'Spironolactone', 'Hyperkalemia', 'The use of potassium-sparing diuretics is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in all patients treated with potassium-sparing diuretics, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  The diuretic should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.  The combined use of a potassium-sparing diuretic with a kaliuretic diuretic (e.g., thiazides) may decrease the risk of hyperkalemia.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006):  49-58', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26377, 25079, 'Spironolactone', 'Hyperkalemia', 'The use of potassium-sparing diuretics is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in all patients treated with potassium-sparing diuretics, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  The diuretic should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.  The combined use of a potassium-sparing diuretic with a kaliuretic diuretic (e.g., thiazides) may decrease the risk of hyperkalemia.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006):  49-58', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26378, 25080, 'Spironolactone', 'Hyperkalemia', 'The use of potassium-sparing diuretics is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in all patients treated with potassium-sparing diuretics, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  The diuretic should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.  The combined use of a potassium-sparing diuretic with a kaliuretic diuretic (e.g., thiazides) may decrease the risk of hyperkalemia.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006):  49-58', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26379, 25081, 'Spironolactone', 'Hyperkalemia', 'The use of potassium-sparing diuretics is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in all patients treated with potassium-sparing diuretics, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  The diuretic should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.  The combined use of a potassium-sparing diuretic with a kaliuretic diuretic (e.g., thiazides) may decrease the risk of hyperkalemia.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006):  49-58', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26380, 266, 'Spironolactone', 'Liver Diseases', 'Rapid alterations in fluid and electrolyte balance may precipitate hepatic coma in patients with liver disease.  Hepatic encephalopathy has been associated with the use of diuretics, most frequently thiazides but also some potassium-sparing diuretics.  Therapy with all diuretics should be administered cautiously in patients with severely impaired hepatic function.  These patients should be monitored carefully for signs and symptoms of hepatic encephalopathy such as tremors, confusion, increased jaundice, and coma.  Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment.', '3', 'Karim A, Zagarella J, Hribar J, Dooley M "Spironolactone I: disposition and metabolism." Clin Pharmacol Ther 19 (1976):  158-69|Sadee W, Schroder R, Leitner E, Dagcioglu M "Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure." Eur J Clin Pharmacol 7 (1974):  195-200|Villeneuve JP, Rocheleau F, Raymond G "Triamterene kinetics and dynamics in cirrhosis." Clin Pharmacol Ther 35 (1984):  831-7|Mutschler E, Gilfrich HJ, Knauf H, Mohrke W, Volger KD "Pharmacokinetics of triamterene." Clin Exp Hypertens A 5 (1983):  249-69|Dao MT, Villeneuve JP "Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis." Clin Invest Med 11 (1988):  6-9|Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E "Spironolactone pharmacokinetics and pharmacodynamics in patis with cirrhotic ascites." Gastroenterology 102 (1992):  1680-5|Abshagen U, Rennekamp H, Luszpinski G "Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment." Eur J Clin Pharmacol 11 (1977):  169-76|Overdiek HW, Merkus FW "The metabolism and biopharmaceutics of spironolactone in man." Rev Drug Metab Drug Interact 5 (1987):  273-302|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Renkes P, Gaucher P, Trechot P "Spironolactone and hepatic toxicity." JAMA 273 (1995):  376-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26381, 268, 'Spironolactone', 'Liver Diseases', 'Rapid alterations in fluid and electrolyte balance may precipitate hepatic coma in patients with liver disease.  Hepatic encephalopathy has been associated with the use of diuretics, most frequently thiazides but also some potassium-sparing diuretics.  Therapy with all diuretics should be administered cautiously in patients with severely impaired hepatic function.  These patients should be monitored carefully for signs and symptoms of hepatic encephalopathy such as tremors, confusion, increased jaundice, and coma.  Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment.', '3', 'Karim A, Zagarella J, Hribar J, Dooley M "Spironolactone I: disposition and metabolism." Clin Pharmacol Ther 19 (1976):  158-69|Sadee W, Schroder R, Leitner E, Dagcioglu M "Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure." Eur J Clin Pharmacol 7 (1974):  195-200|Villeneuve JP, Rocheleau F, Raymond G "Triamterene kinetics and dynamics in cirrhosis." Clin Pharmacol Ther 35 (1984):  831-7|Mutschler E, Gilfrich HJ, Knauf H, Mohrke W, Volger KD "Pharmacokinetics of triamterene." Clin Exp Hypertens A 5 (1983):  249-69|Dao MT, Villeneuve JP "Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis." Clin Invest Med 11 (1988):  6-9|Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E "Spironolactone pharmacokinetics and pharmacodynamics in patis with cirrhotic ascites." Gastroenterology 102 (1992):  1680-5|Abshagen U, Rennekamp H, Luszpinski G "Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment." Eur J Clin Pharmacol 11 (1977):  169-76|Overdiek HW, Merkus FW "The metabolism and biopharmaceutics of spironolactone in man." Rev Drug Metab Drug Interact 5 (1987):  273-302|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Renkes P, Gaucher P, Trechot P "Spironolactone and hepatic toxicity." JAMA 273 (1995):  376-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26382, 10788, 'Spironolactone', 'Liver Diseases', 'Rapid alterations in fluid and electrolyte balance may precipitate hepatic coma in patients with liver disease.  Hepatic encephalopathy has been associated with the use of diuretics, most frequently thiazides but also some potassium-sparing diuretics.  Therapy with all diuretics should be administered cautiously in patients with severely impaired hepatic function.  These patients should be monitored carefully for signs and symptoms of hepatic encephalopathy such as tremors, confusion, increased jaundice, and coma.  Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment.', '3', 'Karim A, Zagarella J, Hribar J, Dooley M "Spironolactone I: disposition and metabolism." Clin Pharmacol Ther 19 (1976):  158-69|Sadee W, Schroder R, Leitner E, Dagcioglu M "Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure." Eur J Clin Pharmacol 7 (1974):  195-200|Villeneuve JP, Rocheleau F, Raymond G "Triamterene kinetics and dynamics in cirrhosis." Clin Pharmacol Ther 35 (1984):  831-7|Mutschler E, Gilfrich HJ, Knauf H, Mohrke W, Volger KD "Pharmacokinetics of triamterene." Clin Exp Hypertens A 5 (1983):  249-69|Dao MT, Villeneuve JP "Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis." Clin Invest Med 11 (1988):  6-9|Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E "Spironolactone pharmacokinetics and pharmacodynamics in patis with cirrhotic ascites." Gastroenterology 102 (1992):  1680-5|Abshagen U, Rennekamp H, Luszpinski G "Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment." Eur J Clin Pharmacol 11 (1977):  169-76|Overdiek HW, Merkus FW "The metabolism and biopharmaceutics of spironolactone in man." Rev Drug Metab Drug Interact 5 (1987):  273-302|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Renkes P, Gaucher P, Trechot P "Spironolactone and hepatic toxicity." JAMA 273 (1995):  376-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26383, 10789, 'Spironolactone', 'Liver Diseases', 'Rapid alterations in fluid and electrolyte balance may precipitate hepatic coma in patients with liver disease.  Hepatic encephalopathy has been associated with the use of diuretics, most frequently thiazides but also some potassium-sparing diuretics.  Therapy with all diuretics should be administered cautiously in patients with severely impaired hepatic function.  These patients should be monitored carefully for signs and symptoms of hepatic encephalopathy such as tremors, confusion, increased jaundice, and coma.  Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment.', '3', 'Karim A, Zagarella J, Hribar J, Dooley M "Spironolactone I: disposition and metabolism." Clin Pharmacol Ther 19 (1976):  158-69|Sadee W, Schroder R, Leitner E, Dagcioglu M "Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure." Eur J Clin Pharmacol 7 (1974):  195-200|Villeneuve JP, Rocheleau F, Raymond G "Triamterene kinetics and dynamics in cirrhosis." Clin Pharmacol Ther 35 (1984):  831-7|Mutschler E, Gilfrich HJ, Knauf H, Mohrke W, Volger KD "Pharmacokinetics of triamterene." Clin Exp Hypertens A 5 (1983):  249-69|Dao MT, Villeneuve JP "Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis." Clin Invest Med 11 (1988):  6-9|Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E "Spironolactone pharmacokinetics and pharmacodynamics in patis with cirrhotic ascites." Gastroenterology 102 (1992):  1680-5|Abshagen U, Rennekamp H, Luszpinski G "Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment." Eur J Clin Pharmacol 11 (1977):  169-76|Overdiek HW, Merkus FW "The metabolism and biopharmaceutics of spironolactone in man." Rev Drug Metab Drug Interact 5 (1987):  273-302|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Renkes P, Gaucher P, Trechot P "Spironolactone and hepatic toxicity." JAMA 273 (1995):  376-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26384, 10816, 'Spironolactone', 'Liver Diseases', 'Rapid alterations in fluid and electrolyte balance may precipitate hepatic coma in patients with liver disease.  Hepatic encephalopathy has been associated with the use of diuretics, most frequently thiazides but also some potassium-sparing diuretics.  Therapy with all diuretics should be administered cautiously in patients with severely impaired hepatic function.  These patients should be monitored carefully for signs and symptoms of hepatic encephalopathy such as tremors, confusion, increased jaundice, and coma.  Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment.', '3', 'Karim A, Zagarella J, Hribar J, Dooley M "Spironolactone I: disposition and metabolism." Clin Pharmacol Ther 19 (1976):  158-69|Sadee W, Schroder R, Leitner E, Dagcioglu M "Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure." Eur J Clin Pharmacol 7 (1974):  195-200|Villeneuve JP, Rocheleau F, Raymond G "Triamterene kinetics and dynamics in cirrhosis." Clin Pharmacol Ther 35 (1984):  831-7|Mutschler E, Gilfrich HJ, Knauf H, Mohrke W, Volger KD "Pharmacokinetics of triamterene." Clin Exp Hypertens A 5 (1983):  249-69|Dao MT, Villeneuve JP "Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis." Clin Invest Med 11 (1988):  6-9|Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E "Spironolactone pharmacokinetics and pharmacodynamics in patis with cirrhotic ascites." Gastroenterology 102 (1992):  1680-5|Abshagen U, Rennekamp H, Luszpinski G "Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment." Eur J Clin Pharmacol 11 (1977):  169-76|Overdiek HW, Merkus FW "The metabolism and biopharmaceutics of spironolactone in man." Rev Drug Metab Drug Interact 5 (1987):  273-302|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Renkes P, Gaucher P, Trechot P "Spironolactone and hepatic toxicity." JAMA 273 (1995):  376-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26385, 10817, 'Spironolactone', 'Liver Diseases', 'Rapid alterations in fluid and electrolyte balance may precipitate hepatic coma in patients with liver disease.  Hepatic encephalopathy has been associated with the use of diuretics, most frequently thiazides but also some potassium-sparing diuretics.  Therapy with all diuretics should be administered cautiously in patients with severely impaired hepatic function.  These patients should be monitored carefully for signs and symptoms of hepatic encephalopathy such as tremors, confusion, increased jaundice, and coma.  Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment.', '3', 'Karim A, Zagarella J, Hribar J, Dooley M "Spironolactone I: disposition and metabolism." Clin Pharmacol Ther 19 (1976):  158-69|Sadee W, Schroder R, Leitner E, Dagcioglu M "Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure." Eur J Clin Pharmacol 7 (1974):  195-200|Villeneuve JP, Rocheleau F, Raymond G "Triamterene kinetics and dynamics in cirrhosis." Clin Pharmacol Ther 35 (1984):  831-7|Mutschler E, Gilfrich HJ, Knauf H, Mohrke W, Volger KD "Pharmacokinetics of triamterene." Clin Exp Hypertens A 5 (1983):  249-69|Dao MT, Villeneuve JP "Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis." Clin Invest Med 11 (1988):  6-9|Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E "Spironolactone pharmacokinetics and pharmacodynamics in patis with cirrhotic ascites." Gastroenterology 102 (1992):  1680-5|Abshagen U, Rennekamp H, Luszpinski G "Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment." Eur J Clin Pharmacol 11 (1977):  169-76|Overdiek HW, Merkus FW "The metabolism and biopharmaceutics of spironolactone in man." Rev Drug Metab Drug Interact 5 (1987):  273-302|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Renkes P, Gaucher P, Trechot P "Spironolactone and hepatic toxicity." JAMA 273 (1995):  376-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26386, 10818, 'Spironolactone', 'Liver Diseases', 'Rapid alterations in fluid and electrolyte balance may precipitate hepatic coma in patients with liver disease.  Hepatic encephalopathy has been associated with the use of diuretics, most frequently thiazides but also some potassium-sparing diuretics.  Therapy with all diuretics should be administered cautiously in patients with severely impaired hepatic function.  These patients should be monitored carefully for signs and symptoms of hepatic encephalopathy such as tremors, confusion, increased jaundice, and coma.  Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment.', '3', 'Karim A, Zagarella J, Hribar J, Dooley M "Spironolactone I: disposition and metabolism." Clin Pharmacol Ther 19 (1976):  158-69|Sadee W, Schroder R, Leitner E, Dagcioglu M "Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure." Eur J Clin Pharmacol 7 (1974):  195-200|Villeneuve JP, Rocheleau F, Raymond G "Triamterene kinetics and dynamics in cirrhosis." Clin Pharmacol Ther 35 (1984):  831-7|Mutschler E, Gilfrich HJ, Knauf H, Mohrke W, Volger KD "Pharmacokinetics of triamterene." Clin Exp Hypertens A 5 (1983):  249-69|Dao MT, Villeneuve JP "Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis." Clin Invest Med 11 (1988):  6-9|Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E "Spironolactone pharmacokinetics and pharmacodynamics in patis with cirrhotic ascites." Gastroenterology 102 (1992):  1680-5|Abshagen U, Rennekamp H, Luszpinski G "Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment." Eur J Clin Pharmacol 11 (1977):  169-76|Overdiek HW, Merkus FW "The metabolism and biopharmaceutics of spironolactone in man." Rev Drug Metab Drug Interact 5 (1987):  273-302|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Renkes P, Gaucher P, Trechot P "Spironolactone and hepatic toxicity." JAMA 273 (1995):  376-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26387, 25078, 'Spironolactone', 'Liver Diseases', 'Rapid alterations in fluid and electrolyte balance may precipitate hepatic coma in patients with liver disease.  Hepatic encephalopathy has been associated with the use of diuretics, most frequently thiazides but also some potassium-sparing diuretics.  Therapy with all diuretics should be administered cautiously in patients with severely impaired hepatic function.  These patients should be monitored carefully for signs and symptoms of hepatic encephalopathy such as tremors, confusion, increased jaundice, and coma.  Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment.', '3', 'Karim A, Zagarella J, Hribar J, Dooley M "Spironolactone I: disposition and metabolism." Clin Pharmacol Ther 19 (1976):  158-69|Sadee W, Schroder R, Leitner E, Dagcioglu M "Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure." Eur J Clin Pharmacol 7 (1974):  195-200|Villeneuve JP, Rocheleau F, Raymond G "Triamterene kinetics and dynamics in cirrhosis." Clin Pharmacol Ther 35 (1984):  831-7|Mutschler E, Gilfrich HJ, Knauf H, Mohrke W, Volger KD "Pharmacokinetics of triamterene." Clin Exp Hypertens A 5 (1983):  249-69|Dao MT, Villeneuve JP "Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis." Clin Invest Med 11 (1988):  6-9|Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E "Spironolactone pharmacokinetics and pharmacodynamics in patis with cirrhotic ascites." Gastroenterology 102 (1992):  1680-5|Abshagen U, Rennekamp H, Luszpinski G "Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment." Eur J Clin Pharmacol 11 (1977):  169-76|Overdiek HW, Merkus FW "The metabolism and biopharmaceutics of spironolactone in man." Rev Drug Metab Drug Interact 5 (1987):  273-302|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Renkes P, Gaucher P, Trechot P "Spironolactone and hepatic toxicity." JAMA 273 (1995):  376-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26388, 25079, 'Spironolactone', 'Liver Diseases', 'Rapid alterations in fluid and electrolyte balance may precipitate hepatic coma in patients with liver disease.  Hepatic encephalopathy has been associated with the use of diuretics, most frequently thiazides but also some potassium-sparing diuretics.  Therapy with all diuretics should be administered cautiously in patients with severely impaired hepatic function.  These patients should be monitored carefully for signs and symptoms of hepatic encephalopathy such as tremors, confusion, increased jaundice, and coma.  Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment.', '3', 'Karim A, Zagarella J, Hribar J, Dooley M "Spironolactone I: disposition and metabolism." Clin Pharmacol Ther 19 (1976):  158-69|Sadee W, Schroder R, Leitner E, Dagcioglu M "Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure." Eur J Clin Pharmacol 7 (1974):  195-200|Villeneuve JP, Rocheleau F, Raymond G "Triamterene kinetics and dynamics in cirrhosis." Clin Pharmacol Ther 35 (1984):  831-7|Mutschler E, Gilfrich HJ, Knauf H, Mohrke W, Volger KD "Pharmacokinetics of triamterene." Clin Exp Hypertens A 5 (1983):  249-69|Dao MT, Villeneuve JP "Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis." Clin Invest Med 11 (1988):  6-9|Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E "Spironolactone pharmacokinetics and pharmacodynamics in patis with cirrhotic ascites." Gastroenterology 102 (1992):  1680-5|Abshagen U, Rennekamp H, Luszpinski G "Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment." Eur J Clin Pharmacol 11 (1977):  169-76|Overdiek HW, Merkus FW "The metabolism and biopharmaceutics of spironolactone in man." Rev Drug Metab Drug Interact 5 (1987):  273-302|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Renkes P, Gaucher P, Trechot P "Spironolactone and hepatic toxicity." JAMA 273 (1995):  376-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26389, 25080, 'Spironolactone', 'Liver Diseases', 'Rapid alterations in fluid and electrolyte balance may precipitate hepatic coma in patients with liver disease.  Hepatic encephalopathy has been associated with the use of diuretics, most frequently thiazides but also some potassium-sparing diuretics.  Therapy with all diuretics should be administered cautiously in patients with severely impaired hepatic function.  These patients should be monitored carefully for signs and symptoms of hepatic encephalopathy such as tremors, confusion, increased jaundice, and coma.  Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment.', '3', 'Karim A, Zagarella J, Hribar J, Dooley M "Spironolactone I: disposition and metabolism." Clin Pharmacol Ther 19 (1976):  158-69|Sadee W, Schroder R, Leitner E, Dagcioglu M "Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure." Eur J Clin Pharmacol 7 (1974):  195-200|Villeneuve JP, Rocheleau F, Raymond G "Triamterene kinetics and dynamics in cirrhosis." Clin Pharmacol Ther 35 (1984):  831-7|Mutschler E, Gilfrich HJ, Knauf H, Mohrke W, Volger KD "Pharmacokinetics of triamterene." Clin Exp Hypertens A 5 (1983):  249-69|Dao MT, Villeneuve JP "Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis." Clin Invest Med 11 (1988):  6-9|Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E "Spironolactone pharmacokinetics and pharmacodynamics in patis with cirrhotic ascites." Gastroenterology 102 (1992):  1680-5|Abshagen U, Rennekamp H, Luszpinski G "Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment." Eur J Clin Pharmacol 11 (1977):  169-76|Overdiek HW, Merkus FW "The metabolism and biopharmaceutics of spironolactone in man." Rev Drug Metab Drug Interact 5 (1987):  273-302|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Renkes P, Gaucher P, Trechot P "Spironolactone and hepatic toxicity." JAMA 273 (1995):  376-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26390, 25081, 'Spironolactone', 'Liver Diseases', 'Rapid alterations in fluid and electrolyte balance may precipitate hepatic coma in patients with liver disease.  Hepatic encephalopathy has been associated with the use of diuretics, most frequently thiazides but also some potassium-sparing diuretics.  Therapy with all diuretics should be administered cautiously in patients with severely impaired hepatic function.  These patients should be monitored carefully for signs and symptoms of hepatic encephalopathy such as tremors, confusion, increased jaundice, and coma.  Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment.', '3', 'Karim A, Zagarella J, Hribar J, Dooley M "Spironolactone I: disposition and metabolism." Clin Pharmacol Ther 19 (1976):  158-69|Sadee W, Schroder R, Leitner E, Dagcioglu M "Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure." Eur J Clin Pharmacol 7 (1974):  195-200|Villeneuve JP, Rocheleau F, Raymond G "Triamterene kinetics and dynamics in cirrhosis." Clin Pharmacol Ther 35 (1984):  831-7|Mutschler E, Gilfrich HJ, Knauf H, Mohrke W, Volger KD "Pharmacokinetics of triamterene." Clin Exp Hypertens A 5 (1983):  249-69|Dao MT, Villeneuve JP "Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis." Clin Invest Med 11 (1988):  6-9|Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E "Spironolactone pharmacokinetics and pharmacodynamics in patis with cirrhotic ascites." Gastroenterology 102 (1992):  1680-5|Abshagen U, Rennekamp H, Luszpinski G "Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment." Eur J Clin Pharmacol 11 (1977):  169-76|Overdiek HW, Merkus FW "The metabolism and biopharmaceutics of spironolactone in man." Rev Drug Metab Drug Interact 5 (1987):  273-302|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Renkes P, Gaucher P, Trechot P "Spironolactone and hepatic toxicity." JAMA 273 (1995):  376-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26391, 266, 'Spironolactone', 'Kidney Diseases', 'The use of potassium-sparing diuretics is contraindicated in patients with anuria, acute or progressive renal insufficiency, or diabetic nephropathy.  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with impaired renal function may be particularly susceptible to the hyperkalemic effect of these drugs.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with evidence of renal function impairment (BUN > 30 mg/dL or serum creatinine > 1.5 mg/dL).  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|Lynn KL, Bailey RR, Swainson CP, Sainsbury R, Low WI "Renal failure with potassium-sparing diuretics." N Z Med J 98 (1985):  629-33|George CF "Amiloride handling in renal failure." Br J Clin Pharmacol 9 (1980):  94-5|Somogyi A, Hewson D, Muirhead M, Bochner F "Amiloride disposition in geriatric patients: importance of renal function." Br J Clin Pharmacol 29 (1990):  1-8|Knauf H, Reuter K, Mutschler E "Limitation on the use of amiloride in early renal failure." Eur J Clin Pharmacol 28 (1985):  61-6|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|"Triamterene and the kidney." Lancet 1 (1986):  424|Roy LF, Villeneuve JP, Dumont A, Dufresne LR, Duran MA, Morin C, Jobin J "Irreversible renal failure associated with triamterene." Am J Nephrol 11 (1991):  486-8|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Neale TJ, Lynn KL, Bailey RR "Spironolactone-associated aggravation of renal functional impairment." N Z Med J 83 (1976):  147-9|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26392, 268, 'Spironolactone', 'Kidney Diseases', 'The use of potassium-sparing diuretics is contraindicated in patients with anuria, acute or progressive renal insufficiency, or diabetic nephropathy.  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with impaired renal function may be particularly susceptible to the hyperkalemic effect of these drugs.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with evidence of renal function impairment (BUN > 30 mg/dL or serum creatinine > 1.5 mg/dL).  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|Lynn KL, Bailey RR, Swainson CP, Sainsbury R, Low WI "Renal failure with potassium-sparing diuretics." N Z Med J 98 (1985):  629-33|George CF "Amiloride handling in renal failure." Br J Clin Pharmacol 9 (1980):  94-5|Somogyi A, Hewson D, Muirhead M, Bochner F "Amiloride disposition in geriatric patients: importance of renal function." Br J Clin Pharmacol 29 (1990):  1-8|Knauf H, Reuter K, Mutschler E "Limitation on the use of amiloride in early renal failure." Eur J Clin Pharmacol 28 (1985):  61-6|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|"Triamterene and the kidney." Lancet 1 (1986):  424|Roy LF, Villeneuve JP, Dumont A, Dufresne LR, Duran MA, Morin C, Jobin J "Irreversible renal failure associated with triamterene." Am J Nephrol 11 (1991):  486-8|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Neale TJ, Lynn KL, Bailey RR "Spironolactone-associated aggravation of renal functional impairment." N Z Med J 83 (1976):  147-9|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26393, 10788, 'Spironolactone', 'Kidney Diseases', 'The use of potassium-sparing diuretics is contraindicated in patients with anuria, acute or progressive renal insufficiency, or diabetic nephropathy.  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with impaired renal function may be particularly susceptible to the hyperkalemic effect of these drugs.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with evidence of renal function impairment (BUN > 30 mg/dL or serum creatinine > 1.5 mg/dL).  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|Lynn KL, Bailey RR, Swainson CP, Sainsbury R, Low WI "Renal failure with potassium-sparing diuretics." N Z Med J 98 (1985):  629-33|George CF "Amiloride handling in renal failure." Br J Clin Pharmacol 9 (1980):  94-5|Somogyi A, Hewson D, Muirhead M, Bochner F "Amiloride disposition in geriatric patients: importance of renal function." Br J Clin Pharmacol 29 (1990):  1-8|Knauf H, Reuter K, Mutschler E "Limitation on the use of amiloride in early renal failure." Eur J Clin Pharmacol 28 (1985):  61-6|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|"Triamterene and the kidney." Lancet 1 (1986):  424|Roy LF, Villeneuve JP, Dumont A, Dufresne LR, Duran MA, Morin C, Jobin J "Irreversible renal failure associated with triamterene." Am J Nephrol 11 (1991):  486-8|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Neale TJ, Lynn KL, Bailey RR "Spironolactone-associated aggravation of renal functional impairment." N Z Med J 83 (1976):  147-9|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26394, 10789, 'Spironolactone', 'Kidney Diseases', 'The use of potassium-sparing diuretics is contraindicated in patients with anuria, acute or progressive renal insufficiency, or diabetic nephropathy.  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with impaired renal function may be particularly susceptible to the hyperkalemic effect of these drugs.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with evidence of renal function impairment (BUN > 30 mg/dL or serum creatinine > 1.5 mg/dL).  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|Lynn KL, Bailey RR, Swainson CP, Sainsbury R, Low WI "Renal failure with potassium-sparing diuretics." N Z Med J 98 (1985):  629-33|George CF "Amiloride handling in renal failure." Br J Clin Pharmacol 9 (1980):  94-5|Somogyi A, Hewson D, Muirhead M, Bochner F "Amiloride disposition in geriatric patients: importance of renal function." Br J Clin Pharmacol 29 (1990):  1-8|Knauf H, Reuter K, Mutschler E "Limitation on the use of amiloride in early renal failure." Eur J Clin Pharmacol 28 (1985):  61-6|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|"Triamterene and the kidney." Lancet 1 (1986):  424|Roy LF, Villeneuve JP, Dumont A, Dufresne LR, Duran MA, Morin C, Jobin J "Irreversible renal failure associated with triamterene." Am J Nephrol 11 (1991):  486-8|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Neale TJ, Lynn KL, Bailey RR "Spironolactone-associated aggravation of renal functional impairment." N Z Med J 83 (1976):  147-9|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26395, 10816, 'Spironolactone', 'Kidney Diseases', 'The use of potassium-sparing diuretics is contraindicated in patients with anuria, acute or progressive renal insufficiency, or diabetic nephropathy.  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with impaired renal function may be particularly susceptible to the hyperkalemic effect of these drugs.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with evidence of renal function impairment (BUN > 30 mg/dL or serum creatinine > 1.5 mg/dL).  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|Lynn KL, Bailey RR, Swainson CP, Sainsbury R, Low WI "Renal failure with potassium-sparing diuretics." N Z Med J 98 (1985):  629-33|George CF "Amiloride handling in renal failure." Br J Clin Pharmacol 9 (1980):  94-5|Somogyi A, Hewson D, Muirhead M, Bochner F "Amiloride disposition in geriatric patients: importance of renal function." Br J Clin Pharmacol 29 (1990):  1-8|Knauf H, Reuter K, Mutschler E "Limitation on the use of amiloride in early renal failure." Eur J Clin Pharmacol 28 (1985):  61-6|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|"Triamterene and the kidney." Lancet 1 (1986):  424|Roy LF, Villeneuve JP, Dumont A, Dufresne LR, Duran MA, Morin C, Jobin J "Irreversible renal failure associated with triamterene." Am J Nephrol 11 (1991):  486-8|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Neale TJ, Lynn KL, Bailey RR "Spironolactone-associated aggravation of renal functional impairment." N Z Med J 83 (1976):  147-9|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26396, 10817, 'Spironolactone', 'Kidney Diseases', 'The use of potassium-sparing diuretics is contraindicated in patients with anuria, acute or progressive renal insufficiency, or diabetic nephropathy.  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with impaired renal function may be particularly susceptible to the hyperkalemic effect of these drugs.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with evidence of renal function impairment (BUN > 30 mg/dL or serum creatinine > 1.5 mg/dL).  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|Lynn KL, Bailey RR, Swainson CP, Sainsbury R, Low WI "Renal failure with potassium-sparing diuretics." N Z Med J 98 (1985):  629-33|George CF "Amiloride handling in renal failure." Br J Clin Pharmacol 9 (1980):  94-5|Somogyi A, Hewson D, Muirhead M, Bochner F "Amiloride disposition in geriatric patients: importance of renal function." Br J Clin Pharmacol 29 (1990):  1-8|Knauf H, Reuter K, Mutschler E "Limitation on the use of amiloride in early renal failure." Eur J Clin Pharmacol 28 (1985):  61-6|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|"Triamterene and the kidney." Lancet 1 (1986):  424|Roy LF, Villeneuve JP, Dumont A, Dufresne LR, Duran MA, Morin C, Jobin J "Irreversible renal failure associated with triamterene." Am J Nephrol 11 (1991):  486-8|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Neale TJ, Lynn KL, Bailey RR "Spironolactone-associated aggravation of renal functional impairment." N Z Med J 83 (1976):  147-9|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26397, 10818, 'Spironolactone', 'Kidney Diseases', 'The use of potassium-sparing diuretics is contraindicated in patients with anuria, acute or progressive renal insufficiency, or diabetic nephropathy.  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with impaired renal function may be particularly susceptible to the hyperkalemic effect of these drugs.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with evidence of renal function impairment (BUN > 30 mg/dL or serum creatinine > 1.5 mg/dL).  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|Lynn KL, Bailey RR, Swainson CP, Sainsbury R, Low WI "Renal failure with potassium-sparing diuretics." N Z Med J 98 (1985):  629-33|George CF "Amiloride handling in renal failure." Br J Clin Pharmacol 9 (1980):  94-5|Somogyi A, Hewson D, Muirhead M, Bochner F "Amiloride disposition in geriatric patients: importance of renal function." Br J Clin Pharmacol 29 (1990):  1-8|Knauf H, Reuter K, Mutschler E "Limitation on the use of amiloride in early renal failure." Eur J Clin Pharmacol 28 (1985):  61-6|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|"Triamterene and the kidney." Lancet 1 (1986):  424|Roy LF, Villeneuve JP, Dumont A, Dufresne LR, Duran MA, Morin C, Jobin J "Irreversible renal failure associated with triamterene." Am J Nephrol 11 (1991):  486-8|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Neale TJ, Lynn KL, Bailey RR "Spironolactone-associated aggravation of renal functional impairment." N Z Med J 83 (1976):  147-9|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26398, 25078, 'Spironolactone', 'Kidney Diseases', 'The use of potassium-sparing diuretics is contraindicated in patients with anuria, acute or progressive renal insufficiency, or diabetic nephropathy.  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with impaired renal function may be particularly susceptible to the hyperkalemic effect of these drugs.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with evidence of renal function impairment (BUN > 30 mg/dL or serum creatinine > 1.5 mg/dL).  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|Lynn KL, Bailey RR, Swainson CP, Sainsbury R, Low WI "Renal failure with potassium-sparing diuretics." N Z Med J 98 (1985):  629-33|George CF "Amiloride handling in renal failure." Br J Clin Pharmacol 9 (1980):  94-5|Somogyi A, Hewson D, Muirhead M, Bochner F "Amiloride disposition in geriatric patients: importance of renal function." Br J Clin Pharmacol 29 (1990):  1-8|Knauf H, Reuter K, Mutschler E "Limitation on the use of amiloride in early renal failure." Eur J Clin Pharmacol 28 (1985):  61-6|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|"Triamterene and the kidney." Lancet 1 (1986):  424|Roy LF, Villeneuve JP, Dumont A, Dufresne LR, Duran MA, Morin C, Jobin J "Irreversible renal failure associated with triamterene." Am J Nephrol 11 (1991):  486-8|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Neale TJ, Lynn KL, Bailey RR "Spironolactone-associated aggravation of renal functional impairment." N Z Med J 83 (1976):  147-9|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26399, 25079, 'Spironolactone', 'Kidney Diseases', 'The use of potassium-sparing diuretics is contraindicated in patients with anuria, acute or progressive renal insufficiency, or diabetic nephropathy.  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with impaired renal function may be particularly susceptible to the hyperkalemic effect of these drugs.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with evidence of renal function impairment (BUN > 30 mg/dL or serum creatinine > 1.5 mg/dL).  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|Lynn KL, Bailey RR, Swainson CP, Sainsbury R, Low WI "Renal failure with potassium-sparing diuretics." N Z Med J 98 (1985):  629-33|George CF "Amiloride handling in renal failure." Br J Clin Pharmacol 9 (1980):  94-5|Somogyi A, Hewson D, Muirhead M, Bochner F "Amiloride disposition in geriatric patients: importance of renal function." Br J Clin Pharmacol 29 (1990):  1-8|Knauf H, Reuter K, Mutschler E "Limitation on the use of amiloride in early renal failure." Eur J Clin Pharmacol 28 (1985):  61-6|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|"Triamterene and the kidney." Lancet 1 (1986):  424|Roy LF, Villeneuve JP, Dumont A, Dufresne LR, Duran MA, Morin C, Jobin J "Irreversible renal failure associated with triamterene." Am J Nephrol 11 (1991):  486-8|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Neale TJ, Lynn KL, Bailey RR "Spironolactone-associated aggravation of renal functional impairment." N Z Med J 83 (1976):  147-9|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26400, 25080, 'Spironolactone', 'Kidney Diseases', 'The use of potassium-sparing diuretics is contraindicated in patients with anuria, acute or progressive renal insufficiency, or diabetic nephropathy.  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with impaired renal function may be particularly susceptible to the hyperkalemic effect of these drugs.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with evidence of renal function impairment (BUN > 30 mg/dL or serum creatinine > 1.5 mg/dL).  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|Lynn KL, Bailey RR, Swainson CP, Sainsbury R, Low WI "Renal failure with potassium-sparing diuretics." N Z Med J 98 (1985):  629-33|George CF "Amiloride handling in renal failure." Br J Clin Pharmacol 9 (1980):  94-5|Somogyi A, Hewson D, Muirhead M, Bochner F "Amiloride disposition in geriatric patients: importance of renal function." Br J Clin Pharmacol 29 (1990):  1-8|Knauf H, Reuter K, Mutschler E "Limitation on the use of amiloride in early renal failure." Eur J Clin Pharmacol 28 (1985):  61-6|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|"Triamterene and the kidney." Lancet 1 (1986):  424|Roy LF, Villeneuve JP, Dumont A, Dufresne LR, Duran MA, Morin C, Jobin J "Irreversible renal failure associated with triamterene." Am J Nephrol 11 (1991):  486-8|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Neale TJ, Lynn KL, Bailey RR "Spironolactone-associated aggravation of renal functional impairment." N Z Med J 83 (1976):  147-9|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26401, 25081, 'Spironolactone', 'Kidney Diseases', 'The use of potassium-sparing diuretics is contraindicated in patients with anuria, acute or progressive renal insufficiency, or diabetic nephropathy.  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with impaired renal function may be particularly susceptible to the hyperkalemic effect of these drugs.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with evidence of renal function impairment (BUN > 30 mg/dL or serum creatinine > 1.5 mg/dL).  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|Lynn KL, Bailey RR, Swainson CP, Sainsbury R, Low WI "Renal failure with potassium-sparing diuretics." N Z Med J 98 (1985):  629-33|George CF "Amiloride handling in renal failure." Br J Clin Pharmacol 9 (1980):  94-5|Somogyi A, Hewson D, Muirhead M, Bochner F "Amiloride disposition in geriatric patients: importance of renal function." Br J Clin Pharmacol 29 (1990):  1-8|Knauf H, Reuter K, Mutschler E "Limitation on the use of amiloride in early renal failure." Eur J Clin Pharmacol 28 (1985):  61-6|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|"Triamterene and the kidney." Lancet 1 (1986):  424|Roy LF, Villeneuve JP, Dumont A, Dufresne LR, Duran MA, Morin C, Jobin J "Irreversible renal failure associated with triamterene." Am J Nephrol 11 (1991):  486-8|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Neale TJ, Lynn KL, Bailey RR "Spironolactone-associated aggravation of renal functional impairment." N Z Med J 83 (1976):  147-9|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26402, 266, 'Spironolactone', 'Hyperuricemia', 'Potassium-sparing diuretics have been reported to elevate serum uric acid levels.  Therapy with these agents should be administered cautiously in patients with a history of gout.', '2', '"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26403, 268, 'Spironolactone', 'Hyperuricemia', 'Potassium-sparing diuretics have been reported to elevate serum uric acid levels.  Therapy with these agents should be administered cautiously in patients with a history of gout.', '2', '"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26404, 10788, 'Spironolactone', 'Hyperuricemia', 'Potassium-sparing diuretics have been reported to elevate serum uric acid levels.  Therapy with these agents should be administered cautiously in patients with a history of gout.', '2', '"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26405, 10789, 'Spironolactone', 'Hyperuricemia', 'Potassium-sparing diuretics have been reported to elevate serum uric acid levels.  Therapy with these agents should be administered cautiously in patients with a history of gout.', '2', '"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26406, 10816, 'Spironolactone', 'Hyperuricemia', 'Potassium-sparing diuretics have been reported to elevate serum uric acid levels.  Therapy with these agents should be administered cautiously in patients with a history of gout.', '2', '"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26407, 10817, 'Spironolactone', 'Hyperuricemia', 'Potassium-sparing diuretics have been reported to elevate serum uric acid levels.  Therapy with these agents should be administered cautiously in patients with a history of gout.', '2', '"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26408, 10818, 'Spironolactone', 'Hyperuricemia', 'Potassium-sparing diuretics have been reported to elevate serum uric acid levels.  Therapy with these agents should be administered cautiously in patients with a history of gout.', '2', '"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26409, 25078, 'Spironolactone', 'Hyperuricemia', 'Potassium-sparing diuretics have been reported to elevate serum uric acid levels.  Therapy with these agents should be administered cautiously in patients with a history of gout.', '2', '"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26410, 25079, 'Spironolactone', 'Hyperuricemia', 'Potassium-sparing diuretics have been reported to elevate serum uric acid levels.  Therapy with these agents should be administered cautiously in patients with a history of gout.', '2', '"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26411, 25080, 'Spironolactone', 'Hyperuricemia', 'Potassium-sparing diuretics have been reported to elevate serum uric acid levels.  Therapy with these agents should be administered cautiously in patients with a history of gout.', '2', '"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26412, 25081, 'Spironolactone', 'Hyperuricemia', 'Potassium-sparing diuretics have been reported to elevate serum uric acid levels.  Therapy with these agents should be administered cautiously in patients with a history of gout.', '2', '"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26413, 0, 'Sonidegib', 'Musculoskeletal Diseases', 'Musculoskeletal adverse reactions, which may be accompanied by serum creatine kinase elevations have been reported with the use of drugs that inhibit the hedgehog pathway.  It is recommended to obtain serum creatine kinase levels and renal function tests prior to initiating therapy, periodically during treatment, and as clinically indicated.  Care should be taken when prescribing these agents to patients presenting musculoskeletal pain or myalgia.  Temporary dose interruption or discontinuation of therapy may be required based on the severity of musculoskeletal adverse reactions.', '2', '"Product Information. Odomzo (sonidegib)." Novartis Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26414, 0, 'Sonidegib', 'Kidney Diseases', 'Mild (CrCl 60 to 89 mL/min) and moderate (CrCl 30 to 59 mL/min) renal impairment had no effect on sonidegib steady-state exposure.  Caution is recommended when this agent is administered to patients with severe renal impairment as no data is available from the manufacturer.', '2', '"Product Information. Odomzo (sonidegib)." Novartis Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26415, 0, 'Stanozolol', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26416, 0, 'Stanozolol', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26417, 0, 'Stanozolol', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26418, 0, 'Stanozolol', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26419, 0, 'Stanozolol', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26420, 0, 'Stanozolol', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26421, 0, 'Stanozolol', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26422, 0, 'Stanozolol', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26423, 0, 'Stanozolol', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26424, 0, 'Stanozolol', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26425, 27440, 'Stavudine', 'Bone Marrow Failure Disorders', 'The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC) and stavudine (d4T), may infrequently cause bone marrow suppression at recommended dosages.  Anemia, leukopenia, thrombocytopenia and neutropenia have been reported.  Therapy with these agents should be administered cautiously in patients with preexisting bone marrow depression or blood dyscrasias.  Routine blood counts are recommended.', '3', '"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26426, 29884, 'Stavudine', 'Bone Marrow Failure Disorders', 'The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC) and stavudine (d4T), may infrequently cause bone marrow suppression at recommended dosages.  Anemia, leukopenia, thrombocytopenia and neutropenia have been reported.  Therapy with these agents should be administered cautiously in patients with preexisting bone marrow depression or blood dyscrasias.  Routine blood counts are recommended.', '3', '"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26427, 29885, 'Stavudine', 'Bone Marrow Failure Disorders', 'The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC) and stavudine (d4T), may infrequently cause bone marrow suppression at recommended dosages.  Anemia, leukopenia, thrombocytopenia and neutropenia have been reported.  Therapy with these agents should be administered cautiously in patients with preexisting bone marrow depression or blood dyscrasias.  Routine blood counts are recommended.', '3', '"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26428, 29886, 'Stavudine', 'Bone Marrow Failure Disorders', 'The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC) and stavudine (d4T), may infrequently cause bone marrow suppression at recommended dosages.  Anemia, leukopenia, thrombocytopenia and neutropenia have been reported.  Therapy with these agents should be administered cautiously in patients with preexisting bone marrow depression or blood dyscrasias.  Routine blood counts are recommended.', '3', '"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26429, 29887, 'Stavudine', 'Bone Marrow Failure Disorders', 'The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC) and stavudine (d4T), may infrequently cause bone marrow suppression at recommended dosages.  Anemia, leukopenia, thrombocytopenia and neutropenia have been reported.  Therapy with these agents should be administered cautiously in patients with preexisting bone marrow depression or blood dyscrasias.  Routine blood counts are recommended.', '3', '"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26430, 27440, 'Stavudine', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26431, 29884, 'Stavudine', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26432, 29885, 'Stavudine', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26433, 29886, 'Stavudine', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26434, 29887, 'Stavudine', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26435, 27440, 'Stavudine', 'Pancreatitis', 'The reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), stavudine (d4T) and lamivudine (3TC), may cause pancreatitis.  The incidence is generally low but is approximately 7% with ddI, and up to 15% in pediatric patients given 3TC.  Patients with a history of or known risk factors for pancreatitis, such as alcohol abuse or hypertriglyceridemia, should be monitored closely during therapy with these agents.  Therapy should be discontinued at the first signs or symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.', '3', 'Shelton MJ, O''Donnell AM, Morse GD "Didanosine." Ann Pharmacother 26 (1992):  660-70|Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Bouvet E, Casalino E, Prevost MH, Vachon F "Fatal case of 2'',3''-dideoxyinosine-associated pancreatitis." Lancet 336 (1990):  1515|Maxson CJ, Greenfield SM, Turner JL "Acute pancreatitis as a common complication of 2'',3''-dideoxyinosine therapy in the acquired immunodeficiency syndrome." Am J Gastroenterol 87 (1992):  708-13|Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992):  656-83|Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991):  419-49|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Grasela TH, Walawander CA, Beltangady M, Knupp CA, Martin RR, Dunkle LM, Barbhaiya RH, Pittman KA, Dolin R, Valentine FT, "Analysis of potential risk factors associated with the development of pancreatitis in phase i patients with AIDS or AIDS-related complex receiving didanosine." J Infect Dis 169 (1994):  1250-5|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|Schindzielorz A, Pike I, Daniels M, Pacelli L, Smaldone L "Rates and risk factors for adverse events associated with didanosine in the expanded access program." Clin Infect Dis 19 (1994):  1076-83|van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, Jonker P, Danner SA "The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study." AIDS 6 (1992):  1471-5|van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, et al. "Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study." J Infect Dis 171 (1995):  1166-71|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26436, 29884, 'Stavudine', 'Pancreatitis', 'The reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), stavudine (d4T) and lamivudine (3TC), may cause pancreatitis.  The incidence is generally low but is approximately 7% with ddI, and up to 15% in pediatric patients given 3TC.  Patients with a history of or known risk factors for pancreatitis, such as alcohol abuse or hypertriglyceridemia, should be monitored closely during therapy with these agents.  Therapy should be discontinued at the first signs or symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.', '3', 'Shelton MJ, O''Donnell AM, Morse GD "Didanosine." Ann Pharmacother 26 (1992):  660-70|Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Bouvet E, Casalino E, Prevost MH, Vachon F "Fatal case of 2'',3''-dideoxyinosine-associated pancreatitis." Lancet 336 (1990):  1515|Maxson CJ, Greenfield SM, Turner JL "Acute pancreatitis as a common complication of 2'',3''-dideoxyinosine therapy in the acquired immunodeficiency syndrome." Am J Gastroenterol 87 (1992):  708-13|Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992):  656-83|Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991):  419-49|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Grasela TH, Walawander CA, Beltangady M, Knupp CA, Martin RR, Dunkle LM, Barbhaiya RH, Pittman KA, Dolin R, Valentine FT, "Analysis of potential risk factors associated with the development of pancreatitis in phase i patients with AIDS or AIDS-related complex receiving didanosine." J Infect Dis 169 (1994):  1250-5|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|Schindzielorz A, Pike I, Daniels M, Pacelli L, Smaldone L "Rates and risk factors for adverse events associated with didanosine in the expanded access program." Clin Infect Dis 19 (1994):  1076-83|van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, Jonker P, Danner SA "The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study." AIDS 6 (1992):  1471-5|van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, et al. "Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study." J Infect Dis 171 (1995):  1166-71|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26437, 29885, 'Stavudine', 'Pancreatitis', 'The reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), stavudine (d4T) and lamivudine (3TC), may cause pancreatitis.  The incidence is generally low but is approximately 7% with ddI, and up to 15% in pediatric patients given 3TC.  Patients with a history of or known risk factors for pancreatitis, such as alcohol abuse or hypertriglyceridemia, should be monitored closely during therapy with these agents.  Therapy should be discontinued at the first signs or symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.', '3', 'Shelton MJ, O''Donnell AM, Morse GD "Didanosine." Ann Pharmacother 26 (1992):  660-70|Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Bouvet E, Casalino E, Prevost MH, Vachon F "Fatal case of 2'',3''-dideoxyinosine-associated pancreatitis." Lancet 336 (1990):  1515|Maxson CJ, Greenfield SM, Turner JL "Acute pancreatitis as a common complication of 2'',3''-dideoxyinosine therapy in the acquired immunodeficiency syndrome." Am J Gastroenterol 87 (1992):  708-13|Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992):  656-83|Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991):  419-49|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Grasela TH, Walawander CA, Beltangady M, Knupp CA, Martin RR, Dunkle LM, Barbhaiya RH, Pittman KA, Dolin R, Valentine FT, "Analysis of potential risk factors associated with the development of pancreatitis in phase i patients with AIDS or AIDS-related complex receiving didanosine." J Infect Dis 169 (1994):  1250-5|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|Schindzielorz A, Pike I, Daniels M, Pacelli L, Smaldone L "Rates and risk factors for adverse events associated with didanosine in the expanded access program." Clin Infect Dis 19 (1994):  1076-83|van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, Jonker P, Danner SA "The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study." AIDS 6 (1992):  1471-5|van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, et al. "Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study." J Infect Dis 171 (1995):  1166-71|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26438, 29886, 'Stavudine', 'Pancreatitis', 'The reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), stavudine (d4T) and lamivudine (3TC), may cause pancreatitis.  The incidence is generally low but is approximately 7% with ddI, and up to 15% in pediatric patients given 3TC.  Patients with a history of or known risk factors for pancreatitis, such as alcohol abuse or hypertriglyceridemia, should be monitored closely during therapy with these agents.  Therapy should be discontinued at the first signs or symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.', '3', 'Shelton MJ, O''Donnell AM, Morse GD "Didanosine." Ann Pharmacother 26 (1992):  660-70|Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Bouvet E, Casalino E, Prevost MH, Vachon F "Fatal case of 2'',3''-dideoxyinosine-associated pancreatitis." Lancet 336 (1990):  1515|Maxson CJ, Greenfield SM, Turner JL "Acute pancreatitis as a common complication of 2'',3''-dideoxyinosine therapy in the acquired immunodeficiency syndrome." Am J Gastroenterol 87 (1992):  708-13|Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992):  656-83|Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991):  419-49|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Grasela TH, Walawander CA, Beltangady M, Knupp CA, Martin RR, Dunkle LM, Barbhaiya RH, Pittman KA, Dolin R, Valentine FT, "Analysis of potential risk factors associated with the development of pancreatitis in phase i patients with AIDS or AIDS-related complex receiving didanosine." J Infect Dis 169 (1994):  1250-5|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|Schindzielorz A, Pike I, Daniels M, Pacelli L, Smaldone L "Rates and risk factors for adverse events associated with didanosine in the expanded access program." Clin Infect Dis 19 (1994):  1076-83|van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, Jonker P, Danner SA "The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study." AIDS 6 (1992):  1471-5|van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, et al. "Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study." J Infect Dis 171 (1995):  1166-71|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26439, 29887, 'Stavudine', 'Pancreatitis', 'The reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), stavudine (d4T) and lamivudine (3TC), may cause pancreatitis.  The incidence is generally low but is approximately 7% with ddI, and up to 15% in pediatric patients given 3TC.  Patients with a history of or known risk factors for pancreatitis, such as alcohol abuse or hypertriglyceridemia, should be monitored closely during therapy with these agents.  Therapy should be discontinued at the first signs or symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.', '3', 'Shelton MJ, O''Donnell AM, Morse GD "Didanosine." Ann Pharmacother 26 (1992):  660-70|Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Bouvet E, Casalino E, Prevost MH, Vachon F "Fatal case of 2'',3''-dideoxyinosine-associated pancreatitis." Lancet 336 (1990):  1515|Maxson CJ, Greenfield SM, Turner JL "Acute pancreatitis as a common complication of 2'',3''-dideoxyinosine therapy in the acquired immunodeficiency syndrome." Am J Gastroenterol 87 (1992):  708-13|Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992):  656-83|Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991):  419-49|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Grasela TH, Walawander CA, Beltangady M, Knupp CA, Martin RR, Dunkle LM, Barbhaiya RH, Pittman KA, Dolin R, Valentine FT, "Analysis of potential risk factors associated with the development of pancreatitis in phase i patients with AIDS or AIDS-related complex receiving didanosine." J Infect Dis 169 (1994):  1250-5|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|Schindzielorz A, Pike I, Daniels M, Pacelli L, Smaldone L "Rates and risk factors for adverse events associated with didanosine in the expanded access program." Clin Infect Dis 19 (1994):  1076-83|van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, Jonker P, Danner SA "The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study." AIDS 6 (1992):  1471-5|van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, et al. "Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study." J Infect Dis 171 (1995):  1166-71|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26440, 27440, 'Stavudine', 'Peripheral Nervous System Diseases', 'The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), and stavudine (d4T), may commonly cause dose-related peripheral neuropathy, particularly in patients with advanced HIV disease.  Usually, the neuropathy resolves slowly following prompt discontinuation of therapy, but it can be irreversible.  These agents should be administered cautiously to patients with a history of neuropathy and avoided in patients with existing polyneuropathy.  Therapy may be reinstituted following resolution of symptoms in patients who have previously experienced neuropathy with these drugs, but reduced dosages are recommended.', '3', 'LeLacheur SF, Simon GL "Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine." J Acquir Immune Defic Syndr 4 (1991):  538-9|Broder S, Yarchoan R "Dideoxycytidine: current clinical experience and future prospects." Am J Med 88 (1990):  s31-3|Dubinsky RM, Yarchoan R, Dalakas M, Broder S "Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2'',3''-dideoxycytidine (ddC)." Muscle Nerve 12 (1989):  856-60|Dubinsky RM, Dalakas M, Yarchoan R, Broder S "Follow-up of neuropathy from 2''3''-dideoxycytidine." Lancet 1 (1988):  832|Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992):  656-83|Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991):  419-49|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|Martinez OP, French MA "Acoustic neuropathy associated with zalcitabine-induced peripheral neuropathy." AIDS 7 (1993):  901-2|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|Fichtenbaum CJ, Clifford DB, Powderly WG "Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection." J Acquir Immune Defic Syndr Hum Retrovirol 10 (1995):  169-74|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26441, 29884, 'Stavudine', 'Peripheral Nervous System Diseases', 'The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), and stavudine (d4T), may commonly cause dose-related peripheral neuropathy, particularly in patients with advanced HIV disease.  Usually, the neuropathy resolves slowly following prompt discontinuation of therapy, but it can be irreversible.  These agents should be administered cautiously to patients with a history of neuropathy and avoided in patients with existing polyneuropathy.  Therapy may be reinstituted following resolution of symptoms in patients who have previously experienced neuropathy with these drugs, but reduced dosages are recommended.', '3', 'LeLacheur SF, Simon GL "Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine." J Acquir Immune Defic Syndr 4 (1991):  538-9|Broder S, Yarchoan R "Dideoxycytidine: current clinical experience and future prospects." Am J Med 88 (1990):  s31-3|Dubinsky RM, Yarchoan R, Dalakas M, Broder S "Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2'',3''-dideoxycytidine (ddC)." Muscle Nerve 12 (1989):  856-60|Dubinsky RM, Dalakas M, Yarchoan R, Broder S "Follow-up of neuropathy from 2''3''-dideoxycytidine." Lancet 1 (1988):  832|Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992):  656-83|Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991):  419-49|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|Martinez OP, French MA "Acoustic neuropathy associated with zalcitabine-induced peripheral neuropathy." AIDS 7 (1993):  901-2|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|Fichtenbaum CJ, Clifford DB, Powderly WG "Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection." J Acquir Immune Defic Syndr Hum Retrovirol 10 (1995):  169-74|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26442, 29885, 'Stavudine', 'Peripheral Nervous System Diseases', 'The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), and stavudine (d4T), may commonly cause dose-related peripheral neuropathy, particularly in patients with advanced HIV disease.  Usually, the neuropathy resolves slowly following prompt discontinuation of therapy, but it can be irreversible.  These agents should be administered cautiously to patients with a history of neuropathy and avoided in patients with existing polyneuropathy.  Therapy may be reinstituted following resolution of symptoms in patients who have previously experienced neuropathy with these drugs, but reduced dosages are recommended.', '3', 'LeLacheur SF, Simon GL "Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine." J Acquir Immune Defic Syndr 4 (1991):  538-9|Broder S, Yarchoan R "Dideoxycytidine: current clinical experience and future prospects." Am J Med 88 (1990):  s31-3|Dubinsky RM, Yarchoan R, Dalakas M, Broder S "Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2'',3''-dideoxycytidine (ddC)." Muscle Nerve 12 (1989):  856-60|Dubinsky RM, Dalakas M, Yarchoan R, Broder S "Follow-up of neuropathy from 2''3''-dideoxycytidine." Lancet 1 (1988):  832|Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992):  656-83|Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991):  419-49|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|Martinez OP, French MA "Acoustic neuropathy associated with zalcitabine-induced peripheral neuropathy." AIDS 7 (1993):  901-2|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|Fichtenbaum CJ, Clifford DB, Powderly WG "Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection." J Acquir Immune Defic Syndr Hum Retrovirol 10 (1995):  169-74|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26443, 29886, 'Stavudine', 'Peripheral Nervous System Diseases', 'The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), and stavudine (d4T), may commonly cause dose-related peripheral neuropathy, particularly in patients with advanced HIV disease.  Usually, the neuropathy resolves slowly following prompt discontinuation of therapy, but it can be irreversible.  These agents should be administered cautiously to patients with a history of neuropathy and avoided in patients with existing polyneuropathy.  Therapy may be reinstituted following resolution of symptoms in patients who have previously experienced neuropathy with these drugs, but reduced dosages are recommended.', '3', 'LeLacheur SF, Simon GL "Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine." J Acquir Immune Defic Syndr 4 (1991):  538-9|Broder S, Yarchoan R "Dideoxycytidine: current clinical experience and future prospects." Am J Med 88 (1990):  s31-3|Dubinsky RM, Yarchoan R, Dalakas M, Broder S "Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2'',3''-dideoxycytidine (ddC)." Muscle Nerve 12 (1989):  856-60|Dubinsky RM, Dalakas M, Yarchoan R, Broder S "Follow-up of neuropathy from 2''3''-dideoxycytidine." Lancet 1 (1988):  832|Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992):  656-83|Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991):  419-49|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|Martinez OP, French MA "Acoustic neuropathy associated with zalcitabine-induced peripheral neuropathy." AIDS 7 (1993):  901-2|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|Fichtenbaum CJ, Clifford DB, Powderly WG "Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection." J Acquir Immune Defic Syndr Hum Retrovirol 10 (1995):  169-74|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26444, 29887, 'Stavudine', 'Peripheral Nervous System Diseases', 'The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), and stavudine (d4T), may commonly cause dose-related peripheral neuropathy, particularly in patients with advanced HIV disease.  Usually, the neuropathy resolves slowly following prompt discontinuation of therapy, but it can be irreversible.  These agents should be administered cautiously to patients with a history of neuropathy and avoided in patients with existing polyneuropathy.  Therapy may be reinstituted following resolution of symptoms in patients who have previously experienced neuropathy with these drugs, but reduced dosages are recommended.', '3', 'LeLacheur SF, Simon GL "Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine." J Acquir Immune Defic Syndr 4 (1991):  538-9|Broder S, Yarchoan R "Dideoxycytidine: current clinical experience and future prospects." Am J Med 88 (1990):  s31-3|Dubinsky RM, Yarchoan R, Dalakas M, Broder S "Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2'',3''-dideoxycytidine (ddC)." Muscle Nerve 12 (1989):  856-60|Dubinsky RM, Dalakas M, Yarchoan R, Broder S "Follow-up of neuropathy from 2''3''-dideoxycytidine." Lancet 1 (1988):  832|Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992):  656-83|Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991):  419-49|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|Martinez OP, French MA "Acoustic neuropathy associated with zalcitabine-induced peripheral neuropathy." AIDS 7 (1993):  901-2|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|Fichtenbaum CJ, Clifford DB, Powderly WG "Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection." J Acquir Immune Defic Syndr Hum Retrovirol 10 (1995):  169-74|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26445, 27440, 'Stavudine', 'Kidney Diseases', 'Patients with clinically significant renal impairment may be at greater risk for toxicities and adverse effects from nucleoside reverse transcriptase inhibitors (NRTIs) due to decreased drug clearance.  Dosage adjustments are recommended.  In addition, these patients should be monitored closely during NRTI therapy, and dosages adjusted further if necessary.', '3', '"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26446, 29884, 'Stavudine', 'Kidney Diseases', 'Patients with clinically significant renal impairment may be at greater risk for toxicities and adverse effects from nucleoside reverse transcriptase inhibitors (NRTIs) due to decreased drug clearance.  Dosage adjustments are recommended.  In addition, these patients should be monitored closely during NRTI therapy, and dosages adjusted further if necessary.', '3', '"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26447, 29885, 'Stavudine', 'Kidney Diseases', 'Patients with clinically significant renal impairment may be at greater risk for toxicities and adverse effects from nucleoside reverse transcriptase inhibitors (NRTIs) due to decreased drug clearance.  Dosage adjustments are recommended.  In addition, these patients should be monitored closely during NRTI therapy, and dosages adjusted further if necessary.', '3', '"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26448, 29886, 'Stavudine', 'Kidney Diseases', 'Patients with clinically significant renal impairment may be at greater risk for toxicities and adverse effects from nucleoside reverse transcriptase inhibitors (NRTIs) due to decreased drug clearance.  Dosage adjustments are recommended.  In addition, these patients should be monitored closely during NRTI therapy, and dosages adjusted further if necessary.', '3', '"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26449, 29887, 'Stavudine', 'Kidney Diseases', 'Patients with clinically significant renal impairment may be at greater risk for toxicities and adverse effects from nucleoside reverse transcriptase inhibitors (NRTIs) due to decreased drug clearance.  Dosage adjustments are recommended.  In addition, these patients should be monitored closely during NRTI therapy, and dosages adjusted further if necessary.', '3', '"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26450, 0, 'Stiripentol', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26451, 0, 'Stiripentol', 'Neutropenia', 'Stiripentol can cause a significant decline in neutrophil and platelet counts.  Exercise care when prescribing this agent to immunosuppressed patients and those with bone marrow suppression.  Hematologic testing should be obtained before starting treatment, and then every six months.', '2', '"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26452, 0, 'Stiripentol', 'Phenylketonurias', 'Certain formulations of stiripentol contain phenylalanine, a component of aspartame.  Phenylalanine can be harmful to patients with phenylketonuria (PKU).  Before prescribing stiripentol formulations containing phenylalanine to a patient with PKU, it is recommended to consider the combined daily amount of phenylalanine from all sources.', '2', '"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26453, 0, 'Stiripentol', 'Feeding and Eating Disorders', 'Stiripentol can cause decreases in appetite and weight.  It is recommended to monitor pediatric patients'' growth and, in some cases, to decrease the dose of concomitant valproate by 30% per week to reduce the decrease in appetite and weight.  Exercise caution when prescribing this agent to patients at risk.', '2', '"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26454, 0, 'Stiripentol', 'Hepatic Insufficiency', 'Stiripentol is mainly metabolized by the liver.  There has been no formal study of the pharmacokinetics of stiripentol in patients with liver impairment.  Therefore, the administration of stiripentol to patients with moderate or severe liver impairment is not recommended.', '2', '"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26455, 0, 'Stiripentol', 'Kidney Diseases', 'Stiripentol metabolites are eliminated mainly through the kidney.  There is no formal study on the pharmacokinetics and metabolism of stiripentol in patients with renal impairment.  Therefore, the administration of stiripentol to patients with moderate or severe liver impairment is not recommended.', '2', '"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26456, 0, 'Stiripentol', 'Sleepiness', 'Stiripentol can cause somnolence.  If somnolence occurs during co-administration with clobazam, consider an initial reduction of clobazam by 25%.  If somnolence persists, further clobazam reduction by an additional 25% should be considered.  Adjust the dosage of other concomitant anticonvulsant drugs with sedating properties if needed.  Exercise caution when prescribing this agent to patients with CNS disorders.  Prescribers should monitor patients for somnolence and caution against engaging in hazardous activities requiring mental alertness.', '2', '"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26457, 17968, 'Streptokinase', 'Hemorrhagic Disorders', 'The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma/surgery (recent CPR/intracranial/intraspinal surgery within 2 months), bleeding diathesis, history of cerebrovascular (CV) accident, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), or severe uncontrolled arterial hypertension (SBP>180/DBP>110).  Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy.  Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy.  Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.', '3', 'Kase CS, Pessin MS, Zivin JA, del Zoppo GJ, Furlan AJ, Buckley JW, Snipes RG, LittleJohn JK "Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator." Am J Med 92 (1992):  384-90|Califf RM, Topol EJ, George BS, Boswick JM, Abbottsmith C, Sigmon KN, Candela R, Masek R, Kereiakes D, O''Neill WW, et al. "Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction." Am J Med 85 (1988):  353-9|Topol EJ, Herskowitz A, Hutchins GM "Massive hemorrhagic myocardial infarction after coronary thrombolysis." Am J Med 81 (1986):  339-43|Dabbs CK, Aaberg TM, Aguilar HE, Sternberg P, Jr  Meredith TA, Ward AR "Complications of tissue plasminogen activator therapy after vitrectomy for diabetes." Am J Ophthalmol 110 (1990):  354-60|Fromm RE, Hoskins E, Cronin L, Pratt CM, Spencer WH, Roberts R "Bleeding complications following initiation of thrombolytic therapy for acute myocardial infarction: a comparison of helicopter- transported and nontransported patients." Ann Emerg Med 20 (1991):  892-5|Kase CS, O''Neal AM, Fisher M, Girgis GN, Ordia JI "Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis." Ann Intern Med 112 (1990):  17-21|Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G "The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell''Infarto Miocardico II (GISSI-2), andThe International Study Group." N Engl J Med 327 (1992):  1-6|Garcia-Rubira JC, Lopez V, Rojas J, Garcia-Martinez JT, Cruz JM "Thrombolytic therapy soon after left heart catheterization--is it safe?" Intensive Care Med 17 (1991):  501-3|Tisdale JE, Colucci RD, Ujhelyi MR, Kluger J, Fieldman A, Chow MS "Evaluation and comparison of the adverse effects of streptokinase and alteplase." Pharmacotherapy 12 (1992):  440-4|Brenot F, Pacouret G, Meyer G, Sors H, Charbonnier B, Simonneau G "Adverse reactions with anistreplase." Lancet 338 (1991):  114-5|McNeill AJ, Roberts MJ, Wilson CM, Dalzell GW, Dickey W, Flannery DJ, Campbell NP, Khan MM, Molajo AO, Patterson GC, et al. "Anistreplase in early acute myocardial infarction and the one-year follow-up." Int J Cardiol 31 (1991):  39-49|Hirsch DR, Goldhaber SZ "Bleeding time and other laboratory tests to monitor the safety and efficacy of thrombolytic therapy." Chest 97 (1990):  s124-31|Levine SR, Brott TG "Thrombolytic therapy in cerebrovascular disorders." Prog Cardiovasc Dis 34 (1992):  235-62|Hanaway J, Torack R, Fletcher AP, Landau WM "Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke." Stroke 7 (1976):  143-6|Erlemeier HH, Zangemeister W, Burmester L, Schofer J, Mathey DG, Bleifeld W "Bleeding after thrombolysis in acute myocardial infarction." Eur Heart J 10 (1989):  16-23|Schneeman NJ, Stein EM "Thrombolytic therapy and gastrointestinal bleeding." Am Fam Physician 43 (1991):  53-6,|Haugeberg G, Bonarjee V, Dickstein K "Fatal intrathoracic haemorrhage after cardiopulmonary resuscitation and treatment with streptokinase and heparin." Br Heart J 62 (1989):  157-8|Berridge DC, Makin GS, Hopkinson BR "Local low dose intra-arterial thrombolytic therapy: the risk of stroke or major haemorrhage." Br J Surg 76 (1989):  1230-3|De Jaegere PP, Arnold AA, Balk AH, Simoons ML "Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors." J Am Coll Cardiol 19 (1992):  289-94|Aldrich MS, Sherman SA, Greenberg HS "Cerebrovascular complications of streptokinase infusion." JAMA 253 (1985):  1777-9|London NJ, Williams B, Stein A "Systemic thrombolysis causing haemorrhage around a prosthetic abdominal aortic graft." BMJ 306 (1993):  1530-1|McLeod DC, Coln WG, Thayer CF, Perfetto EM, Hartzema AG "Pharmacoepidemiology of bleeding events after use of r-alteplase or streptokinase in acute myocardial infarction." Ann Pharmacother 27 (1993):  956-62|"Product Information. Eminase (anistreplase)." SmithKline Beecham  (2001):|"Product Information. Abbokinase Open-Cath (urokinase)." Abbott Pharmaceutical  (2022):|"Product Information. Activase (alteplase)." Genentech  (2001):|"Product Information. Streptase (streptokinase)." Astra-Zeneca Pharmaceuticals  (2001):|Wagstaff AJ, Gillis JC, Goa KL "Alteplase - a reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction." Drugs 50 (1995):  289-316|Levine MN, Goldhaber SZ, Gore JM, Hirsh J Califf RM "Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism." Chest 108 Suppl (1995):  s291-301|"Product Information. Retavase (reteplase)." Boehringer Mannheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26458, 21214, 'Streptokinase', 'Hemorrhagic Disorders', 'The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma/surgery (recent CPR/intracranial/intraspinal surgery within 2 months), bleeding diathesis, history of cerebrovascular (CV) accident, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), or severe uncontrolled arterial hypertension (SBP>180/DBP>110).  Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy.  Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy.  Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.', '3', 'Kase CS, Pessin MS, Zivin JA, del Zoppo GJ, Furlan AJ, Buckley JW, Snipes RG, LittleJohn JK "Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator." Am J Med 92 (1992):  384-90|Califf RM, Topol EJ, George BS, Boswick JM, Abbottsmith C, Sigmon KN, Candela R, Masek R, Kereiakes D, O''Neill WW, et al. "Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction." Am J Med 85 (1988):  353-9|Topol EJ, Herskowitz A, Hutchins GM "Massive hemorrhagic myocardial infarction after coronary thrombolysis." Am J Med 81 (1986):  339-43|Dabbs CK, Aaberg TM, Aguilar HE, Sternberg P, Jr  Meredith TA, Ward AR "Complications of tissue plasminogen activator therapy after vitrectomy for diabetes." Am J Ophthalmol 110 (1990):  354-60|Fromm RE, Hoskins E, Cronin L, Pratt CM, Spencer WH, Roberts R "Bleeding complications following initiation of thrombolytic therapy for acute myocardial infarction: a comparison of helicopter- transported and nontransported patients." Ann Emerg Med 20 (1991):  892-5|Kase CS, O''Neal AM, Fisher M, Girgis GN, Ordia JI "Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis." Ann Intern Med 112 (1990):  17-21|Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G "The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell''Infarto Miocardico II (GISSI-2), andThe International Study Group." N Engl J Med 327 (1992):  1-6|Garcia-Rubira JC, Lopez V, Rojas J, Garcia-Martinez JT, Cruz JM "Thrombolytic therapy soon after left heart catheterization--is it safe?" Intensive Care Med 17 (1991):  501-3|Tisdale JE, Colucci RD, Ujhelyi MR, Kluger J, Fieldman A, Chow MS "Evaluation and comparison of the adverse effects of streptokinase and alteplase." Pharmacotherapy 12 (1992):  440-4|Brenot F, Pacouret G, Meyer G, Sors H, Charbonnier B, Simonneau G "Adverse reactions with anistreplase." Lancet 338 (1991):  114-5|McNeill AJ, Roberts MJ, Wilson CM, Dalzell GW, Dickey W, Flannery DJ, Campbell NP, Khan MM, Molajo AO, Patterson GC, et al. "Anistreplase in early acute myocardial infarction and the one-year follow-up." Int J Cardiol 31 (1991):  39-49|Hirsch DR, Goldhaber SZ "Bleeding time and other laboratory tests to monitor the safety and efficacy of thrombolytic therapy." Chest 97 (1990):  s124-31|Levine SR, Brott TG "Thrombolytic therapy in cerebrovascular disorders." Prog Cardiovasc Dis 34 (1992):  235-62|Hanaway J, Torack R, Fletcher AP, Landau WM "Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke." Stroke 7 (1976):  143-6|Erlemeier HH, Zangemeister W, Burmester L, Schofer J, Mathey DG, Bleifeld W "Bleeding after thrombolysis in acute myocardial infarction." Eur Heart J 10 (1989):  16-23|Schneeman NJ, Stein EM "Thrombolytic therapy and gastrointestinal bleeding." Am Fam Physician 43 (1991):  53-6,|Haugeberg G, Bonarjee V, Dickstein K "Fatal intrathoracic haemorrhage after cardiopulmonary resuscitation and treatment with streptokinase and heparin." Br Heart J 62 (1989):  157-8|Berridge DC, Makin GS, Hopkinson BR "Local low dose intra-arterial thrombolytic therapy: the risk of stroke or major haemorrhage." Br J Surg 76 (1989):  1230-3|De Jaegere PP, Arnold AA, Balk AH, Simoons ML "Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors." J Am Coll Cardiol 19 (1992):  289-94|Aldrich MS, Sherman SA, Greenberg HS "Cerebrovascular complications of streptokinase infusion." JAMA 253 (1985):  1777-9|London NJ, Williams B, Stein A "Systemic thrombolysis causing haemorrhage around a prosthetic abdominal aortic graft." BMJ 306 (1993):  1530-1|McLeod DC, Coln WG, Thayer CF, Perfetto EM, Hartzema AG "Pharmacoepidemiology of bleeding events after use of r-alteplase or streptokinase in acute myocardial infarction." Ann Pharmacother 27 (1993):  956-62|"Product Information. Eminase (anistreplase)." SmithKline Beecham  (2001):|"Product Information. Abbokinase Open-Cath (urokinase)." Abbott Pharmaceutical  (2022):|"Product Information. Activase (alteplase)." Genentech  (2001):|"Product Information. Streptase (streptokinase)." Astra-Zeneca Pharmaceuticals  (2001):|Wagstaff AJ, Gillis JC, Goa KL "Alteplase - a reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction." Drugs 50 (1995):  289-316|Levine MN, Goldhaber SZ, Gore JM, Hirsh J Califf RM "Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism." Chest 108 Suppl (1995):  s291-301|"Product Information. Retavase (reteplase)." Boehringer Mannheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26459, 26688, 'Streptokinase', 'Hemorrhagic Disorders', 'The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma/surgery (recent CPR/intracranial/intraspinal surgery within 2 months), bleeding diathesis, history of cerebrovascular (CV) accident, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), or severe uncontrolled arterial hypertension (SBP>180/DBP>110).  Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy.  Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy.  Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.', '3', 'Kase CS, Pessin MS, Zivin JA, del Zoppo GJ, Furlan AJ, Buckley JW, Snipes RG, LittleJohn JK "Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator." Am J Med 92 (1992):  384-90|Califf RM, Topol EJ, George BS, Boswick JM, Abbottsmith C, Sigmon KN, Candela R, Masek R, Kereiakes D, O''Neill WW, et al. "Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction." Am J Med 85 (1988):  353-9|Topol EJ, Herskowitz A, Hutchins GM "Massive hemorrhagic myocardial infarction after coronary thrombolysis." Am J Med 81 (1986):  339-43|Dabbs CK, Aaberg TM, Aguilar HE, Sternberg P, Jr  Meredith TA, Ward AR "Complications of tissue plasminogen activator therapy after vitrectomy for diabetes." Am J Ophthalmol 110 (1990):  354-60|Fromm RE, Hoskins E, Cronin L, Pratt CM, Spencer WH, Roberts R "Bleeding complications following initiation of thrombolytic therapy for acute myocardial infarction: a comparison of helicopter- transported and nontransported patients." Ann Emerg Med 20 (1991):  892-5|Kase CS, O''Neal AM, Fisher M, Girgis GN, Ordia JI "Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis." Ann Intern Med 112 (1990):  17-21|Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G "The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell''Infarto Miocardico II (GISSI-2), andThe International Study Group." N Engl J Med 327 (1992):  1-6|Garcia-Rubira JC, Lopez V, Rojas J, Garcia-Martinez JT, Cruz JM "Thrombolytic therapy soon after left heart catheterization--is it safe?" Intensive Care Med 17 (1991):  501-3|Tisdale JE, Colucci RD, Ujhelyi MR, Kluger J, Fieldman A, Chow MS "Evaluation and comparison of the adverse effects of streptokinase and alteplase." Pharmacotherapy 12 (1992):  440-4|Brenot F, Pacouret G, Meyer G, Sors H, Charbonnier B, Simonneau G "Adverse reactions with anistreplase." Lancet 338 (1991):  114-5|McNeill AJ, Roberts MJ, Wilson CM, Dalzell GW, Dickey W, Flannery DJ, Campbell NP, Khan MM, Molajo AO, Patterson GC, et al. "Anistreplase in early acute myocardial infarction and the one-year follow-up." Int J Cardiol 31 (1991):  39-49|Hirsch DR, Goldhaber SZ "Bleeding time and other laboratory tests to monitor the safety and efficacy of thrombolytic therapy." Chest 97 (1990):  s124-31|Levine SR, Brott TG "Thrombolytic therapy in cerebrovascular disorders." Prog Cardiovasc Dis 34 (1992):  235-62|Hanaway J, Torack R, Fletcher AP, Landau WM "Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke." Stroke 7 (1976):  143-6|Erlemeier HH, Zangemeister W, Burmester L, Schofer J, Mathey DG, Bleifeld W "Bleeding after thrombolysis in acute myocardial infarction." Eur Heart J 10 (1989):  16-23|Schneeman NJ, Stein EM "Thrombolytic therapy and gastrointestinal bleeding." Am Fam Physician 43 (1991):  53-6,|Haugeberg G, Bonarjee V, Dickstein K "Fatal intrathoracic haemorrhage after cardiopulmonary resuscitation and treatment with streptokinase and heparin." Br Heart J 62 (1989):  157-8|Berridge DC, Makin GS, Hopkinson BR "Local low dose intra-arterial thrombolytic therapy: the risk of stroke or major haemorrhage." Br J Surg 76 (1989):  1230-3|De Jaegere PP, Arnold AA, Balk AH, Simoons ML "Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors." J Am Coll Cardiol 19 (1992):  289-94|Aldrich MS, Sherman SA, Greenberg HS "Cerebrovascular complications of streptokinase infusion." JAMA 253 (1985):  1777-9|London NJ, Williams B, Stein A "Systemic thrombolysis causing haemorrhage around a prosthetic abdominal aortic graft." BMJ 306 (1993):  1530-1|McLeod DC, Coln WG, Thayer CF, Perfetto EM, Hartzema AG "Pharmacoepidemiology of bleeding events after use of r-alteplase or streptokinase in acute myocardial infarction." Ann Pharmacother 27 (1993):  956-62|"Product Information. Eminase (anistreplase)." SmithKline Beecham  (2001):|"Product Information. Abbokinase Open-Cath (urokinase)." Abbott Pharmaceutical  (2022):|"Product Information. Activase (alteplase)." Genentech  (2001):|"Product Information. Streptase (streptokinase)." Astra-Zeneca Pharmaceuticals  (2001):|Wagstaff AJ, Gillis JC, Goa KL "Alteplase - a reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction." Drugs 50 (1995):  289-316|Levine MN, Goldhaber SZ, Gore JM, Hirsh J Califf RM "Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism." Chest 108 Suppl (1995):  s291-301|"Product Information. Retavase (reteplase)." Boehringer Mannheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26460, 26689, 'Streptokinase', 'Hemorrhagic Disorders', 'The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma/surgery (recent CPR/intracranial/intraspinal surgery within 2 months), bleeding diathesis, history of cerebrovascular (CV) accident, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), or severe uncontrolled arterial hypertension (SBP>180/DBP>110).  Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy.  Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy.  Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.', '3', 'Kase CS, Pessin MS, Zivin JA, del Zoppo GJ, Furlan AJ, Buckley JW, Snipes RG, LittleJohn JK "Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator." Am J Med 92 (1992):  384-90|Califf RM, Topol EJ, George BS, Boswick JM, Abbottsmith C, Sigmon KN, Candela R, Masek R, Kereiakes D, O''Neill WW, et al. "Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction." Am J Med 85 (1988):  353-9|Topol EJ, Herskowitz A, Hutchins GM "Massive hemorrhagic myocardial infarction after coronary thrombolysis." Am J Med 81 (1986):  339-43|Dabbs CK, Aaberg TM, Aguilar HE, Sternberg P, Jr  Meredith TA, Ward AR "Complications of tissue plasminogen activator therapy after vitrectomy for diabetes." Am J Ophthalmol 110 (1990):  354-60|Fromm RE, Hoskins E, Cronin L, Pratt CM, Spencer WH, Roberts R "Bleeding complications following initiation of thrombolytic therapy for acute myocardial infarction: a comparison of helicopter- transported and nontransported patients." Ann Emerg Med 20 (1991):  892-5|Kase CS, O''Neal AM, Fisher M, Girgis GN, Ordia JI "Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis." Ann Intern Med 112 (1990):  17-21|Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G "The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell''Infarto Miocardico II (GISSI-2), andThe International Study Group." N Engl J Med 327 (1992):  1-6|Garcia-Rubira JC, Lopez V, Rojas J, Garcia-Martinez JT, Cruz JM "Thrombolytic therapy soon after left heart catheterization--is it safe?" Intensive Care Med 17 (1991):  501-3|Tisdale JE, Colucci RD, Ujhelyi MR, Kluger J, Fieldman A, Chow MS "Evaluation and comparison of the adverse effects of streptokinase and alteplase." Pharmacotherapy 12 (1992):  440-4|Brenot F, Pacouret G, Meyer G, Sors H, Charbonnier B, Simonneau G "Adverse reactions with anistreplase." Lancet 338 (1991):  114-5|McNeill AJ, Roberts MJ, Wilson CM, Dalzell GW, Dickey W, Flannery DJ, Campbell NP, Khan MM, Molajo AO, Patterson GC, et al. "Anistreplase in early acute myocardial infarction and the one-year follow-up." Int J Cardiol 31 (1991):  39-49|Hirsch DR, Goldhaber SZ "Bleeding time and other laboratory tests to monitor the safety and efficacy of thrombolytic therapy." Chest 97 (1990):  s124-31|Levine SR, Brott TG "Thrombolytic therapy in cerebrovascular disorders." Prog Cardiovasc Dis 34 (1992):  235-62|Hanaway J, Torack R, Fletcher AP, Landau WM "Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke." Stroke 7 (1976):  143-6|Erlemeier HH, Zangemeister W, Burmester L, Schofer J, Mathey DG, Bleifeld W "Bleeding after thrombolysis in acute myocardial infarction." Eur Heart J 10 (1989):  16-23|Schneeman NJ, Stein EM "Thrombolytic therapy and gastrointestinal bleeding." Am Fam Physician 43 (1991):  53-6,|Haugeberg G, Bonarjee V, Dickstein K "Fatal intrathoracic haemorrhage after cardiopulmonary resuscitation and treatment with streptokinase and heparin." Br Heart J 62 (1989):  157-8|Berridge DC, Makin GS, Hopkinson BR "Local low dose intra-arterial thrombolytic therapy: the risk of stroke or major haemorrhage." Br J Surg 76 (1989):  1230-3|De Jaegere PP, Arnold AA, Balk AH, Simoons ML "Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors." J Am Coll Cardiol 19 (1992):  289-94|Aldrich MS, Sherman SA, Greenberg HS "Cerebrovascular complications of streptokinase infusion." JAMA 253 (1985):  1777-9|London NJ, Williams B, Stein A "Systemic thrombolysis causing haemorrhage around a prosthetic abdominal aortic graft." BMJ 306 (1993):  1530-1|McLeod DC, Coln WG, Thayer CF, Perfetto EM, Hartzema AG "Pharmacoepidemiology of bleeding events after use of r-alteplase or streptokinase in acute myocardial infarction." Ann Pharmacother 27 (1993):  956-62|"Product Information. Eminase (anistreplase)." SmithKline Beecham  (2001):|"Product Information. Abbokinase Open-Cath (urokinase)." Abbott Pharmaceutical  (2022):|"Product Information. Activase (alteplase)." Genentech  (2001):|"Product Information. Streptase (streptokinase)." Astra-Zeneca Pharmaceuticals  (2001):|Wagstaff AJ, Gillis JC, Goa KL "Alteplase - a reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction." Drugs 50 (1995):  289-316|Levine MN, Goldhaber SZ, Gore JM, Hirsh J Califf RM "Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism." Chest 108 Suppl (1995):  s291-301|"Product Information. Retavase (reteplase)." Boehringer Mannheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26461, 27569, 'Streptokinase', 'Hemorrhagic Disorders', 'The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma/surgery (recent CPR/intracranial/intraspinal surgery within 2 months), bleeding diathesis, history of cerebrovascular (CV) accident, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), or severe uncontrolled arterial hypertension (SBP>180/DBP>110).  Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy.  Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy.  Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.', '3', 'Kase CS, Pessin MS, Zivin JA, del Zoppo GJ, Furlan AJ, Buckley JW, Snipes RG, LittleJohn JK "Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator." Am J Med 92 (1992):  384-90|Califf RM, Topol EJ, George BS, Boswick JM, Abbottsmith C, Sigmon KN, Candela R, Masek R, Kereiakes D, O''Neill WW, et al. "Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction." Am J Med 85 (1988):  353-9|Topol EJ, Herskowitz A, Hutchins GM "Massive hemorrhagic myocardial infarction after coronary thrombolysis." Am J Med 81 (1986):  339-43|Dabbs CK, Aaberg TM, Aguilar HE, Sternberg P, Jr  Meredith TA, Ward AR "Complications of tissue plasminogen activator therapy after vitrectomy for diabetes." Am J Ophthalmol 110 (1990):  354-60|Fromm RE, Hoskins E, Cronin L, Pratt CM, Spencer WH, Roberts R "Bleeding complications following initiation of thrombolytic therapy for acute myocardial infarction: a comparison of helicopter- transported and nontransported patients." Ann Emerg Med 20 (1991):  892-5|Kase CS, O''Neal AM, Fisher M, Girgis GN, Ordia JI "Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis." Ann Intern Med 112 (1990):  17-21|Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G "The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell''Infarto Miocardico II (GISSI-2), andThe International Study Group." N Engl J Med 327 (1992):  1-6|Garcia-Rubira JC, Lopez V, Rojas J, Garcia-Martinez JT, Cruz JM "Thrombolytic therapy soon after left heart catheterization--is it safe?" Intensive Care Med 17 (1991):  501-3|Tisdale JE, Colucci RD, Ujhelyi MR, Kluger J, Fieldman A, Chow MS "Evaluation and comparison of the adverse effects of streptokinase and alteplase." Pharmacotherapy 12 (1992):  440-4|Brenot F, Pacouret G, Meyer G, Sors H, Charbonnier B, Simonneau G "Adverse reactions with anistreplase." Lancet 338 (1991):  114-5|McNeill AJ, Roberts MJ, Wilson CM, Dalzell GW, Dickey W, Flannery DJ, Campbell NP, Khan MM, Molajo AO, Patterson GC, et al. "Anistreplase in early acute myocardial infarction and the one-year follow-up." Int J Cardiol 31 (1991):  39-49|Hirsch DR, Goldhaber SZ "Bleeding time and other laboratory tests to monitor the safety and efficacy of thrombolytic therapy." Chest 97 (1990):  s124-31|Levine SR, Brott TG "Thrombolytic therapy in cerebrovascular disorders." Prog Cardiovasc Dis 34 (1992):  235-62|Hanaway J, Torack R, Fletcher AP, Landau WM "Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke." Stroke 7 (1976):  143-6|Erlemeier HH, Zangemeister W, Burmester L, Schofer J, Mathey DG, Bleifeld W "Bleeding after thrombolysis in acute myocardial infarction." Eur Heart J 10 (1989):  16-23|Schneeman NJ, Stein EM "Thrombolytic therapy and gastrointestinal bleeding." Am Fam Physician 43 (1991):  53-6,|Haugeberg G, Bonarjee V, Dickstein K "Fatal intrathoracic haemorrhage after cardiopulmonary resuscitation and treatment with streptokinase and heparin." Br Heart J 62 (1989):  157-8|Berridge DC, Makin GS, Hopkinson BR "Local low dose intra-arterial thrombolytic therapy: the risk of stroke or major haemorrhage." Br J Surg 76 (1989):  1230-3|De Jaegere PP, Arnold AA, Balk AH, Simoons ML "Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors." J Am Coll Cardiol 19 (1992):  289-94|Aldrich MS, Sherman SA, Greenberg HS "Cerebrovascular complications of streptokinase infusion." JAMA 253 (1985):  1777-9|London NJ, Williams B, Stein A "Systemic thrombolysis causing haemorrhage around a prosthetic abdominal aortic graft." BMJ 306 (1993):  1530-1|McLeod DC, Coln WG, Thayer CF, Perfetto EM, Hartzema AG "Pharmacoepidemiology of bleeding events after use of r-alteplase or streptokinase in acute myocardial infarction." Ann Pharmacother 27 (1993):  956-62|"Product Information. Eminase (anistreplase)." SmithKline Beecham  (2001):|"Product Information. Abbokinase Open-Cath (urokinase)." Abbott Pharmaceutical  (2022):|"Product Information. Activase (alteplase)." Genentech  (2001):|"Product Information. Streptase (streptokinase)." Astra-Zeneca Pharmaceuticals  (2001):|Wagstaff AJ, Gillis JC, Goa KL "Alteplase - a reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction." Drugs 50 (1995):  289-316|Levine MN, Goldhaber SZ, Gore JM, Hirsh J Califf RM "Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism." Chest 108 Suppl (1995):  s291-301|"Product Information. Retavase (reteplase)." Boehringer Mannheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26462, 4116, 'Succinylcholine', 'Hypersensitivity', 'Some neuromuscular blocking agents stimulate the release of histamine, which can cause wheezing, bronchospasm, increased bronchial secretions, hypotension, tachycardia, and circulatory collapse.  Hypotension may also occur due to ganglionic blockade or as a complication of positive pressure respiration.  Tubocurarine appears to be the most potent inducer of histamine, followed by metocurine (no longer commercially available in the U.S.) and succinylcholine.  Other agents with varying but lesser degrees of histamine-releasing properties include atracurium, mivacurium, and pancuronium (at excessive dosages).  Therapy with these neuromuscular blocking agents should be administered cautiously in patients with clinically significant cardiovascular disease and/or a history of asthma or severe allergic reactions.  Certain agents may prolong the QTc interval, especially during general anesthesia in pediatric patients.  The initial dosage and rate of administration may need to be reduced, and hemodynamic and respiratory status carefully monitored.  Neuromuscular blocking agents that appear to have little or no histamine-inducing effects include cisatracurium, doxacurium, pipecuronium, rocuronium, and vecuronium.', '3', '"Product Information. Zemuron (rocuronium)." Organon  (2001):|"Product Information. Anectine (succinylcholine)." Glaxo Wellcome  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|"Product Information. Norcuron (vecuronium)." Organon  (2001):|"Product Information. Metubine Iodide (metocurine)." Dista Products Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26463, 4116, 'Succinylcholine', 'Respiratory Insufficiency', 'Neuromuscular blocking agents can cause respiratory depression and paralysis.  Therapy with neuromuscular blocking agents should be administered cautiously in patients with pulmonary impairment.  Treatment of respiratory paralysis consists of positive-pressure artificial respiration with oxygen and maintenance of a patent airway until the recovery of normal respiration is assured.', '3', '"Product Information. Zemuron (rocuronium)." Organon  (2001):|"Product Information. Anectine (succinylcholine)." Glaxo Wellcome  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|"Product Information. Norcuron (vecuronium)." Organon  (2001):|"Product Information. Metubine Iodide (metocurine)." Dista Products Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26464, 4116, 'Succinylcholine', 'Burns', 'The use of succinylcholine is contraindicated in patients after the acute phase of injury following major burns.  These patients are more likely to develop significant hyperkalemia which may lead to cardiac arrest.  The risk of hyperkalemia typically peaks at about 7 to 10 days after injury.', '3', '"Product Information. Anectine (succinylcholine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26465, 4116, 'Succinylcholine', 'Hyperkalemia', 'The use of succinylcholine is contraindicated in patients after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury.  has been associated with an elevation in potassium levels due to rapid release of potassium from intracellular sites.  Therapy with succinylcholine should be administered cautiously in patients with hyperkalemic states such as extensive soft-tissue trauma, burns, chronic abdominal infections, and subarachnoid hemorrhage.', '3', '"Product Information. Anectine (succinylcholine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26466, 4116, 'Succinylcholine', 'Malignant Hyperthermia', 'The use of succinylcholine is contraindicated in patients with a personal or family history of malignant hyperthermia.  Succinylcholine administration has been associated with acute onset of malignant hyperthermia, especially during the concomitant use of volatile anesthetics.  If malignant hyperthermia occurs, anesthesia should be discontinued and supportive measures rendered promptly, including rapid cooling, inhalation of 100% oxygen, control of acidosis, support of circulation, and assurance of adequate urinary output.  In addition, intravenous dantrolene sodium is recommended.', '3', '"Product Information. Anectine (succinylcholine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26467, 4116, 'Succinylcholine', 'Musculoskeletal Diseases', 'The use of succinylcholine is contraindicated in patients with a personal or family history of skeletal muscle myopathies.  Acute rhabdomyolysis with hyperkalemia followed by ventricular arrhythmias, cardiac arrest, and death have been reported following the administration of succinylcholine in apparently healthy children who were later found to have undiagnosed skeletal muscle myopathy, most frequently Duchenne muscular dystrophy.  Immediate treatment of hyperkalemia should be instituted whenever a healthy appearing infant or child develops cardiac arrest with no obvious cause soon after administration of succinylcholine.', '3', '"Product Information. Anectine (succinylcholine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26468, 4116, 'Succinylcholine', 'Motor Neuron Disease', 'The use of succinylcholine is contraindicated in patients with upper motor neuron injury that can be a sequelae of cerebral vasculopathy.  The risk of hyperkalemia is increased in these patients.', '3', '"Product Information. Anectine (succinylcholine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26469, 4116, 'Succinylcholine', 'Bradycardia', 'The use of succinylcholine may exacerbate bradycardia via vagal stimulation leading to asystole, especially after a second dose.  Therapy with succinylcholine should be administered cautiously in patients with bradycardia.', '2', '"Product Information. Anectine (succinylcholine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26470, 4116, 'Succinylcholine', 'Glaucoma', 'The use of succinylcholine has been associated with an increase in intraocular pressure.  Therapy with succinylcholine should be administered cautiously in patients with narrow-angle glaucoma.', '2', '"Product Information. Anectine (succinylcholine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26471, 4116, 'Succinylcholine', 'Myasthenia Gravis', 'Depolarizing agents, including succinylcholine, should be used with caution in patients with known neuromuscular junction disease.  The succinylcholine-induced neuromuscular blockade may be prolonged in patients with myasthenia gravis (MG).  Care should be exercised when using this agent in patients with existing, previously diagnosed MG.', '2', '"Product Information. Anectine (succinylcholine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26472, 10932, 'Streptomycin', 'Dehydration', 'Adequate hydration is crucial to minimize the risk of oto- and nephrotoxicity associated with the use of aminoglycosides.  Dehydration should preferably be corrected prior to initiation of therapy.  In patients who may be at risk for dehydration, such as those with severe and/or prolonged diarrhea or vomiting, fluid status should be monitored closely.  If signs of renal irritation develop during therapy, hydration should be increased as indicated, accompanied by a reduction in dosage if necessary.  Therapy should be withdrawn if urinary output decreases progressively or azotemia increases.', '3', '"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26473, 27570, 'Streptomycin', 'Dehydration', 'Adequate hydration is crucial to minimize the risk of oto- and nephrotoxicity associated with the use of aminoglycosides.  Dehydration should preferably be corrected prior to initiation of therapy.  In patients who may be at risk for dehydration, such as those with severe and/or prolonged diarrhea or vomiting, fluid status should be monitored closely.  If signs of renal irritation develop during therapy, hydration should be increased as indicated, accompanied by a reduction in dosage if necessary.  Therapy should be withdrawn if urinary output decreases progressively or azotemia increases.', '3', '"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26474, 27571, 'Streptomycin', 'Dehydration', 'Adequate hydration is crucial to minimize the risk of oto- and nephrotoxicity associated with the use of aminoglycosides.  Dehydration should preferably be corrected prior to initiation of therapy.  In patients who may be at risk for dehydration, such as those with severe and/or prolonged diarrhea or vomiting, fluid status should be monitored closely.  If signs of renal irritation develop during therapy, hydration should be increased as indicated, accompanied by a reduction in dosage if necessary.  Therapy should be withdrawn if urinary output decreases progressively or azotemia increases.', '3', '"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26475, 10932, 'Streptomycin', 'Neuromuscular Diseases', 'Aminoglycosides can cause dose-related neuromuscular blockade and muscle weakness, particularly in patients with neuromuscular disease or hypocalcemia and in patients receiving general anesthetics, neuromuscular blocking agents, or massive transfusions of citrate-anticoagulated blood.  Although aminoglycoside- induced neuromuscular blockade is generally self-limiting, it may rarely result in respiratory paralysis.  Neomycin is thought to be the most potent neuromuscular blocking agent in the class.  However, the risk is greatest with intraperitoneal or intrapleural instillation of large doses or rapid intravenous administration of parenteral aminoglycosides.  Therapy with aminoglycosides should be administered cautiously in patients with neuromuscular disorders (e.g., myasthenia gravis, parkinsonian syndrome, botulism) or hypocalcemia.  If signs of respiratory paralysis occur during aminoglycoside therapy, the drug should be discontinued and mechanical respiratory assistance provided if necessary.', '3', 'Kaeser HE "Drug-induced myasthenic syndromes." Acta Neurol Scand 70 (1984):  39-47|Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982):  303-12|"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Arikayce (amikacin liposome)." Insmed Incorporated  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26476, 27570, 'Streptomycin', 'Neuromuscular Diseases', 'Aminoglycosides can cause dose-related neuromuscular blockade and muscle weakness, particularly in patients with neuromuscular disease or hypocalcemia and in patients receiving general anesthetics, neuromuscular blocking agents, or massive transfusions of citrate-anticoagulated blood.  Although aminoglycoside- induced neuromuscular blockade is generally self-limiting, it may rarely result in respiratory paralysis.  Neomycin is thought to be the most potent neuromuscular blocking agent in the class.  However, the risk is greatest with intraperitoneal or intrapleural instillation of large doses or rapid intravenous administration of parenteral aminoglycosides.  Therapy with aminoglycosides should be administered cautiously in patients with neuromuscular disorders (e.g., myasthenia gravis, parkinsonian syndrome, botulism) or hypocalcemia.  If signs of respiratory paralysis occur during aminoglycoside therapy, the drug should be discontinued and mechanical respiratory assistance provided if necessary.', '3', 'Kaeser HE "Drug-induced myasthenic syndromes." Acta Neurol Scand 70 (1984):  39-47|Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982):  303-12|"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Arikayce (amikacin liposome)." Insmed Incorporated  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26477, 27571, 'Streptomycin', 'Neuromuscular Diseases', 'Aminoglycosides can cause dose-related neuromuscular blockade and muscle weakness, particularly in patients with neuromuscular disease or hypocalcemia and in patients receiving general anesthetics, neuromuscular blocking agents, or massive transfusions of citrate-anticoagulated blood.  Although aminoglycoside- induced neuromuscular blockade is generally self-limiting, it may rarely result in respiratory paralysis.  Neomycin is thought to be the most potent neuromuscular blocking agent in the class.  However, the risk is greatest with intraperitoneal or intrapleural instillation of large doses or rapid intravenous administration of parenteral aminoglycosides.  Therapy with aminoglycosides should be administered cautiously in patients with neuromuscular disorders (e.g., myasthenia gravis, parkinsonian syndrome, botulism) or hypocalcemia.  If signs of respiratory paralysis occur during aminoglycoside therapy, the drug should be discontinued and mechanical respiratory assistance provided if necessary.', '3', 'Kaeser HE "Drug-induced myasthenic syndromes." Acta Neurol Scand 70 (1984):  39-47|Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982):  303-12|"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Arikayce (amikacin liposome)." Insmed Incorporated  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26478, 10932, 'Streptomycin', 'Ototoxicity', 'Aminoglycosides can cause eighth cranial nerve damage, resulting in vestibular and/or auditory toxicities.  Symptoms include dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Permanent hearing loss may occur, including, rarely, total or partial irreversible bilateral deafness after the drug has been discontinued.  Therapy with aminoglycosides, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other ototoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Serial audiograms should be obtained in patients old enough to be tested, since loss of high- frequency perception usually precedes clinical hearing loss.  The dosage should be reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.', '3', 'Barza M, Lauermann MW, Tally FP, Gorbach SL "Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity." Antimicrob Agents Chemother 17 (1980):  707-14|Barza M, Lauermann MW, Tally FP, Gorbach SL "Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity." Antimicrob Agents Chemother 17 (1980):  707-14|Bock BV, Edelstein PH, Meyer RD "Prospective comparative study of efficacy and toxicity of netilmicin and amikacin." Antimicrob Agents Chemother 17 (1980):  217-25|Danhauer FJ, Fortner CL, Schimpff SC, DeJongh CA, Wesley MN, Wiernik PH "Ototoxicity and pharmacokinetically determined dosages of amikacin in granulocytopenic cancer patients." Clin Pharm 1 (1982):  539-43|Uziel A "Non-genetic factors affecting hearing development." Acta Otolaryngol (Stockh) 421 (1985):  57-61|Lerner SA, Schmitt BA, Seligsohn R, Matz G "Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin." Am J Med 80 Suppl 6 (1986):  98-104|Bock BV, Edelstein PH, Meyer RD "Prospective comparative study of efficacy and toxicity of netilmicin and amikacin." Antimicrob Agents Chemother 17 (1980):  217-25|Bernstein JM, Gorse GJ, Linzmayer MI, et al. "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients." Arch Intern Med 146 (1986):  2329-34|Smith CR, Lipsky JJ, Laskin OL, et al. "Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin." N Engl J Med 302 (1980):  1106-9|Tablan OC, Reyes MP, Rintelmann WF, Lerner AM "Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis." J Infect Dis 149 (1984):  257-63|Gatell JM, SanMiguel JG, Araujo V, et al. "Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin." Antimicrob Agents Chemother 26 (1984):  766-9|Bernstein JM, Gorse GJ, Linzmayer I, et al. "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients." Arch Intern Med 146 (1986):  2329-34|Mathog RH, Klein WJ "Ototoxicity of ethacrynic acid and aminoglycoside antibiotics in uremia." N Engl J Med 280 (1969):  1223-4|Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982):  303-12|Gailiunas P, Dominguez-Moreno M, Lazarus JM, et al. "Vestibular toxicity of gentamicin: incidence in patients receiving long-term hemodialysis therapy." Arch Intern Med 138 (1978):  1621-4|Deka RC, Ghosh P, Kacker SK "Streptomycin ototoxicity: an audiologic and vestibular study." Ear Nose Throat J 56 (1977):  218-24|Esterhai JL, Bednar J, Kimmelman CP "Gentamicin-induced ototoxicity complicating treatment of chronic osteomyelitis." Clin Orthop Aug (1986):  185-6|"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|Gendeh BS, Said H, Gibb AG, Aziz NS, Kong N, Zahir ZM "Gentamicin ototoxicity in continuous ambulatory peritoneal dialysis." J Laryngol Otol 107 (1993):  681-5|Hybels RL "Drug toxicity of the inner ear." Med Clin North Am 63 (1979):  309-19|Marlowe FI "Ototoxic agents." Otolaryngol Clin North Am 11 (1978):  791-800|Sheffield PA, Turner JS Jr "Ototoxic drugs: a review of clinical aspects, histopathologic changes and mechanisms of action." South Med J 64 (1971):  359-63|Ballantyne J "Ototoxicity: a clinical review." Audiology 12 (1973):  325-36|Ajodhia JM, Dix MR "Drug-induced deafness and its treatment." Practitioner 216 (1976):  561-70|Boston Collaborative Drug Surveillance Program "Drug-induced deafness." JAMA 224 (1973):  515-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Minor LB "Gentamicin-induced bilateral vestibular hypofunction." JAMA 279 (1998):  541-4|ElBakri F, Pallett A, Smith AG, Duncombe AS "Ototoxicity induced by once-daily gentamicin." Lancet 351 (1998):  1407-8|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Arikayce (amikacin liposome)." Insmed Incorporated  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26479, 27570, 'Streptomycin', 'Ototoxicity', 'Aminoglycosides can cause eighth cranial nerve damage, resulting in vestibular and/or auditory toxicities.  Symptoms include dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Permanent hearing loss may occur, including, rarely, total or partial irreversible bilateral deafness after the drug has been discontinued.  Therapy with aminoglycosides, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other ototoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Serial audiograms should be obtained in patients old enough to be tested, since loss of high- frequency perception usually precedes clinical hearing loss.  The dosage should be reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.', '3', 'Barza M, Lauermann MW, Tally FP, Gorbach SL "Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity." Antimicrob Agents Chemother 17 (1980):  707-14|Barza M, Lauermann MW, Tally FP, Gorbach SL "Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity." Antimicrob Agents Chemother 17 (1980):  707-14|Bock BV, Edelstein PH, Meyer RD "Prospective comparative study of efficacy and toxicity of netilmicin and amikacin." Antimicrob Agents Chemother 17 (1980):  217-25|Danhauer FJ, Fortner CL, Schimpff SC, DeJongh CA, Wesley MN, Wiernik PH "Ototoxicity and pharmacokinetically determined dosages of amikacin in granulocytopenic cancer patients." Clin Pharm 1 (1982):  539-43|Uziel A "Non-genetic factors affecting hearing development." Acta Otolaryngol (Stockh) 421 (1985):  57-61|Lerner SA, Schmitt BA, Seligsohn R, Matz G "Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin." Am J Med 80 Suppl 6 (1986):  98-104|Bock BV, Edelstein PH, Meyer RD "Prospective comparative study of efficacy and toxicity of netilmicin and amikacin." Antimicrob Agents Chemother 17 (1980):  217-25|Bernstein JM, Gorse GJ, Linzmayer MI, et al. "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients." Arch Intern Med 146 (1986):  2329-34|Smith CR, Lipsky JJ, Laskin OL, et al. "Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin." N Engl J Med 302 (1980):  1106-9|Tablan OC, Reyes MP, Rintelmann WF, Lerner AM "Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis." J Infect Dis 149 (1984):  257-63|Gatell JM, SanMiguel JG, Araujo V, et al. "Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin." Antimicrob Agents Chemother 26 (1984):  766-9|Bernstein JM, Gorse GJ, Linzmayer I, et al. "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients." Arch Intern Med 146 (1986):  2329-34|Mathog RH, Klein WJ "Ototoxicity of ethacrynic acid and aminoglycoside antibiotics in uremia." N Engl J Med 280 (1969):  1223-4|Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982):  303-12|Gailiunas P, Dominguez-Moreno M, Lazarus JM, et al. "Vestibular toxicity of gentamicin: incidence in patients receiving long-term hemodialysis therapy." Arch Intern Med 138 (1978):  1621-4|Deka RC, Ghosh P, Kacker SK "Streptomycin ototoxicity: an audiologic and vestibular study." Ear Nose Throat J 56 (1977):  218-24|Esterhai JL, Bednar J, Kimmelman CP "Gentamicin-induced ototoxicity complicating treatment of chronic osteomyelitis." Clin Orthop Aug (1986):  185-6|"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|Gendeh BS, Said H, Gibb AG, Aziz NS, Kong N, Zahir ZM "Gentamicin ototoxicity in continuous ambulatory peritoneal dialysis." J Laryngol Otol 107 (1993):  681-5|Hybels RL "Drug toxicity of the inner ear." Med Clin North Am 63 (1979):  309-19|Marlowe FI "Ototoxic agents." Otolaryngol Clin North Am 11 (1978):  791-800|Sheffield PA, Turner JS Jr "Ototoxic drugs: a review of clinical aspects, histopathologic changes and mechanisms of action." South Med J 64 (1971):  359-63|Ballantyne J "Ototoxicity: a clinical review." Audiology 12 (1973):  325-36|Ajodhia JM, Dix MR "Drug-induced deafness and its treatment." Practitioner 216 (1976):  561-70|Boston Collaborative Drug Surveillance Program "Drug-induced deafness." JAMA 224 (1973):  515-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Minor LB "Gentamicin-induced bilateral vestibular hypofunction." JAMA 279 (1998):  541-4|ElBakri F, Pallett A, Smith AG, Duncombe AS "Ototoxicity induced by once-daily gentamicin." Lancet 351 (1998):  1407-8|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Arikayce (amikacin liposome)." Insmed Incorporated  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26480, 27571, 'Streptomycin', 'Ototoxicity', 'Aminoglycosides can cause eighth cranial nerve damage, resulting in vestibular and/or auditory toxicities.  Symptoms include dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Permanent hearing loss may occur, including, rarely, total or partial irreversible bilateral deafness after the drug has been discontinued.  Therapy with aminoglycosides, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other ototoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Serial audiograms should be obtained in patients old enough to be tested, since loss of high- frequency perception usually precedes clinical hearing loss.  The dosage should be reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.', '3', 'Barza M, Lauermann MW, Tally FP, Gorbach SL "Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity." Antimicrob Agents Chemother 17 (1980):  707-14|Barza M, Lauermann MW, Tally FP, Gorbach SL "Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity." Antimicrob Agents Chemother 17 (1980):  707-14|Bock BV, Edelstein PH, Meyer RD "Prospective comparative study of efficacy and toxicity of netilmicin and amikacin." Antimicrob Agents Chemother 17 (1980):  217-25|Danhauer FJ, Fortner CL, Schimpff SC, DeJongh CA, Wesley MN, Wiernik PH "Ototoxicity and pharmacokinetically determined dosages of amikacin in granulocytopenic cancer patients." Clin Pharm 1 (1982):  539-43|Uziel A "Non-genetic factors affecting hearing development." Acta Otolaryngol (Stockh) 421 (1985):  57-61|Lerner SA, Schmitt BA, Seligsohn R, Matz G "Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin." Am J Med 80 Suppl 6 (1986):  98-104|Bock BV, Edelstein PH, Meyer RD "Prospective comparative study of efficacy and toxicity of netilmicin and amikacin." Antimicrob Agents Chemother 17 (1980):  217-25|Bernstein JM, Gorse GJ, Linzmayer MI, et al. "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients." Arch Intern Med 146 (1986):  2329-34|Smith CR, Lipsky JJ, Laskin OL, et al. "Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin." N Engl J Med 302 (1980):  1106-9|Tablan OC, Reyes MP, Rintelmann WF, Lerner AM "Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis." J Infect Dis 149 (1984):  257-63|Gatell JM, SanMiguel JG, Araujo V, et al. "Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin." Antimicrob Agents Chemother 26 (1984):  766-9|Bernstein JM, Gorse GJ, Linzmayer I, et al. "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients." Arch Intern Med 146 (1986):  2329-34|Mathog RH, Klein WJ "Ototoxicity of ethacrynic acid and aminoglycoside antibiotics in uremia." N Engl J Med 280 (1969):  1223-4|Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982):  303-12|Gailiunas P, Dominguez-Moreno M, Lazarus JM, et al. "Vestibular toxicity of gentamicin: incidence in patients receiving long-term hemodialysis therapy." Arch Intern Med 138 (1978):  1621-4|Deka RC, Ghosh P, Kacker SK "Streptomycin ototoxicity: an audiologic and vestibular study." Ear Nose Throat J 56 (1977):  218-24|Esterhai JL, Bednar J, Kimmelman CP "Gentamicin-induced ototoxicity complicating treatment of chronic osteomyelitis." Clin Orthop Aug (1986):  185-6|"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|Gendeh BS, Said H, Gibb AG, Aziz NS, Kong N, Zahir ZM "Gentamicin ototoxicity in continuous ambulatory peritoneal dialysis." J Laryngol Otol 107 (1993):  681-5|Hybels RL "Drug toxicity of the inner ear." Med Clin North Am 63 (1979):  309-19|Marlowe FI "Ototoxic agents." Otolaryngol Clin North Am 11 (1978):  791-800|Sheffield PA, Turner JS Jr "Ototoxic drugs: a review of clinical aspects, histopathologic changes and mechanisms of action." South Med J 64 (1971):  359-63|Ballantyne J "Ototoxicity: a clinical review." Audiology 12 (1973):  325-36|Ajodhia JM, Dix MR "Drug-induced deafness and its treatment." Practitioner 216 (1976):  561-70|Boston Collaborative Drug Surveillance Program "Drug-induced deafness." JAMA 224 (1973):  515-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Minor LB "Gentamicin-induced bilateral vestibular hypofunction." JAMA 279 (1998):  541-4|ElBakri F, Pallett A, Smith AG, Duncombe AS "Ototoxicity induced by once-daily gentamicin." Lancet 351 (1998):  1407-8|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Arikayce (amikacin liposome)." Insmed Incorporated  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26481, 10932, 'Streptomycin', 'Kidney Diseases', 'Aminoglycosides are potentially oto- and nephrotoxic.  Eighth cranial nerve damage may manifest as vestibular and/or auditory toxicities, including dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by tubular necrosis; increases in BUN, nonprotein nitrogen, and serum creatinine concentration; decreases in urine specific gravity and creatinine clearance; proteinuria; and cells or casts in the urine.  Rarely, renal electrolyte wasting may occur, resulting in hypocalcemia, hypomagnesemia, and hypokalemia that may be associated with paresthesia, tetany, confusion, and positive Chvostek and Trousseau signs.  Although aminoglycoside- induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred rarely.  Therapy with aminoglycosides should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.', '3', 'Beauchamp D, Gourde P, Theriault G, Bergeron MG "Age-dependent gentamicin experimental nephrotoxicity." J Pharmacol Exp Ther 260 (1992):  444-9|Dahlgren JG, Anderson ET, Hewitt WL "Gentamicin blood levels: a guide to nephrotoxicity." Antimicrob Agents Chemother 8 (1975):  58-62|Fanning WL, Gump D, Jick H "Gentamicin and cephalothin-associated rises in blood urea nitrogen." Antimicrob Agents Chemother 10 (1976):  80-2|Madhavan T, Yaremchuk K, Levin N, et al. "Effect of renal failure and dialysis on the serum concentration of the aminoglycoside amikacin." Antimicrob Agents Chemother 10 (1976):  464-5|Plantier J, Forrey AW, O''Neill MA, Blair AD, Christopher TG, Cutler RE "Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay." J Infect Dis 134 Suppl (1976):  s323-30|McHenry MC, Wagner JG, Hall PM, Vidt DG, Gavan TL "Pharmacokinetics of amikacin in patients with impaired renal function." J Infect Dis 134 Suppl (1976):  s343-54|Sarubbi FA, Hull JH "Amikacin serum concentrations: prediction of levels and dosage guidelines." Ann Intern Med 89 (1978):  612-8|Bock BV, Edelstein PH, Meyer RD "Prospective comparative study of efficacy and toxicity of netilmicin and amikacin." Antimicrob Agents Chemother 17 (1980):  217-25|Lerner SA, Schmitt BA, Seligsohn R, Matz G "Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin." Am J Med 80 Suppl 6 (1986):  98-104|Williams PJ, Hull JH, Sarubbi FA, Rogers JF, Wargin WA "Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin." J Clin Pharmacol 26 (1986):  79-86|Emanuelli G, Anfossi G, Calcamuggi G, Marcarino C, Lanzio M "Urinary enzyme release following aminoglycoside administration in single low dose." Enzyme 39 (1988):  119-22|Contreras AM, Gamba G, Cortes J, et al. "Serial trough and peak amikacin levels in plasma as predictors of nephrotoxicity." Antimicrob Agents Chemother 33 (1989):  973-6|French MA, Cerra FB, Plaut ME, Schentag JJ "Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients." Antimicrob Agents Chemother 19 (1981):  147-52|Pijck J, Hallynck T, Soep H, Baert L, Daniels R, Boelaert J "Pharmacokinetics of amikacin in patients with renal insufficiency: relation of half-life and creatinine clearance." J Infect Dis 134 (1976):  s331-41|Solberg CO, Madsen ST, Digranes A, et al. "High dose netilmicin therapy: efficacy, tolerance and tissue penetration." J Antimicrob Chemother 6 (1980):  133-41|Bhattacharya BK, Gorringe H, Farr MJ "Netilmicin and nephrotoxicity." Lancet 2 (1983):  216-7|Bergeron MG, Lessard C, Ronald A, Stiver G, Van Roogen CE, Chadwick P "Three to eight weeks of therapy with netilmicin: toxicity in normal and diabetic patients." J Antimicrob Chemother 12 (1983):  245-8|Bernstein JM, Gorse GJ, Linzmayer MI, et al. "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients." Arch Intern Med 146 (1986):  2329-34|Matzke GR, Millikin, Kovarik JM "Variability in pharmacokinetic values for gentamicin, tobramycin, and netilmicin in patients with renal insufficiency." Clin Pharm 8 (1989):  800-6|Herrero A, Alarco FR, Diez JM, Mahiques E, Domingo JV "Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis." Int J Clin Pharmacol Ther Toxicol 26 (1988):  84-7|Craig WA, Gudmundsson S, Reich RM "Netilmicin sulfate: a comparative evaluation of antimicrobial activity, pharmacokinetics, adverse reactions and clinical efficacy." Pharmacotherapy 3 (1983):  305-15|Luft FC, Brannon DR, Stropes LL, Costello RJ, Sloan RS, Maxwell DR "Pharmacokinetics of netilmicin in patients with renal impairment and in patients on dialysis." Antimicrob Agents Chemother 14 (1978):  403-7|Humbert G, Leroy A, Fillastre JP, Oksenhendler G "Pharmacokinetics of netilmicin in the presence of normal or impaired renal function." Antimicrob Agents Chemother 14 (1978):  40-4|Russo ME, Atkin-Thor E "Gentamicin and ticarcillin in subjects with end-stage renal disease." Clin Nephrol 15 (1981):  175-80|Federspil P, Schatzle W, Tiesler E "Pharmacokinetics and ototoxicity of gentamicin, tobramycin and amikacin." J Infect Dis 134 (1976):  s200-5|Smith CR, Lipsky JJ, Laskin OL, et al. "Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin." N Engl J Med 302 (1980):  1106-9|Kumin GD "Clinical nephrotoxicity of tobramycin and gentamicin." JAMA 244 (1980):  1808-10|Keys TF, Kurtz SB, Jones JD, Muller SM "Renal toxicity during therapy with gentamicin or tobramycin." Mayo Clin Proc 56 (1981):  556-9|Schentag JJ, Cerra FB, Plaut ME "Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients." Antimicrob Agents Chemother 21 (1982):  721-6|Pines A, Goldhammer E, Kaplinsky N, Frankl O "Hypopotassemia associated with tobramycin treatment." Infection 10 (1982):  101-|Tablan OC, Reyes MP, Rintelmann WF, Lerner AM "Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis." J Infect Dis 149 (1984):  257-63|Watson AJ, Watson MM, Keogh JA "Metabolic abnormalities associated with tobramycin therapy." Isr J Med Sci 153 (1984):  96-9|Gatell JM, SanMiguel JG, Araujo V, et al. "Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin." Antimicrob Agents Chemother 26 (1984):  766-9|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Contrepois A, Brion N, Garaud JJ, et al. "Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans." Antimicrob Agents Chemother 27 (1985):  520-4|Wilkinson R, Lucas GL, Heath DA, et al. "Hypomagnesaemic tetany associated with prolonged treatment with aminoglycosides." Br Med J 292 (1986):  818-9|Pedersen SS, Jensen J, Osterhammel D, Osterhammel P "Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis." Antimicrob Agents Chemother 31 (1987):  594-9|Kunin CM, Finland M "Persistence of antibiotics in blood of patients with acute renal failure. III. Penicillin, streptomycin, erythromycin and kanamycin." J Clin Invest 38 (1959):  1509-19|Yoshikawa TT, Nagami PH "Adverse drug reactions in TB therapy: risks and recommendations." Geriatrics 37 (1982):  61-3, 67-8|Siegenthaler WE, Bonetti A, Luthy R "Aminoglycoside antibiotics in infectious diseases: an overview." Am J Med 80 (1986):  2-14|Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982):  303-12|Trollfors B, Alestig K, Krantz I, Norrby R "Quantitative nephrotoxicity of gentamicin in nontoxic doses." J Infect Dis 141 (1980):  306-9|Letona JM, Barbolla L, Frieyro E, et al. "Immune haemolytic anaemia and renal failure induced by streptomycin." Br J Haematol 35 (1977):  561-71|McQueen EG "Antibiotic allergy and acute renal failure." N Z Med J 64 (1965):  561-3|Gyselnyck AM, Forrey A, Cutler R "Pharmacokinetics of gentamicin: distribution and plasma and renal clearance." J Infect Dis 124 (1971):  s70|Jaffe, Meyers BR, Hirschman SZ "Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis." Antimicrob Agents Chemother 5 (1974):  611-6|Schentag JJ, Lasezkay G, Cumbo TJ, et al. "Accumulation pharmacokinetics of tobramycin." Antimicrob Agents Chemother 13 (1978):  649-56|Pechere JC, Dugal R, Pechere MM "Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis." Clin Pharmacokinet 3 (1978):  395-406|"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|Gilbert DN, Bennett WM "Use of antimicrobial agents in renal failure." Infect Dis Clin North Am 3 (1989):  517-31|Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968):  2119|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Arikayce (amikacin liposome)." Insmed Incorporated  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26482, 27570, 'Streptomycin', 'Kidney Diseases', 'Aminoglycosides are potentially oto- and nephrotoxic.  Eighth cranial nerve damage may manifest as vestibular and/or auditory toxicities, including dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by tubular necrosis; increases in BUN, nonprotein nitrogen, and serum creatinine concentration; decreases in urine specific gravity and creatinine clearance; proteinuria; and cells or casts in the urine.  Rarely, renal electrolyte wasting may occur, resulting in hypocalcemia, hypomagnesemia, and hypokalemia that may be associated with paresthesia, tetany, confusion, and positive Chvostek and Trousseau signs.  Although aminoglycoside- induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred rarely.  Therapy with aminoglycosides should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.', '3', 'Beauchamp D, Gourde P, Theriault G, Bergeron MG "Age-dependent gentamicin experimental nephrotoxicity." J Pharmacol Exp Ther 260 (1992):  444-9|Dahlgren JG, Anderson ET, Hewitt WL "Gentamicin blood levels: a guide to nephrotoxicity." Antimicrob Agents Chemother 8 (1975):  58-62|Fanning WL, Gump D, Jick H "Gentamicin and cephalothin-associated rises in blood urea nitrogen." Antimicrob Agents Chemother 10 (1976):  80-2|Madhavan T, Yaremchuk K, Levin N, et al. "Effect of renal failure and dialysis on the serum concentration of the aminoglycoside amikacin." Antimicrob Agents Chemother 10 (1976):  464-5|Plantier J, Forrey AW, O''Neill MA, Blair AD, Christopher TG, Cutler RE "Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay." J Infect Dis 134 Suppl (1976):  s323-30|McHenry MC, Wagner JG, Hall PM, Vidt DG, Gavan TL "Pharmacokinetics of amikacin in patients with impaired renal function." J Infect Dis 134 Suppl (1976):  s343-54|Sarubbi FA, Hull JH "Amikacin serum concentrations: prediction of levels and dosage guidelines." Ann Intern Med 89 (1978):  612-8|Bock BV, Edelstein PH, Meyer RD "Prospective comparative study of efficacy and toxicity of netilmicin and amikacin." Antimicrob Agents Chemother 17 (1980):  217-25|Lerner SA, Schmitt BA, Seligsohn R, Matz G "Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin." Am J Med 80 Suppl 6 (1986):  98-104|Williams PJ, Hull JH, Sarubbi FA, Rogers JF, Wargin WA "Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin." J Clin Pharmacol 26 (1986):  79-86|Emanuelli G, Anfossi G, Calcamuggi G, Marcarino C, Lanzio M "Urinary enzyme release following aminoglycoside administration in single low dose." Enzyme 39 (1988):  119-22|Contreras AM, Gamba G, Cortes J, et al. "Serial trough and peak amikacin levels in plasma as predictors of nephrotoxicity." Antimicrob Agents Chemother 33 (1989):  973-6|French MA, Cerra FB, Plaut ME, Schentag JJ "Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients." Antimicrob Agents Chemother 19 (1981):  147-52|Pijck J, Hallynck T, Soep H, Baert L, Daniels R, Boelaert J "Pharmacokinetics of amikacin in patients with renal insufficiency: relation of half-life and creatinine clearance." J Infect Dis 134 (1976):  s331-41|Solberg CO, Madsen ST, Digranes A, et al. "High dose netilmicin therapy: efficacy, tolerance and tissue penetration." J Antimicrob Chemother 6 (1980):  133-41|Bhattacharya BK, Gorringe H, Farr MJ "Netilmicin and nephrotoxicity." Lancet 2 (1983):  216-7|Bergeron MG, Lessard C, Ronald A, Stiver G, Van Roogen CE, Chadwick P "Three to eight weeks of therapy with netilmicin: toxicity in normal and diabetic patients." J Antimicrob Chemother 12 (1983):  245-8|Bernstein JM, Gorse GJ, Linzmayer MI, et al. "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients." Arch Intern Med 146 (1986):  2329-34|Matzke GR, Millikin, Kovarik JM "Variability in pharmacokinetic values for gentamicin, tobramycin, and netilmicin in patients with renal insufficiency." Clin Pharm 8 (1989):  800-6|Herrero A, Alarco FR, Diez JM, Mahiques E, Domingo JV "Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis." Int J Clin Pharmacol Ther Toxicol 26 (1988):  84-7|Craig WA, Gudmundsson S, Reich RM "Netilmicin sulfate: a comparative evaluation of antimicrobial activity, pharmacokinetics, adverse reactions and clinical efficacy." Pharmacotherapy 3 (1983):  305-15|Luft FC, Brannon DR, Stropes LL, Costello RJ, Sloan RS, Maxwell DR "Pharmacokinetics of netilmicin in patients with renal impairment and in patients on dialysis." Antimicrob Agents Chemother 14 (1978):  403-7|Humbert G, Leroy A, Fillastre JP, Oksenhendler G "Pharmacokinetics of netilmicin in the presence of normal or impaired renal function." Antimicrob Agents Chemother 14 (1978):  40-4|Russo ME, Atkin-Thor E "Gentamicin and ticarcillin in subjects with end-stage renal disease." Clin Nephrol 15 (1981):  175-80|Federspil P, Schatzle W, Tiesler E "Pharmacokinetics and ototoxicity of gentamicin, tobramycin and amikacin." J Infect Dis 134 (1976):  s200-5|Smith CR, Lipsky JJ, Laskin OL, et al. "Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin." N Engl J Med 302 (1980):  1106-9|Kumin GD "Clinical nephrotoxicity of tobramycin and gentamicin." JAMA 244 (1980):  1808-10|Keys TF, Kurtz SB, Jones JD, Muller SM "Renal toxicity during therapy with gentamicin or tobramycin." Mayo Clin Proc 56 (1981):  556-9|Schentag JJ, Cerra FB, Plaut ME "Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients." Antimicrob Agents Chemother 21 (1982):  721-6|Pines A, Goldhammer E, Kaplinsky N, Frankl O "Hypopotassemia associated with tobramycin treatment." Infection 10 (1982):  101-|Tablan OC, Reyes MP, Rintelmann WF, Lerner AM "Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis." J Infect Dis 149 (1984):  257-63|Watson AJ, Watson MM, Keogh JA "Metabolic abnormalities associated with tobramycin therapy." Isr J Med Sci 153 (1984):  96-9|Gatell JM, SanMiguel JG, Araujo V, et al. "Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin." Antimicrob Agents Chemother 26 (1984):  766-9|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Contrepois A, Brion N, Garaud JJ, et al. "Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans." Antimicrob Agents Chemother 27 (1985):  520-4|Wilkinson R, Lucas GL, Heath DA, et al. "Hypomagnesaemic tetany associated with prolonged treatment with aminoglycosides." Br Med J 292 (1986):  818-9|Pedersen SS, Jensen J, Osterhammel D, Osterhammel P "Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis." Antimicrob Agents Chemother 31 (1987):  594-9|Kunin CM, Finland M "Persistence of antibiotics in blood of patients with acute renal failure. III. Penicillin, streptomycin, erythromycin and kanamycin." J Clin Invest 38 (1959):  1509-19|Yoshikawa TT, Nagami PH "Adverse drug reactions in TB therapy: risks and recommendations." Geriatrics 37 (1982):  61-3, 67-8|Siegenthaler WE, Bonetti A, Luthy R "Aminoglycoside antibiotics in infectious diseases: an overview." Am J Med 80 (1986):  2-14|Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982):  303-12|Trollfors B, Alestig K, Krantz I, Norrby R "Quantitative nephrotoxicity of gentamicin in nontoxic doses." J Infect Dis 141 (1980):  306-9|Letona JM, Barbolla L, Frieyro E, et al. "Immune haemolytic anaemia and renal failure induced by streptomycin." Br J Haematol 35 (1977):  561-71|McQueen EG "Antibiotic allergy and acute renal failure." N Z Med J 64 (1965):  561-3|Gyselnyck AM, Forrey A, Cutler R "Pharmacokinetics of gentamicin: distribution and plasma and renal clearance." J Infect Dis 124 (1971):  s70|Jaffe, Meyers BR, Hirschman SZ "Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis." Antimicrob Agents Chemother 5 (1974):  611-6|Schentag JJ, Lasezkay G, Cumbo TJ, et al. "Accumulation pharmacokinetics of tobramycin." Antimicrob Agents Chemother 13 (1978):  649-56|Pechere JC, Dugal R, Pechere MM "Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis." Clin Pharmacokinet 3 (1978):  395-406|"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|Gilbert DN, Bennett WM "Use of antimicrobial agents in renal failure." Infect Dis Clin North Am 3 (1989):  517-31|Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968):  2119|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Arikayce (amikacin liposome)." Insmed Incorporated  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26483, 27571, 'Streptomycin', 'Kidney Diseases', 'Aminoglycosides are potentially oto- and nephrotoxic.  Eighth cranial nerve damage may manifest as vestibular and/or auditory toxicities, including dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by tubular necrosis; increases in BUN, nonprotein nitrogen, and serum creatinine concentration; decreases in urine specific gravity and creatinine clearance; proteinuria; and cells or casts in the urine.  Rarely, renal electrolyte wasting may occur, resulting in hypocalcemia, hypomagnesemia, and hypokalemia that may be associated with paresthesia, tetany, confusion, and positive Chvostek and Trousseau signs.  Although aminoglycoside- induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred rarely.  Therapy with aminoglycosides should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.', '3', 'Beauchamp D, Gourde P, Theriault G, Bergeron MG "Age-dependent gentamicin experimental nephrotoxicity." J Pharmacol Exp Ther 260 (1992):  444-9|Dahlgren JG, Anderson ET, Hewitt WL "Gentamicin blood levels: a guide to nephrotoxicity." Antimicrob Agents Chemother 8 (1975):  58-62|Fanning WL, Gump D, Jick H "Gentamicin and cephalothin-associated rises in blood urea nitrogen." Antimicrob Agents Chemother 10 (1976):  80-2|Madhavan T, Yaremchuk K, Levin N, et al. "Effect of renal failure and dialysis on the serum concentration of the aminoglycoside amikacin." Antimicrob Agents Chemother 10 (1976):  464-5|Plantier J, Forrey AW, O''Neill MA, Blair AD, Christopher TG, Cutler RE "Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay." J Infect Dis 134 Suppl (1976):  s323-30|McHenry MC, Wagner JG, Hall PM, Vidt DG, Gavan TL "Pharmacokinetics of amikacin in patients with impaired renal function." J Infect Dis 134 Suppl (1976):  s343-54|Sarubbi FA, Hull JH "Amikacin serum concentrations: prediction of levels and dosage guidelines." Ann Intern Med 89 (1978):  612-8|Bock BV, Edelstein PH, Meyer RD "Prospective comparative study of efficacy and toxicity of netilmicin and amikacin." Antimicrob Agents Chemother 17 (1980):  217-25|Lerner SA, Schmitt BA, Seligsohn R, Matz G "Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin." Am J Med 80 Suppl 6 (1986):  98-104|Williams PJ, Hull JH, Sarubbi FA, Rogers JF, Wargin WA "Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin." J Clin Pharmacol 26 (1986):  79-86|Emanuelli G, Anfossi G, Calcamuggi G, Marcarino C, Lanzio M "Urinary enzyme release following aminoglycoside administration in single low dose." Enzyme 39 (1988):  119-22|Contreras AM, Gamba G, Cortes J, et al. "Serial trough and peak amikacin levels in plasma as predictors of nephrotoxicity." Antimicrob Agents Chemother 33 (1989):  973-6|French MA, Cerra FB, Plaut ME, Schentag JJ "Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients." Antimicrob Agents Chemother 19 (1981):  147-52|Pijck J, Hallynck T, Soep H, Baert L, Daniels R, Boelaert J "Pharmacokinetics of amikacin in patients with renal insufficiency: relation of half-life and creatinine clearance." J Infect Dis 134 (1976):  s331-41|Solberg CO, Madsen ST, Digranes A, et al. "High dose netilmicin therapy: efficacy, tolerance and tissue penetration." J Antimicrob Chemother 6 (1980):  133-41|Bhattacharya BK, Gorringe H, Farr MJ "Netilmicin and nephrotoxicity." Lancet 2 (1983):  216-7|Bergeron MG, Lessard C, Ronald A, Stiver G, Van Roogen CE, Chadwick P "Three to eight weeks of therapy with netilmicin: toxicity in normal and diabetic patients." J Antimicrob Chemother 12 (1983):  245-8|Bernstein JM, Gorse GJ, Linzmayer MI, et al. "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients." Arch Intern Med 146 (1986):  2329-34|Matzke GR, Millikin, Kovarik JM "Variability in pharmacokinetic values for gentamicin, tobramycin, and netilmicin in patients with renal insufficiency." Clin Pharm 8 (1989):  800-6|Herrero A, Alarco FR, Diez JM, Mahiques E, Domingo JV "Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis." Int J Clin Pharmacol Ther Toxicol 26 (1988):  84-7|Craig WA, Gudmundsson S, Reich RM "Netilmicin sulfate: a comparative evaluation of antimicrobial activity, pharmacokinetics, adverse reactions and clinical efficacy." Pharmacotherapy 3 (1983):  305-15|Luft FC, Brannon DR, Stropes LL, Costello RJ, Sloan RS, Maxwell DR "Pharmacokinetics of netilmicin in patients with renal impairment and in patients on dialysis." Antimicrob Agents Chemother 14 (1978):  403-7|Humbert G, Leroy A, Fillastre JP, Oksenhendler G "Pharmacokinetics of netilmicin in the presence of normal or impaired renal function." Antimicrob Agents Chemother 14 (1978):  40-4|Russo ME, Atkin-Thor E "Gentamicin and ticarcillin in subjects with end-stage renal disease." Clin Nephrol 15 (1981):  175-80|Federspil P, Schatzle W, Tiesler E "Pharmacokinetics and ototoxicity of gentamicin, tobramycin and amikacin." J Infect Dis 134 (1976):  s200-5|Smith CR, Lipsky JJ, Laskin OL, et al. "Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin." N Engl J Med 302 (1980):  1106-9|Kumin GD "Clinical nephrotoxicity of tobramycin and gentamicin." JAMA 244 (1980):  1808-10|Keys TF, Kurtz SB, Jones JD, Muller SM "Renal toxicity during therapy with gentamicin or tobramycin." Mayo Clin Proc 56 (1981):  556-9|Schentag JJ, Cerra FB, Plaut ME "Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients." Antimicrob Agents Chemother 21 (1982):  721-6|Pines A, Goldhammer E, Kaplinsky N, Frankl O "Hypopotassemia associated with tobramycin treatment." Infection 10 (1982):  101-|Tablan OC, Reyes MP, Rintelmann WF, Lerner AM "Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis." J Infect Dis 149 (1984):  257-63|Watson AJ, Watson MM, Keogh JA "Metabolic abnormalities associated with tobramycin therapy." Isr J Med Sci 153 (1984):  96-9|Gatell JM, SanMiguel JG, Araujo V, et al. "Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin." Antimicrob Agents Chemother 26 (1984):  766-9|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Contrepois A, Brion N, Garaud JJ, et al. "Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans." Antimicrob Agents Chemother 27 (1985):  520-4|Wilkinson R, Lucas GL, Heath DA, et al. "Hypomagnesaemic tetany associated with prolonged treatment with aminoglycosides." Br Med J 292 (1986):  818-9|Pedersen SS, Jensen J, Osterhammel D, Osterhammel P "Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis." Antimicrob Agents Chemother 31 (1987):  594-9|Kunin CM, Finland M "Persistence of antibiotics in blood of patients with acute renal failure. III. Penicillin, streptomycin, erythromycin and kanamycin." J Clin Invest 38 (1959):  1509-19|Yoshikawa TT, Nagami PH "Adverse drug reactions in TB therapy: risks and recommendations." Geriatrics 37 (1982):  61-3, 67-8|Siegenthaler WE, Bonetti A, Luthy R "Aminoglycoside antibiotics in infectious diseases: an overview." Am J Med 80 (1986):  2-14|Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982):  303-12|Trollfors B, Alestig K, Krantz I, Norrby R "Quantitative nephrotoxicity of gentamicin in nontoxic doses." J Infect Dis 141 (1980):  306-9|Letona JM, Barbolla L, Frieyro E, et al. "Immune haemolytic anaemia and renal failure induced by streptomycin." Br J Haematol 35 (1977):  561-71|McQueen EG "Antibiotic allergy and acute renal failure." N Z Med J 64 (1965):  561-3|Gyselnyck AM, Forrey A, Cutler R "Pharmacokinetics of gentamicin: distribution and plasma and renal clearance." J Infect Dis 124 (1971):  s70|Jaffe, Meyers BR, Hirschman SZ "Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis." Antimicrob Agents Chemother 5 (1974):  611-6|Schentag JJ, Lasezkay G, Cumbo TJ, et al. "Accumulation pharmacokinetics of tobramycin." Antimicrob Agents Chemother 13 (1978):  649-56|Pechere JC, Dugal R, Pechere MM "Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis." Clin Pharmacokinet 3 (1978):  395-406|"Product Information. Amikin (amikacin)." Bristol-Myers Squibb  (2002):|"Product Information. Garamycin (gentamicin)." Schering-Plough Corporation  (2007):|"Product Information. Netromycin (netilmicin)." Schering Corporation  (2002):|"Product Information. Streptomycin Sulfate (streptomycin)." Pfizer U.S. Pharmaceuticals|"Product Information. Nebcin (tobramycin)." Lilly, Eli and Company  (2001):|Gilbert DN, Bennett WM "Use of antimicrobial agents in renal failure." Infect Dis Clin North Am 3 (1989):  517-31|Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968):  2119|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Arikayce (amikacin liposome)." Insmed Incorporated  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26484, 0, 'Belatacept', 'Epstein-Barr Virus Infections', 'Belatacept is contraindicated in transplant recipients who are Epstein-Barr virus (EBV) seronegative or with unknown EBV serostatus due to the risk of post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system.', '3', '"Product Information. Nulojix (belatacept)." Bristol-Myers Squibb  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26485, 0, 'Belatacept', 'Infections', 'Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents.  Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections.  Caution should be exercised when considering their use in patients with severe or chronic infections.  It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.', '3', '"Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc  (2007):|"Product Information. BENLYSTA (belimumab)." GlaxoSmithKline  (2011):|"Product Information. Nulojix (belatacept)." Bristol-Myers Squibb  (2011):|"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):|"Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America  (2014):|"Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation  (2017):|"Product Information. Gamifant (emapalumab)." Sobi Inc  (2018):|"Product Information. Lupkynis (voclosporin)." Aurinia Pharma  (2021):|"Product Information. Saphnelo (anifrolumab)." Astra-Zeneca Pharmaceuticals  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26486, 0, 'Belatacept', 'Leukoencephalopathy, Progressive Multifocal', 'Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML).  Certain agents are contraindicated in patients who have or have had PML.  Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents.  Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML.  Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.', '3', '"Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc  (2004):|"Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc  (2007):|"Product Information. BENLYSTA (belimumab)." GlaxoSmithKline  (2011):|"Product Information. Nulojix (belatacept)." Bristol-Myers Squibb  (2011):|"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):|"Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America  (2014):|"Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26487, 0, 'Belatacept', 'Liver Diseases', 'The use of belatacept in liver transplant patients is not recommended as it may be associated with a higher rate of graft loss and death.', '2', '"Product Information. Nulojix (belatacept)." Bristol-Myers Squibb  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26488, 0, 'Belatacept', 'Tuberculosis', 'Prior to initiating belatacept, patients should be screened for latent tuberculosis infection with a tuberculin skin test.  Treatment of latent tuberculosis infection should be initiated prior to therapy with belatacept.  Anti-tuberculosis therapy should also be considered prior to initiation of belatacept in patients with a past-history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Caution should be exercised and tuberculosis should be strongly considered in patients who develop a new infection during belatacept treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '2', '"Product Information. Nulojix (belatacept)." Bristol-Myers Squibb  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26489, 0, 'Sufentanil', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26490, 0, 'Sufentanil', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26491, 0, 'Sufentanil', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26492, 0, 'Sufentanil', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26493, 0, 'Sufentanil', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'Parke TJ, Nandi PR, Bird KJ, Jewkes DA "Profound hypotension following intravenous codeine phosphate: three case reports and some recommendations." Anaesthesia 47 (1992):  852-4|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Cox RG "Hypoxaemia and hypotension after intravenous codeine phosphate." Can J Anaesth 41 (1994):  1211-3|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26494, 0, 'Sufentanil', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26495, 0, 'Sufentanil', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'Redpath JB, Pleuvry BJ "Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (+/-)-glaucine phosphate in human volunteers." Br J Clin Pharmacol 14 (1982):  555-8|Rigg JR, Ilsley AH, Vedig AE "Relationship of ventilatory depression to steady-state blood pethidine concentrations." Br J Anaesth 53 (1981):  613-9|Samuels SI, Rabinov W "Difficulty reversing drug-induced coma in a patient with sleep apnea." Anesth Analg 65 (1986):  1222-4|Elloway R, Sherman S, Maas L, et al. "Meperidine-induced bronchospasm." Gastrointest Endosc 38 (1992):  93|Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|Bigler D, Eriksen J, Christensen CB "Prolonged respiratory depression caused by slow release morphine." Lancet 06/30/84 (1984):  1477|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sackner MA "Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease." Mt Sinai J Med 51 (1984):  222-6|Comstock MK, Carter JG, Moyers JR, Stevens WC "Rigidity and hypercarbia associated with high dose fentanyl induction of anesthesia." Anesth Analg 60 (1981):  362-3|Eisenach JC "Respiratory depression following intrathecal opioids." Anesthesiology 75 (1991):  712|Palmer CM "Early respiratory depression following intrathecal fentanyl-morphine combination." Anesthesiology 74 (1991):  1153-5|Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH "Profound respiratory depression after extradural fentanyl." Br J Anaesth 64 (1990):  243-5|Harper MH, Hickey RF, Cromwell TH, Linwood S "The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man." J Pharmacol Exp Ther 199 (1976):  464-8|Varrassi G, Celleno D, Capogna G, et al. "Ventilatory effects of subarachnoid fentanyl in the elderly." Anaesthesia 47 (1992):  558-62|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Ogawa K, Iranami H, Yoshiyama T, Maeda H, Hatano Y "Severe respiratory depression after epidural morphine in a patient with myotonic dystrophy." Can J Anaesth 40 (1993):  968-70|Noble DW, Morrison LM, Brockway MS, Mcclure JH "Respiratory depression after extradural fentanyl." Br J Anaesth 72 (1994):  251|Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE "The respiratory depressant effect of morphine - a comparative study in three ethnic groups." Anaesthesia 49 (1994):  197-201|Jackson FW "Fentanyl and the wooden chest." Gastroenterology 106 (1994):  820-1|Etches RC "Respiratory depression associated with patient-controlled analgesia - a review of eight cases." Can J Anaesth 41 (1994):  125-32|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J "A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy: analgesic, respiratory, and pharmacokinetic effects." Anesthesiology 81 (1994):  1169-80|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Hudson RJ "Apnoea and unconsciousness after apparent recovery from alfentanil- supplemented anaesthesia." Can J Anaesth 37 (1990):  255-7|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Morley AD "Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient." Anaesth Intensive Care 24 (1996):  287|Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM "Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil." J Pharmacol Exp Ther 274 (1995):  34-9|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26496, 0, 'Sufentanil', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26497, 0, 'Sufentanil', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26498, 0, 'Sufentanil', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26499, 0, 'Sufentanil', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26500, 0, 'Sufentanil', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26501, 0, 'Sufentanil', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26502, 1656, 'Sulfadiazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26503, 10463, 'Sulfadiazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26504, 20575, 'Sulfadiazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26505, 20576, 'Sulfadiazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26506, 20664, 'Sulfadiazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26507, 26982, 'Sulfadiazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26508, 30886, 'Sulfadiazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26509, 1656, 'Sulfadiazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26510, 10463, 'Sulfadiazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26511, 20575, 'Sulfadiazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26512, 20576, 'Sulfadiazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26513, 20664, 'Sulfadiazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26514, 26982, 'Sulfadiazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26515, 30886, 'Sulfadiazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26516, 1656, 'Sulfadiazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26517, 10463, 'Sulfadiazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26518, 20575, 'Sulfadiazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26519, 20576, 'Sulfadiazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26520, 20664, 'Sulfadiazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26521, 26982, 'Sulfadiazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26522, 30886, 'Sulfadiazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26523, 1656, 'Sulfadiazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26524, 10463, 'Sulfadiazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26525, 20575, 'Sulfadiazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26526, 20576, 'Sulfadiazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26527, 20664, 'Sulfadiazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26528, 26982, 'Sulfadiazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26529, 30886, 'Sulfadiazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26530, 1656, 'Sulfadiazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26531, 10463, 'Sulfadiazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26532, 20575, 'Sulfadiazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26533, 20576, 'Sulfadiazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26534, 20664, 'Sulfadiazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26535, 26982, 'Sulfadiazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26536, 30886, 'Sulfadiazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26537, 1656, 'Sulfadiazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26538, 10463, 'Sulfadiazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26539, 20575, 'Sulfadiazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26540, 20576, 'Sulfadiazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26541, 20664, 'Sulfadiazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26542, 26982, 'Sulfadiazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26543, 30886, 'Sulfadiazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26544, 1656, 'Sulfadiazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26545, 10463, 'Sulfadiazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26546, 20575, 'Sulfadiazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26547, 20576, 'Sulfadiazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26548, 20664, 'Sulfadiazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26549, 26982, 'Sulfadiazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26550, 30886, 'Sulfadiazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26551, 1656, 'Sulfadiazine', 'Diseases requiring hemodialysis', 'The sulfonamides, sulfadiazine, sulfamethoxazole, and sulfisoxazole, are partially removed by hemodialysis and should be administered after dialysis.', '2', 'Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Nissenson AR, Wilson C, Holazo A "Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis." Am J Nephrol 7 (1987):  270-4|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26552, 10463, 'Sulfadiazine', 'Diseases requiring hemodialysis', 'The sulfonamides, sulfadiazine, sulfamethoxazole, and sulfisoxazole, are partially removed by hemodialysis and should be administered after dialysis.', '2', 'Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Nissenson AR, Wilson C, Holazo A "Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis." Am J Nephrol 7 (1987):  270-4|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26553, 20575, 'Sulfadiazine', 'Diseases requiring hemodialysis', 'The sulfonamides, sulfadiazine, sulfamethoxazole, and sulfisoxazole, are partially removed by hemodialysis and should be administered after dialysis.', '2', 'Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Nissenson AR, Wilson C, Holazo A "Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis." Am J Nephrol 7 (1987):  270-4|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26554, 20576, 'Sulfadiazine', 'Diseases requiring hemodialysis', 'The sulfonamides, sulfadiazine, sulfamethoxazole, and sulfisoxazole, are partially removed by hemodialysis and should be administered after dialysis.', '2', 'Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Nissenson AR, Wilson C, Holazo A "Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis." Am J Nephrol 7 (1987):  270-4|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26555, 20664, 'Sulfadiazine', 'Diseases requiring hemodialysis', 'The sulfonamides, sulfadiazine, sulfamethoxazole, and sulfisoxazole, are partially removed by hemodialysis and should be administered after dialysis.', '2', 'Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Nissenson AR, Wilson C, Holazo A "Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis." Am J Nephrol 7 (1987):  270-4|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26556, 26982, 'Sulfadiazine', 'Diseases requiring hemodialysis', 'The sulfonamides, sulfadiazine, sulfamethoxazole, and sulfisoxazole, are partially removed by hemodialysis and should be administered after dialysis.', '2', 'Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Nissenson AR, Wilson C, Holazo A "Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis." Am J Nephrol 7 (1987):  270-4|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26557, 30886, 'Sulfadiazine', 'Diseases requiring hemodialysis', 'The sulfonamides, sulfadiazine, sulfamethoxazole, and sulfisoxazole, are partially removed by hemodialysis and should be administered after dialysis.', '2', 'Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Nissenson AR, Wilson C, Holazo A "Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis." Am J Nephrol 7 (1987):  270-4|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26558, 1656, 'Sulfadiazine', 'Urethral Obstruction', 'Sulfonamides are excreted and concentrated in the urine.  Therapy with sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly, especially during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26559, 10463, 'Sulfadiazine', 'Urethral Obstruction', 'Sulfonamides are excreted and concentrated in the urine.  Therapy with sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly, especially during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26560, 20575, 'Sulfadiazine', 'Urethral Obstruction', 'Sulfonamides are excreted and concentrated in the urine.  Therapy with sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly, especially during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26561, 20576, 'Sulfadiazine', 'Urethral Obstruction', 'Sulfonamides are excreted and concentrated in the urine.  Therapy with sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly, especially during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26562, 20664, 'Sulfadiazine', 'Urethral Obstruction', 'Sulfonamides are excreted and concentrated in the urine.  Therapy with sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly, especially during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26563, 26982, 'Sulfadiazine', 'Urethral Obstruction', 'Sulfonamides are excreted and concentrated in the urine.  Therapy with sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly, especially during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26564, 30886, 'Sulfadiazine', 'Urethral Obstruction', 'Sulfonamides are excreted and concentrated in the urine.  Therapy with sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly, especially during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26565, 15778, 'Sulfinpyrazone', 'Hematologic Diseases', 'The use of sulfinpyrazone is contraindicated in patients with a current or past history of blood dyscrasias.  Anemia, leukopenia, agranulocytosis, thrombocytopenia, and aplastic anemia have been reported rarely with sulfinpyrazone use.  Phenylbutazone, a structurally related agent, has been associated frequently with bone marrow suppression, as well as an increased risk of leukemia.  Periodic blood counts are recommended when sulfinpyrazone or other pyrazole compounds are used.', '3', '"Multum Information Services, Inc. Expert Review Panel"|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26566, 15779, 'Sulfinpyrazone', 'Hematologic Diseases', 'The use of sulfinpyrazone is contraindicated in patients with a current or past history of blood dyscrasias.  Anemia, leukopenia, agranulocytosis, thrombocytopenia, and aplastic anemia have been reported rarely with sulfinpyrazone use.  Phenylbutazone, a structurally related agent, has been associated frequently with bone marrow suppression, as well as an increased risk of leukemia.  Periodic blood counts are recommended when sulfinpyrazone or other pyrazole compounds are used.', '3', '"Multum Information Services, Inc. Expert Review Panel"|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26567, 15778, 'Sulfinpyrazone', 'Gastrointestinal Diseases', 'The use of sulfinpyrazone is contraindicated in patients with active peptic ulcer disease or symptoms of gastrointestinal inflammation or ulceration.  Sulfinpyrazone may commonly cause upper gastrointestinal irritation.  It may also aggravate or reactivate peptic ulcer.  Therapy with sulfinpyrazone may be administered cautiously in patients with a history of healed peptic ulcer.  Taking the medication with food, milk, or antacids may lessen GI adverse effects.', '3', '"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26568, 15779, 'Sulfinpyrazone', 'Gastrointestinal Diseases', 'The use of sulfinpyrazone is contraindicated in patients with active peptic ulcer disease or symptoms of gastrointestinal inflammation or ulceration.  Sulfinpyrazone may commonly cause upper gastrointestinal irritation.  It may also aggravate or reactivate peptic ulcer.  Therapy with sulfinpyrazone may be administered cautiously in patients with a history of healed peptic ulcer.  Taking the medication with food, milk, or antacids may lessen GI adverse effects.', '3', '"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26569, 15778, 'Sulfinpyrazone', 'Dehydration', 'Adequate hydration is necessary during therapy with sulfinpyrazone to prevent the renal precipitation of urates.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26570, 15779, 'Sulfinpyrazone', 'Dehydration', 'Adequate hydration is necessary during therapy with sulfinpyrazone to prevent the renal precipitation of urates.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', '"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26571, 15778, 'Sulfinpyrazone', 'Kidney Diseases', 'Renal failure has occasionally been reported with the use of sulfinpyrazone.  Therapy with sulfinpyrazone should be administered cautiously in patients with significant renal impairment.  Adequate hydration and periodic monitoring of renal function are recommended.', '2', '"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26572, 15779, 'Sulfinpyrazone', 'Kidney Diseases', 'Renal failure has occasionally been reported with the use of sulfinpyrazone.  Therapy with sulfinpyrazone should be administered cautiously in patients with significant renal impairment.  Adequate hydration and periodic monitoring of renal function are recommended.', '2', '"Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26573, 0, 'Sulfasalazine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26574, 0, 'Sulfasalazine', 'Intestinal Obstruction', 'The use of sulfasalazine is contraindicated in patients with intestinal obstruction.  Approximately one-third of orally administered sulfasalazine is systemically absorbed from the small intestine, while the majority is metabolized by intestinal bacteria to 5-aminosalicylic acid (5-ASA) that remains in the colonic lumen and gets excreted in the feces.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26575, 0, 'Sulfasalazine', 'Urethral Obstruction', 'The use of sulfasalazine tablets is contraindicated in patients with urinary obstruction.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26576, 0, 'Sulfasalazine', 'Hematologic Diseases', 'The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia.  Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):|Hopkinson ND, Garcia FS, Gumpel JM "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol 28 (1989):  414-7|Logan EC, Williamson LM, Ryrie DR "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut 27 (1986):  868-72', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26577, 0, 'Sulfasalazine', 'Hypersensitivity, Immediate', 'The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Fischl M, Dickinson G, LaVoie L "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA 259 (1988):  1185-9|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40|"Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26578, 0, 'Sulfasalazine', 'Liver Diseases', 'Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with sulfonamides should be administered cautiously in patients with liver disease.', '3', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Basista MP "Randomized study to evaluate efficacy and safety of ofloxacin vs trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection." Urology 37 (1991):  21-7|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 116 (1941):  2641-7|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Oie S, Gambertoglio JG, Fleckenstein L "Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing." J Pharmacokinet Biopharm 10 (1982):  157-72|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Peppercorn MA "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med 101 (1984):  377-86|Das KM, Chowdhury JR, Zapp B, Fara JW "Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats." Gastroenterology 77 (1979):  280-4|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|Bates CM "HIV medicine: drug side effects and interactions." Postgrad Med J 72 (1996):  30-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26579, 0, 'Sulfasalazine', 'Porphyrias', 'The use of sulfonamides is contraindicated in patients with porphyria, since these drugs can precipitate an acute attack.', '3', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26580, 0, 'Sulfasalazine', 'Kidney Diseases', 'Sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed weekly or as often as indicated by the patient''s status.  Rarely, alkalinization of the urine is necessary.', '3', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981):  206-11|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982):  461-70|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984):  125-31|Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972):  773-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26581, 0, 'Sulfasalazine', 'Folic Acid Deficiency', 'Sulfasalazine may interfere with the absorption of dietary folic acid.  Folate deficiency and megaloblastic anemia have been reported.  Therapy with sulfasalazine should be administered cautiously in patients with preexisting folate deficiency or anemia secondary to folate deficiency.  Folic acid supplementation (1 mg/day) is recommended in all patients during prolonged therapy.', '2', 'American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):|Halsted CH, Gandhi G, Tamura T "Sulfasalazine inhibits the absorption of folates in ulcerative colitis." N Engl J Med 305 (1981):  1513-7', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26582, 0, 'Sulfasalazine', 'Glucosephosphate Dehydrogenase Deficiency', 'Sulfasalazine may cause hemolytic anemia in patients with glucose-6 phosphate dehydrogenase deficiency.  This reaction is frequently dose related.  It is recommended to observe these patients closely for signs of hemolytic anemia, and if toxic reactions occur, the drug should be discontinued immediately.', '2', '"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26583, 0, 'Sulfasalazine', 'Crystalluria', 'Crystalluria can occur during sulfonamide therapy due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration (8 oz. glass of water with each dose and throughout the day) and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  Renal function tests and urinalysis should be performed weekly during prolonged therapy (> 2 weeks).  Rarely, alkalinization of the urine is necessary.', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984):  1467-74|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.|"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories  (2001):|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc  (2001):|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26584, 15480, 'Sugammadex', 'Hemorrhage', 'Sugammadex increases the risk of coagulopathies and bleeding.  It is recommended to carefully monitor coagulation parameters in patients with known coagulopathies being treated with therapeutic anticoagulation, receiving thromboprophylaxis drugs, other than heparin and low molecular weight heparin.', '2', '"Product Information. Bridion (sugammadex)." Merck & Co., Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26585, 15480, 'Sugammadex', 'Liver Diseases', 'Sugammadex is not metabolized nor excreted by the liver.  It is recommended to use caution when administering sugammadex to patients with hepatic impairment as no dedicated trials have been conducted in these patients.', '2', '"Product Information. Bridion (sugammadex)." Merck & Co., Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26586, 15480, 'Sugammadex', 'Kidney Diseases', 'Sugammadex is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be higher in patients with impaired renal function.  Dosage adjustment is not required in patients with mild to moderate renal impairment.  Sugammadex is not recommended for use in patients with severe renal impairment, including those requiring dialysis, due to insufficient safety information combined with the prolonged and increased overall exposure in these patients.', '2', '"Product Information. Bridion (sugammadex)." Merck & Co., Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26587, 5365, 'Sucralfate', 'Hypophosphatemia', 'Sucralfate has phosphate binding properties for which the drug is sometimes used therapeutically.  However, hypophosphatemia may occur in some patients, regardless of renal status.  Therapy with sucralfate should be administered cautiously in patients with preexisting hypophosphatemia.  Monitoring phosphate levels in these patients is recommended.', '3', 'McCarthy DM "Sucralfate." N Engl J Med 325 (1991):  1017-25|Chines A, Pacifici R "Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature." Calcif Tissue Int 47 (1990):  291-5|"Product Information. Carafate (sucralfate)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26588, 10957, 'Sucralfate', 'Hypophosphatemia', 'Sucralfate has phosphate binding properties for which the drug is sometimes used therapeutically.  However, hypophosphatemia may occur in some patients, regardless of renal status.  Therapy with sucralfate should be administered cautiously in patients with preexisting hypophosphatemia.  Monitoring phosphate levels in these patients is recommended.', '3', 'McCarthy DM "Sucralfate." N Engl J Med 325 (1991):  1017-25|Chines A, Pacifici R "Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature." Calcif Tissue Int 47 (1990):  291-5|"Product Information. Carafate (sucralfate)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26589, 27598, 'Sucralfate', 'Hypophosphatemia', 'Sucralfate has phosphate binding properties for which the drug is sometimes used therapeutically.  However, hypophosphatemia may occur in some patients, regardless of renal status.  Therapy with sucralfate should be administered cautiously in patients with preexisting hypophosphatemia.  Monitoring phosphate levels in these patients is recommended.', '3', 'McCarthy DM "Sucralfate." N Engl J Med 325 (1991):  1017-25|Chines A, Pacifici R "Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature." Calcif Tissue Int 47 (1990):  291-5|"Product Information. Carafate (sucralfate)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26590, 5365, 'Sucralfate', 'Kidney Diseases', 'Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum.  Additionally, aluminum does not cross dialysis membranes as it is bound to albumin and transferrin plasma proteins.  Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy), have been described in patients with renal impairment.  Sucralfate must be used with caution in patients with chronic renal failure.', '3', 'McCarthy DM "Sucralfate." N Engl J Med 325 (1991):  1017-25|Robertson JA, Salusky IB, Goodman WG, Norris KC, Coburn JW "Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis." Ann Intern Med 111 (1989):  179-81|Withers DJ, Woolf AS, Kingswood JC, Tsang WN, Mansell MA "Encephalopathy in patient taking aluminium-containing agents, including sucralfate ." Lancet 2 (1989):  674|Min DI, D''Elia JA "Sucralfate-associated aluminum toxicity in a patient with renal failure: treatment with deferoxamine." Clin Pharm 11 (1992):  636-9|Pai S, Melethil S, Cuddy P, Hall T "Elevation of serum aluminum in humans on a two-day sucralfate regimen." J Clin Pharmacol 27 (1987):  213-5|Campistol JM, Cases A, Botey A, Revert A "Acute aluminum encephalopathy in an uremic patient." Nephron 51 (1989):  103-6|"Product Information. Carafate (sucralfate)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26591, 10957, 'Sucralfate', 'Kidney Diseases', 'Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum.  Additionally, aluminum does not cross dialysis membranes as it is bound to albumin and transferrin plasma proteins.  Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy), have been described in patients with renal impairment.  Sucralfate must be used with caution in patients with chronic renal failure.', '3', 'McCarthy DM "Sucralfate." N Engl J Med 325 (1991):  1017-25|Robertson JA, Salusky IB, Goodman WG, Norris KC, Coburn JW "Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis." Ann Intern Med 111 (1989):  179-81|Withers DJ, Woolf AS, Kingswood JC, Tsang WN, Mansell MA "Encephalopathy in patient taking aluminium-containing agents, including sucralfate ." Lancet 2 (1989):  674|Min DI, D''Elia JA "Sucralfate-associated aluminum toxicity in a patient with renal failure: treatment with deferoxamine." Clin Pharm 11 (1992):  636-9|Pai S, Melethil S, Cuddy P, Hall T "Elevation of serum aluminum in humans on a two-day sucralfate regimen." J Clin Pharmacol 27 (1987):  213-5|Campistol JM, Cases A, Botey A, Revert A "Acute aluminum encephalopathy in an uremic patient." Nephron 51 (1989):  103-6|"Product Information. Carafate (sucralfate)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26592, 27598, 'Sucralfate', 'Kidney Diseases', 'Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum.  Additionally, aluminum does not cross dialysis membranes as it is bound to albumin and transferrin plasma proteins.  Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy), have been described in patients with renal impairment.  Sucralfate must be used with caution in patients with chronic renal failure.', '3', 'McCarthy DM "Sucralfate." N Engl J Med 325 (1991):  1017-25|Robertson JA, Salusky IB, Goodman WG, Norris KC, Coburn JW "Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis." Ann Intern Med 111 (1989):  179-81|Withers DJ, Woolf AS, Kingswood JC, Tsang WN, Mansell MA "Encephalopathy in patient taking aluminium-containing agents, including sucralfate ." Lancet 2 (1989):  674|Min DI, D''Elia JA "Sucralfate-associated aluminum toxicity in a patient with renal failure: treatment with deferoxamine." Clin Pharm 11 (1992):  636-9|Pai S, Melethil S, Cuddy P, Hall T "Elevation of serum aluminum in humans on a two-day sucralfate regimen." J Clin Pharmacol 27 (1987):  213-5|Campistol JM, Cases A, Botey A, Revert A "Acute aluminum encephalopathy in an uremic patient." Nephron 51 (1989):  103-6|"Product Information. Carafate (sucralfate)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26593, 0, 'Suprofen (ophthalmic)', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26594, 0, 'Suprofen (ophthalmic)', 'Blood Platelet Disorders', 'Topically applied nonsteroidal anti-inflammatory drugs (NSAIDs) are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  NSAIDs have been shown to reversibly inhibit platelet adhesion and aggregation and may slightly prolong bleeding time in healthy individuals.  These effects may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with ocular NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.', '2', 'Katz ME, Wang P "Fenoprofen-associated thrombocytopenia." Ann Intern Med 92 (1980):  262|Camba L, Joyner MV "Acute thrombocytopenia following ingestion of indomethacin." Acta Haematol 71 (1984):  350-2|Gandini R, Cunietti E, Pappalepore V, et al. "Effects of intravenous high doses of ketoprofen on blood clotting, bleeding time and platelet aggregation in man." J Int Med Res 11 (1983):  243|Poldre PA "Naproxen thrombocytopenia." Am J Hematol 31 (1989):  74|Stambaugh JE Jr, Gordon RL, Geller R "Leukopenia and thrombocytopenia secondary to clinoril therapy." Lancet 2 (1980):  594|Sanz MA, Martinez JA, Gomis F, Garcia-Borras JJ "Sulindac-induced bone marrow toxicity." Lancet 2 (1980):  802-3|Rosenbaum JT, O''Connor M "Thrombocytopenia associated with sulindac." Arthritis Rheum 24 (1981):  753-4|Shojania AM, Rusen SD "Thrombocytopenia secondary to sulindac therapy." Can Med Assoc J 125 (1981):  1313|Karachalios GN, Parigorakis JG "Thrombocytopenia and sulindac." Ann Intern Med 104 (1986):  128|Buchanan GR, Martin V, Levine PH, et al. "The effects of "anti-platelet" drugs on bleeding time and platelet aggregation in normal human subjects." Am J Clin Pathol 68 (1977):  355-9|Bobrove AM "Diflunisal-associated thrombocytopenia in a patient with rheumatoid arthritis ." Arthritis Rheum 31 (1988):  148-9|Green D, Holmes GI, et al. "Effects of diflunisal on platelet function and fecal blood loss." Pharmacotherapy 3 (1983):  s65-9|Khazan U, Toth M, Mutgi A "Diclofenac sodium and bruising ." Ann Intern Med 112 (1990):  472-3|Bondeson J, Berglund S "Diclofenac-induced thrombocytopenic purpura with renal and hepatic involvement." J Intern Med 230 (1991):  543-7|Price AJ, Obeid D "Spontaneous non-gastrointestinal bleeding associated with diclofenac ." Lancet 2 (1989):  1520|Epstein M, Vickars L, Stein H "Diclofenac induced immune thrombocytopenia." J Rheumatol 17 (1990):  1403-4|Kramer MR, Levene C, Hershko C "Severe reversible autoimmune haemolytic anaemia and thrombocytopenia associated with diclofenac therapy." Scand J Haematol 36 (1986):  118-20|Concannon MJ, Meng L, Welsh CF, Puckett CL "Inhibition of perioperative platelet aggregation using toradol (ketorolac)." Ann Plast Surg 30 (1993):  264-6|Bjornstad H, Vik O "Thrombocytopenic purpura associated with piroxicam." Br J Clin Pract 40 (1986):  42|"Product Information. Acular (ketorolac)." Allergan Inc  (2001):|"Product Information. Voltaren (diclofenac)." Ciba Vision Ophthalmics  (2001):|"Product Information. Ocufen (flurbiprofen ophthalmic)." Allergan Inc  (2022):|"Product Information. Profenal (suprofen ophthalmic)." Alcon Laboratories Inc  (2022):|Kim HL, Kovacs MJ "Diclofenac-associated thrombocytopenia and neutropenia." Ann Pharmacother 29 (1995):  713-5|Schafer AI "Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis." J Clin Pharmacol 35 (1995):  209-19|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|Thwaites BK, Nigus DB, Bouska GW, Mongan PD, Ayala EF, Merrill GA "Intravenous ketorolac tromethamine worsens platelet function during knee arthroscopy under spinal anesthesia." Anesth Analg 82 (1996):  1176-81|Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26595, 0, 'Belimumab', 'Infections', 'Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents.  Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections.  Caution should be exercised when considering their use in patients with severe or chronic infections.  It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.', '3', '"Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc  (2007):|"Product Information. BENLYSTA (belimumab)." GlaxoSmithKline  (2011):|"Product Information. Nulojix (belatacept)." Bristol-Myers Squibb  (2011):|"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):|"Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America  (2014):|"Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation  (2017):|"Product Information. Gamifant (emapalumab)." Sobi Inc  (2018):|"Product Information. Lupkynis (voclosporin)." Aurinia Pharma  (2021):|"Product Information. Saphnelo (anifrolumab)." Astra-Zeneca Pharmaceuticals  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26596, 0, 'Belimumab', 'Leukoencephalopathy, Progressive Multifocal', 'Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML).  Certain agents are contraindicated in patients who have or have had PML.  Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents.  Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML.  Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.', '3', '"Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc  (2004):|"Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc  (2007):|"Product Information. BENLYSTA (belimumab)." GlaxoSmithKline  (2011):|"Product Information. Nulojix (belatacept)." Bristol-Myers Squibb  (2011):|"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):|"Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America  (2014):|"Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26597, 0, 'Belimumab', 'Depressive Disorder', 'Psychiatric events have been reported with the use of belimumab.  Caution is recommended when prescribing this agent to patients with serious depression or suicidal behavior, history of depression, or other serious psychiatric disorders.  Patients receiving belimumab should be instructed to contact their healthcare provider if they experience new or worsening depression, suicidal thoughts, or other mood changes while on belimumab.', '2', '"Product Information. BENLYSTA (belimumab)." GlaxoSmithKline  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26598, 33745, 'Talazoparib', 'Hepatic Insufficiency', 'Talazoparib has not been studied in patients with moderate hepatic impairment (total bilirubin >1.5 to 3.0  upper limit of normal [ULN] and any aspartate aminotransferase [AST]) or severe hepatic impairment (total bilirubin >3.0  ULN and any AST).  No dose adjustment is required for patients with mild hepatic impairment (total bilirubin =1  ULN and AST > ULN, or total bilirubin >1.0 to 1.5  ULN and any AST).', '2', '"Product Information. Talzenna (talazoparib)." Pfizer U.S. Pharmaceuticals Group  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26599, 33745, 'Talazoparib', 'Bone Marrow Failure Disorders', 'Myelosuppression consisting of anemia, leukopenia/neutropenia, and/or thrombocytopenia, have been reported in patients treated with talazoparib.  Therapy with talazoparib should not be started in myelosuppressed patients and patients that have not adequately recovered from hematological toxicity caused by previous therapies.  If myelosuppression occurs during therapy, dose modifications are recommended.  Patients should be closely monitored.', '2', '"Product Information. Talzenna (talazoparib)." Pfizer U.S. Pharmaceuticals Group  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26600, 33745, 'Talazoparib', 'Kidney Diseases', 'Talazoparib has not been studied in patients with severe renal impairment (CrCl < 30 mL/min) or patients requiring hemodialysis.  Caution is advised if used in these patients.  A dose reduction is recommended in patients with moderate renal impairment (CrCl 30 - 59 mL/min), and no dose adjustment is required for patients with mild renal impairment (CrCl 60 - 89 mL/min).', '2', '"Product Information. Talzenna (talazoparib)." Pfizer U.S. Pharmaceuticals Group  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26601, 0, 'Tafamidis', 'Hypothyroidism', 'Tafamidis binds to transthyretin (TTR) at the thyroxine binding sites.  The use of tafamidis may decrease serum concentrations of total thyroxine, without an accompanying change in thyroid stimulating hormone (TSH).  The reduction in total thyroxine values is probably the result of reduced thyroxine binding to or displacement from transthyretin due to the high binding affinity of tafamidis to the TTR thyroxine receptor.  No corresponding clinical findings consistent with hypothyroidism have been observed.  Exercise care when using this agent in patients with hypothyroidism.', '2', '"Product Information. Vyndaqel (tafamidis)." Pfizer U.S. Pharmaceuticals Group  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26602, 0, 'Tafamidis', 'Liver Diseases', 'The use of tafamidis in patients with moderate hepatic impairment (Child-Pugh Score of 7 to 9) demonstrated decreased systemic exposure (approximately 40%) and increased clearance (approximately 68%) when compared to healthy subjects.  No clinically significant differences in the pharmacokinetics of tafamidis were observed in patients with mild hepatic impairment (Child Pugh Score of 5 to 6).  Use caution when using this agent in patients with severe hepatic impairment as its effect is unknown.', '2', '"Product Information. Vyndaqel (tafamidis)." Pfizer U.S. Pharmaceuticals Group  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26603, 6116, 'Sulindac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26604, 26395, 'Sulindac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26605, 26396, 'Sulindac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26606, 6116, 'Sulindac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26607, 26395, 'Sulindac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26608, 26396, 'Sulindac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26609, 6116, 'Sulindac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26610, 26395, 'Sulindac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26611, 26396, 'Sulindac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26612, 6116, 'Sulindac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26613, 26395, 'Sulindac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26614, 26396, 'Sulindac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26615, 6116, 'Sulindac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26616, 26395, 'Sulindac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26617, 26396, 'Sulindac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26618, 6116, 'Sulindac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26619, 26395, 'Sulindac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26620, 26396, 'Sulindac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26621, 6116, 'Sulindac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26622, 26395, 'Sulindac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26623, 26396, 'Sulindac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26624, 6116, 'Sulindac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26625, 26395, 'Sulindac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26626, 26396, 'Sulindac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26627, 6116, 'Sulindac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26628, 26395, 'Sulindac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26629, 26396, 'Sulindac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26630, 6116, 'Sulindac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26631, 26395, 'Sulindac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26632, 26396, 'Sulindac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26633, 6116, 'Sulindac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26634, 26395, 'Sulindac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26635, 26396, 'Sulindac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26636, 6116, 'Sulindac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26637, 26395, 'Sulindac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26638, 26396, 'Sulindac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26639, 6116, 'Sulindac', 'Nephrolithiasis', 'Sulindac metabolites have rarely been reported as the major or a minor component in renal stones in association with other calculus components.  Therapy with sulindac should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.', '2', '"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26640, 26395, 'Sulindac', 'Nephrolithiasis', 'Sulindac metabolites have rarely been reported as the major or a minor component in renal stones in association with other calculus components.  Therapy with sulindac should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.', '2', '"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26641, 26396, 'Sulindac', 'Nephrolithiasis', 'Sulindac metabolites have rarely been reported as the major or a minor component in renal stones in association with other calculus components.  Therapy with sulindac should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.', '2', '"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26642, 0, 'Tafenoquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Tafenoquine is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or unknown G6PD status due to the risk of hemolytic anemia.  All patients must be tested for G6PD deficiency prior to prescribing tafenoquine.', '3', '"Product Information. Arakoda (tafenoquine)." 60 Degrees Pharmaceuticals LLC  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26643, 0, 'Tafenoquine', 'Psychotic Disorders', 'Tafenoquine is contraindicated in patients with a history of psychotic disorders or current psychotic symptoms such as hallucinations, delusions, and/or grossly disorganized behavior.  If psychotic symptoms occur (hallucinations, delusions), consider discontinuation of tafenoquine and a prompt evaluation by a mental health professional as soon as possible.  Other psychiatric symptoms, such as changes in mood, anxiety, insomnia, and nightmares, should be promptly evaluated by a medical professional if they are moderate and last more than three days or are severe.', '3', '"Product Information. Arakoda (tafenoquine)." 60 Degrees Pharmaceuticals LLC  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26644, 0, 'Tafenoquine', 'Hepatic Insufficiency', 'The pharmacokinetics of tafenoquine have not been studied in patients with renal or hepatic impairment.  If tafenoquine is administered to such patients, close monitoring for adverse reactions is needed.', '2', '"Product Information. Arakoda (tafenoquine)." 60 Degrees Pharmaceuticals LLC  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26645, 0, 'Tacrine', 'Bradycardia', 'Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities.  Syncopal episodes have been reported in patients with and without cardiac abnormalities.  Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.', '3', 'Wilcock GK, Surmon D, Forsyth D, Morgan R "Cholinergic side-effects of tetrahydroaminoacridine." Lancet 2 (1988):  1305|"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Baldessarini RJ, Gelenberg AJ "Using physostigmine safely." Am J Psychiatry 136 (1979):  1608-9|Janowsky DS, Risch SC, Huey LY, Kennedy B, Ziegler M "Effects of physostigmine on pulse, blood pressure, and serum epinephrine levels." Am J Psychiatry 142 (1985):  738-40|Dysken MW, Janowsky DS "Dose-related physostigmine-induced ventricular arrhythmia: case report." J Clin Psychiatry 46 (1985):  446-7|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):|"Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26646, 0, 'Tacrine', 'Bronchial Spasm', 'Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine.  The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma or obstructive pulmonary disease.  Monitoring respiratory function during dosage initiation and adjustment is recommended.  Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress.  Neostigmine may produce more severe muscarinic side effects than does pyridostigmine and ambenonium.  However, the duration of action is longest for ambenonium and shortest for edrophonium.  Echothiophate iodide ophthalmic may be systemically absorbed and cautious use is recommended in these patients.', '3', 'Wilcock GK, Surmon D, Forsyth D, Morgan R "Cholinergic side-effects of tetrahydroaminoacridine." Lancet 2 (1988):  1305|"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):|"Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26647, 0, 'Tacrine', 'Coronary Artery Disease', 'The use of cholinesterase inhibitors  has been associated with a constriction of coronary arteries.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with coronary artery disease.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26648, 0, 'Tacrine', 'Parkinsonian Disorders', 'Cholinesterase inhibitors should be used with caution in patients with parkinsonism.  Some of these drugs might be contraindicated in these patients (refer to specific prescribing information).  Symptoms of Parkinson''s disease may be exacerbated with the increase in cholinergic activity.  Caregivers and patients should be advised.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|el-Yousef MK, Janowsky D, Davis JM, Sekerke HJ "Reversal of antiparkinsonian drug toxicity by physostigmine: a controlled study." Am J Psychiatry 130 (1973):  141-5|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26649, 0, 'Tacrine', 'Peptic Ulcer', 'The use of cholinesterase inhibitors is associated with an increase in gastric acid secretion and gastric contractions.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with peptic ulcer disease.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):|"Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26650, 0, 'Tacrine', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26651, 0, 'Tacrine', 'Liver Diseases', 'The use of tacrine is contraindicated in patients with a history of tacrine-induced jaundice confirmed by elevated total bilirubin greater than 3.0 mg/dl.  Elevations in liver function tests (LFTs) have been reported in as many as 50% of patients receiving tacrine. Twenty-five percent of patients may experience a 3 fold rise in ALT and 7% a 10 fold rise in ALT.  LFTs should be monitored prior to initiation of tacrine therapy is initiated and when dosages are altered.  Tacrine undergoes extensive first-pass metabolism by the liver (CYP450-1A2) to multiple forms.  The metabolic and therapeutic activity of tacrine can be altered in patients with compromised hepatic function and therapy with tacrine should be administered cautiously in these patients.', '3', 'Ford JM, Truman CA, Wilcock GK, Roberts CJ "Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer''s disease." Clin Pharmacol Ther 53 (1993):  691-5|Summers WK, Koehler AL, Marsh GM, Tachiki K, Kling A "Long-term hepatotoxicity of tacrine." Lancet 1 (1989):  729|Ames DJ, Bhathal PS, Davies BM, Fraser JR "Hepatotoxicity of tetrahydroaminoacridine." Lancet 1 (1988):  887|Ames DJ, Bhathal PS, Davies BM, Fraser JR, Gibson PR, Roberts S "Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine." Aust N Z J Med 20 (1990):  193-5|Hammel P, Larrey D, Bernuau J, Kalafat M, Freneaux E, Babany G, Degott C, Feldmann G, Pessayre D, Benhamou JP "Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer''s disease." J Clin Gastroenterol 12 (1990):  329-31|"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Knapp MJ, Knopman DS, Solomon PR, et al. "A 30-week randomized controlled trial of high-dose tacrine in patients with alzheimers disease." JAMA 271 (1994):  985-91|Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW "Hepatotoxic effects of tacrine administration in patients with alzheimers disease." JAMA 271 (1994):  992-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26652, 0, 'Tacrine', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26653, 0, 'Talimogene laherparepvec', 'IMMUNE SUPPRESSION', 'Talimogene laherparepvec is a live, attenuated herpes simplex virus.  The use talimogene laherparepvec is contraindicated in patients who are immunocompromised as its administration in these patients may cause life-threatening disseminated herpetic infection.', '3', '"Product Information. Imlygic (talimogene laherparepvec)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26654, 0, 'Talimogene laherparepvec', 'Immune Deficiency Disease', 'Do not administer talimogene laherparepvec to patients with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy.', '3', '"Product Information. Imlygic (talimogene laherparepvec)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26655, 0, 'Talimogene laherparepvec', 'Autoimmune Diseases', 'The use of talimogene laherparepvec may result in immune-mediated events.  Exercise care when using this agent in patients with underlying autoimmune disease or before continuing treatment in those patients that have developed immune-mediated events.  Close monitoring is recommended.', '2', '"Product Information. Imlygic (talimogene laherparepvec)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26656, 0, 'Talimogene laherparepvec', 'Multiple Myeloma', 'Plasmacytoma, in proximity to the injection site, has been reported after administration of talimogene laherparepvec in a patient with smoldering multiple myeloma.  It is recommended to consider the risks and benefits of treatment in patients with multiple myeloma or in whom plasmacytoma develops during treatment.  Close monitoring is recommended.', '2', '"Product Information. Imlygic (talimogene laherparepvec)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26657, 0, 'Tasimelteon', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26658, 0, 'Tasimelteon', 'Kidney Failure, Chronic', 'Some anxiolytic, sedative and hypnotic drugs have not been studied in patients with severe renal impairment and should not be used on these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26659, 0, 'Tasimelteon', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26660, 0, 'Tasimelteon', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26661, 12786, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26662, 13379, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26663, 24467, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26664, 24468, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26665, 26432, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26666, 27949, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26667, 27951, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26668, 28331, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26669, 29843, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26670, 29844, 'Tazarotene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26671, 12786, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26672, 13379, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26673, 24467, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26674, 24468, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26675, 26432, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26676, 27949, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26677, 27951, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26678, 28331, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26679, 29843, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26680, 29844, 'Tazarotene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989):  346|"Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Differin (adapalene topical)." Galderma Laboratories Inc  (2001):|"Product Information. Tazorac (tazarotene topical)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26681, 3184, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26682, 6831, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26683, 9228, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26684, 9229, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26685, 11160, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26686, 11161, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26687, 11162, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26688, 15376, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26689, 16953, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26690, 21318, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26691, 22063, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26692, 22204, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26693, 27871, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26694, 27890, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26695, 31881, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26696, 32696, 'Tamsulosin', 'Glaucoma', 'Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha 1 blockers, including tamsulosin.  The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.  The patient''s ophthalmologist should be aware if the patient is receiving treatment with this drug and should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.', '3', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26697, 3184, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26698, 6831, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26699, 9228, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26700, 9229, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26701, 11160, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26702, 11161, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26703, 11162, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26704, 15376, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26705, 16953, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26706, 21318, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26707, 22063, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26708, 22204, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26709, 27871, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26710, 27890, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26711, 31881, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26712, 32696, 'Tamsulosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26713, 3184, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26714, 6831, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26715, 9228, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26716, 9229, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26717, 11160, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26718, 11161, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26719, 11162, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26720, 15376, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26721, 16953, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26722, 21318, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26723, 22063, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26724, 22204, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26725, 27871, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26726, 27890, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26727, 31881, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26728, 32696, 'Tamsulosin', 'Kidney Failure, Chronic', 'Patients with renal impairment do not require an adjustment in tamsulosin dosing.  However, patients with end-stage renal disease (Clcr <10 mL/min) have not been studied.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26729, 3184, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26730, 6831, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26731, 9228, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26732, 9229, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26733, 11160, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26734, 11161, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26735, 11162, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26736, 15376, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26737, 16953, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26738, 21318, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26739, 22063, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26740, 22204, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26741, 27871, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26742, 27890, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26743, 31881, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26744, 32696, 'Tamsulosin', 'Liver Failure', 'Patients with moderate hepatic impairment do not require any adjustment in tamsulosin dosage.  Tamsulosin has not been studied in patients with severe hepatic impairment.', '2', '"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26745, 11196, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26746, 13242, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26747, 13502, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26748, 13503, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26749, 13504, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26750, 13514, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26751, 13515, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26752, 13516, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26753, 13517, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26754, 13518, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26755, 13519, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26756, 13520, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26757, 13521, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26758, 25434, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26759, 28422, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26760, 29518, 'Tacrolimus', 'Diabetes Mellitus', 'Tacrolimus can induce post-transplant insulin-dependent diabetes mellitus (PTDM).  Temporary insulin therapy has been required in some patients, while long-term insulin use has been necessary in others.   Reversible insulin dependence has occurred in kidney and liver transplant patients.  PTDM has occurred in a greater percentage of tacrolimus-treated (20%) versus cyclosporine-treated (4%) kidney transplant patients.   Black and Hispanic patients are at increased risk for PTDM.  Therapy with tacrolimus should be administered cautiously in patients with pre-transplant diabetes mellitus.', '3', 'Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE "Fk 506-associated diabetes mellitus in the pediatric transplant population is a rare complication." Transplant Proc 23 (1991):  3171-2|Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE "New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients." Transplant Proc 23 (1991):  3169-70|Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE "Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression." Transplant Proc 25 (1993):  2433-4|Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE "Long-term insulin requirement after liver transplantation with FK 506 in American veterans." Transplant Proc 25 (1993):  677-8|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26761, 11196, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26762, 13242, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26763, 13502, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26764, 13503, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26765, 13504, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26766, 13514, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26767, 13515, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26768, 13516, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26769, 13517, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26770, 13518, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26771, 13519, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26772, 13520, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26773, 13521, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26774, 25434, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26775, 28422, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26776, 29518, 'Tacrolimus', 'Liver Diseases', 'Tacrolimus undergoes significant hepatic metabolism, primarily by CYP450 3A enzymes.  Less than 5% of tacrolimus is eliminated unchanged in the bile and <1% is eliminated unchanged in the urine.  Moderate or severe hepatic dysfunction or impaired post-transplant hepatic function may alter the metabolic and therapeutic activity of tacrolimus and increase the whole blood tacrolimus concentration.  Therapy with tacrolimus should be administered cautiously and dosage adjustments considered in the presence of moderate or severe hepatic impairment.', '3', 'Mekki Q, Lee C, Aweeka F, et al. "Pharmacokinetics of tacrolimus (FL506) in kidney transplant patients." Clin Pharmacol Ther 53 (1993):  238|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26777, 11196, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26778, 13242, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26779, 13502, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26780, 13503, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26781, 13504, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26782, 13514, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26783, 13515, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26784, 13516, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26785, 13517, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26786, 13518, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26787, 13519, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26788, 13520, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26789, 13521, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26790, 25434, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26791, 28422, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26792, 29518, 'Tacrolimus', 'Infections', 'Due to immunosuppression, patients receiving tacrolimus are at increased risk for infections, including polyoma virus infections, post-transplant lymphoproliferative disorder (PTLD) and CMV viremia and CMV disease.  Polyoma virus infections in transplant patients may have serious, and sometimes fatal, outcomes.  These include polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, and JC virus-associated progressive multifocal leukoencephalopathy (PML).  Cases of PML have been reported in patients treated with tacrolimus.  Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function.  PTLD associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.  Patients that are Epstein-Barr Virus (EBV) seronegative appears to have the greatest risk of developing PTLD.  It is recommended to monitor EBV serology during tacrolimus therapy.  Caution and patient monitoring is recommended when using this drug in immunosuppressed patients.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26793, 11196, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26794, 13242, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26795, 13502, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26796, 13503, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26797, 13504, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26798, 13514, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26799, 13515, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26800, 13516, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26801, 13517, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26802, 13518, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26803, 13519, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26804, 13520, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26805, 13521, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26806, 25434, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26807, 28422, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26808, 29518, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26809, 11196, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26810, 13242, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26811, 13502, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26812, 13503, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26813, 13504, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26814, 13514, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26815, 13515, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26816, 13516, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26817, 13517, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26818, 13518, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26819, 13519, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26820, 13520, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26821, 13521, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26822, 25434, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26823, 28422, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26824, 29518, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', 'Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R "Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients." Transplant Proc 23 (1991):  3153-5|Sumpio BE, Phan S "Nephrotoxic potential of FK 506." Transplant Proc 23 (1991):  2789-90|McCauley J, Takaya S, Fung J, et al. "The question of FK 506 nephrotoxicity after liver transplantation." Transplant Proc 23 (1991):  1444-7|Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH "Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation." Mayo Clin Proc 69 (1994):  105-11|Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H "Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation." Transplant Proc 23 (1991):  3099-100|"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):|Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P "Nephrotoxicity following orthotopic liver transplantation - a comparison between cyclosporine and FK506." Transplantation 58 (1994):  170-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26825, 11196, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26826, 13242, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26827, 13502, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26828, 13503, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26829, 13504, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26830, 13514, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26831, 13515, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26832, 13516, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26833, 13517, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26834, 13518, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26835, 13519, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26836, 13520, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26837, 13521, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26838, 25434, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26839, 28422, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26840, 29518, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26841, 11196, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26842, 13242, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26843, 13502, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26844, 13503, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26845, 13504, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26846, 13514, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26847, 13515, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26848, 13516, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26849, 13517, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26850, 13518, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26851, 13519, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26852, 13520, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26853, 13521, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26854, 25434, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26855, 28422, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26856, 29518, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Prograf (tacrolimus)." Fujisawa  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26857, 6400, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26858, 16897, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26859, 20727, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26860, 27647, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26861, 27648, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26862, 27649, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26863, 6400, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26864, 16897, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26865, 20727, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26866, 27647, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26867, 27648, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26868, 27649, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26869, 6400, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', 'Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH "Disposition of sumatriptan in laboratory animals and humans." Drug Metab Dispos 21 (1993):  761-9|Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS "The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan." Eur Neurol 31 (1991):  291-4|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|"Product Information. Imitrex (SUMAtriptan)." GlaxoSmithKline  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26870, 16897, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', 'Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH "Disposition of sumatriptan in laboratory animals and humans." Drug Metab Dispos 21 (1993):  761-9|Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS "The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan." Eur Neurol 31 (1991):  291-4|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|"Product Information. Imitrex (SUMAtriptan)." GlaxoSmithKline  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26871, 20727, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', 'Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH "Disposition of sumatriptan in laboratory animals and humans." Drug Metab Dispos 21 (1993):  761-9|Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS "The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan." Eur Neurol 31 (1991):  291-4|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|"Product Information. Imitrex (SUMAtriptan)." GlaxoSmithKline  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26872, 27647, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', 'Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH "Disposition of sumatriptan in laboratory animals and humans." Drug Metab Dispos 21 (1993):  761-9|Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS "The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan." Eur Neurol 31 (1991):  291-4|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|"Product Information. Imitrex (SUMAtriptan)." GlaxoSmithKline  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26873, 27648, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', 'Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH "Disposition of sumatriptan in laboratory animals and humans." Drug Metab Dispos 21 (1993):  761-9|Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS "The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan." Eur Neurol 31 (1991):  291-4|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|"Product Information. Imitrex (SUMAtriptan)." GlaxoSmithKline  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26874, 27649, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', 'Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH "Disposition of sumatriptan in laboratory animals and humans." Drug Metab Dispos 21 (1993):  761-9|Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS "The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan." Eur Neurol 31 (1991):  291-4|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|"Product Information. Imitrex (SUMAtriptan)." GlaxoSmithKline  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26875, 6400, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26876, 16897, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26877, 20727, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26878, 27647, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26879, 27648, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26880, 27649, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26881, 8949, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '"Product Information. Soltamox (tamoxifen)." Cytogen Corporation  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26882, 11153, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '"Product Information. Soltamox (tamoxifen)." Cytogen Corporation  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26883, 11155, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '"Product Information. Soltamox (tamoxifen)." Cytogen Corporation  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26884, 27883, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '"Product Information. Soltamox (tamoxifen)." Cytogen Corporation  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26885, 27884, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '"Product Information. Soltamox (tamoxifen)." Cytogen Corporation  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26886, 27885, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '"Product Information. Soltamox (tamoxifen)." Cytogen Corporation  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26887, 8949, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', 'Ford MR, Turner MJ, Wood C, Soutter WP "Endometriosis developing during tamoxifen therapy." Am J Obstet Gynecol 158 (1988):  1119|Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA "Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy." Obstet Gynecol 79 (1992):  111-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Divers MJ "Massive endometrial polyp after tamoxifen therapy." Br J Clin Pract 49 (1995):  275-6|Neven P "Endometrial changes in patients on tamoxifen." Lancet 346 (1995):  1292|Shushan A, Peretz T, Uziely B, Lewin A, Moryosef S "Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer." Am J Obstet Gynecol 174 (1996):  141-4|Mcgonigle KF, Lantry SA, Odommaryon TL, Chai A, Vasilev SA, Simpson JF "Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status." Cancer Lett 101 (1996):  59-66|Court C "International group evaluates tamoxifen risks for women." BMJ 312 (1996):  529|Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, Muraca MG "Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen." Gynecol Oncol 60 (1996):  409-11|Fisher B "Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients." J Clin Oncol 14 (1996):  1027-39|Sasco AJ "Tamoxifen and menopausal status: risks and benefits." Lancet 347 (1996):  761|Coleman MP "Safety of tamoxifen." Lancet 347 (1996):  836-7|Cuenca RE, Giachino J, Arrendondo MA, Hempling R, Edge SB "Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use." Cancer 77 (1996):  2058-63|Ismail SM "The effects of tamoxifen on the uterus." Curr Opin Obstet Gynecol 8 (1996):  27-31|"Tamoxifen under scrutiny as carcinogen in California." Eur J Cancer 32A (1996):  567|Thylan S "Tamoxifen-associated ovarian cysts may be endometriomas." Am J Obstet Gynecol 175 (1996):  752', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26888, 11153, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', 'Ford MR, Turner MJ, Wood C, Soutter WP "Endometriosis developing during tamoxifen therapy." Am J Obstet Gynecol 158 (1988):  1119|Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA "Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy." Obstet Gynecol 79 (1992):  111-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Divers MJ "Massive endometrial polyp after tamoxifen therapy." Br J Clin Pract 49 (1995):  275-6|Neven P "Endometrial changes in patients on tamoxifen." Lancet 346 (1995):  1292|Shushan A, Peretz T, Uziely B, Lewin A, Moryosef S "Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer." Am J Obstet Gynecol 174 (1996):  141-4|Mcgonigle KF, Lantry SA, Odommaryon TL, Chai A, Vasilev SA, Simpson JF "Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status." Cancer Lett 101 (1996):  59-66|Court C "International group evaluates tamoxifen risks for women." BMJ 312 (1996):  529|Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, Muraca MG "Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen." Gynecol Oncol 60 (1996):  409-11|Fisher B "Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients." J Clin Oncol 14 (1996):  1027-39|Sasco AJ "Tamoxifen and menopausal status: risks and benefits." Lancet 347 (1996):  761|Coleman MP "Safety of tamoxifen." Lancet 347 (1996):  836-7|Cuenca RE, Giachino J, Arrendondo MA, Hempling R, Edge SB "Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use." Cancer 77 (1996):  2058-63|Ismail SM "The effects of tamoxifen on the uterus." Curr Opin Obstet Gynecol 8 (1996):  27-31|"Tamoxifen under scrutiny as carcinogen in California." Eur J Cancer 32A (1996):  567|Thylan S "Tamoxifen-associated ovarian cysts may be endometriomas." Am J Obstet Gynecol 175 (1996):  752', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26889, 11155, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', 'Ford MR, Turner MJ, Wood C, Soutter WP "Endometriosis developing during tamoxifen therapy." Am J Obstet Gynecol 158 (1988):  1119|Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA "Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy." Obstet Gynecol 79 (1992):  111-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Divers MJ "Massive endometrial polyp after tamoxifen therapy." Br J Clin Pract 49 (1995):  275-6|Neven P "Endometrial changes in patients on tamoxifen." Lancet 346 (1995):  1292|Shushan A, Peretz T, Uziely B, Lewin A, Moryosef S "Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer." Am J Obstet Gynecol 174 (1996):  141-4|Mcgonigle KF, Lantry SA, Odommaryon TL, Chai A, Vasilev SA, Simpson JF "Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status." Cancer Lett 101 (1996):  59-66|Court C "International group evaluates tamoxifen risks for women." BMJ 312 (1996):  529|Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, Muraca MG "Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen." Gynecol Oncol 60 (1996):  409-11|Fisher B "Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients." J Clin Oncol 14 (1996):  1027-39|Sasco AJ "Tamoxifen and menopausal status: risks and benefits." Lancet 347 (1996):  761|Coleman MP "Safety of tamoxifen." Lancet 347 (1996):  836-7|Cuenca RE, Giachino J, Arrendondo MA, Hempling R, Edge SB "Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use." Cancer 77 (1996):  2058-63|Ismail SM "The effects of tamoxifen on the uterus." Curr Opin Obstet Gynecol 8 (1996):  27-31|"Tamoxifen under scrutiny as carcinogen in California." Eur J Cancer 32A (1996):  567|Thylan S "Tamoxifen-associated ovarian cysts may be endometriomas." Am J Obstet Gynecol 175 (1996):  752', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26890, 27883, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', 'Ford MR, Turner MJ, Wood C, Soutter WP "Endometriosis developing during tamoxifen therapy." Am J Obstet Gynecol 158 (1988):  1119|Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA "Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy." Obstet Gynecol 79 (1992):  111-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Divers MJ "Massive endometrial polyp after tamoxifen therapy." Br J Clin Pract 49 (1995):  275-6|Neven P "Endometrial changes in patients on tamoxifen." Lancet 346 (1995):  1292|Shushan A, Peretz T, Uziely B, Lewin A, Moryosef S "Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer." Am J Obstet Gynecol 174 (1996):  141-4|Mcgonigle KF, Lantry SA, Odommaryon TL, Chai A, Vasilev SA, Simpson JF "Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status." Cancer Lett 101 (1996):  59-66|Court C "International group evaluates tamoxifen risks for women." BMJ 312 (1996):  529|Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, Muraca MG "Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen." Gynecol Oncol 60 (1996):  409-11|Fisher B "Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients." J Clin Oncol 14 (1996):  1027-39|Sasco AJ "Tamoxifen and menopausal status: risks and benefits." Lancet 347 (1996):  761|Coleman MP "Safety of tamoxifen." Lancet 347 (1996):  836-7|Cuenca RE, Giachino J, Arrendondo MA, Hempling R, Edge SB "Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use." Cancer 77 (1996):  2058-63|Ismail SM "The effects of tamoxifen on the uterus." Curr Opin Obstet Gynecol 8 (1996):  27-31|"Tamoxifen under scrutiny as carcinogen in California." Eur J Cancer 32A (1996):  567|Thylan S "Tamoxifen-associated ovarian cysts may be endometriomas." Am J Obstet Gynecol 175 (1996):  752', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26891, 27884, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', 'Ford MR, Turner MJ, Wood C, Soutter WP "Endometriosis developing during tamoxifen therapy." Am J Obstet Gynecol 158 (1988):  1119|Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA "Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy." Obstet Gynecol 79 (1992):  111-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Divers MJ "Massive endometrial polyp after tamoxifen therapy." Br J Clin Pract 49 (1995):  275-6|Neven P "Endometrial changes in patients on tamoxifen." Lancet 346 (1995):  1292|Shushan A, Peretz T, Uziely B, Lewin A, Moryosef S "Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer." Am J Obstet Gynecol 174 (1996):  141-4|Mcgonigle KF, Lantry SA, Odommaryon TL, Chai A, Vasilev SA, Simpson JF "Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status." Cancer Lett 101 (1996):  59-66|Court C "International group evaluates tamoxifen risks for women." BMJ 312 (1996):  529|Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, Muraca MG "Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen." Gynecol Oncol 60 (1996):  409-11|Fisher B "Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients." J Clin Oncol 14 (1996):  1027-39|Sasco AJ "Tamoxifen and menopausal status: risks and benefits." Lancet 347 (1996):  761|Coleman MP "Safety of tamoxifen." Lancet 347 (1996):  836-7|Cuenca RE, Giachino J, Arrendondo MA, Hempling R, Edge SB "Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use." Cancer 77 (1996):  2058-63|Ismail SM "The effects of tamoxifen on the uterus." Curr Opin Obstet Gynecol 8 (1996):  27-31|"Tamoxifen under scrutiny as carcinogen in California." Eur J Cancer 32A (1996):  567|Thylan S "Tamoxifen-associated ovarian cysts may be endometriomas." Am J Obstet Gynecol 175 (1996):  752', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26892, 27885, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', 'Ford MR, Turner MJ, Wood C, Soutter WP "Endometriosis developing during tamoxifen therapy." Am J Obstet Gynecol 158 (1988):  1119|Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA "Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy." Obstet Gynecol 79 (1992):  111-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Divers MJ "Massive endometrial polyp after tamoxifen therapy." Br J Clin Pract 49 (1995):  275-6|Neven P "Endometrial changes in patients on tamoxifen." Lancet 346 (1995):  1292|Shushan A, Peretz T, Uziely B, Lewin A, Moryosef S "Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer." Am J Obstet Gynecol 174 (1996):  141-4|Mcgonigle KF, Lantry SA, Odommaryon TL, Chai A, Vasilev SA, Simpson JF "Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status." Cancer Lett 101 (1996):  59-66|Court C "International group evaluates tamoxifen risks for women." BMJ 312 (1996):  529|Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, Muraca MG "Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen." Gynecol Oncol 60 (1996):  409-11|Fisher B "Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients." J Clin Oncol 14 (1996):  1027-39|Sasco AJ "Tamoxifen and menopausal status: risks and benefits." Lancet 347 (1996):  761|Coleman MP "Safety of tamoxifen." Lancet 347 (1996):  836-7|Cuenca RE, Giachino J, Arrendondo MA, Hempling R, Edge SB "Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use." Cancer 77 (1996):  2058-63|Ismail SM "The effects of tamoxifen on the uterus." Curr Opin Obstet Gynecol 8 (1996):  27-31|"Tamoxifen under scrutiny as carcinogen in California." Eur J Cancer 32A (1996):  567|Thylan S "Tamoxifen-associated ovarian cysts may be endometriomas." Am J Obstet Gynecol 175 (1996):  752', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26893, 8949, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', 'Loomus GN, Aneja P, Bota RA "A case of peliosis hepatis in association with tamoxifen therapy." Am J Clin Pathol 80 (1983):  881-3|Agrawal BL, Zelkowitz L "Bone ''flare,'' hypercalcemia, and jaundice after tamoxifen therapy ." Arch Intern Med 141 (1981):  1240|Blackburn AM, Amiel SA, Millis RR, Rubens RD "Tamoxifen and liver damage." Br Med J (Clin Res Ed) 289 (1984):  288|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Van Hoof M, Rahier J, Horsmans Y "Tamoxifen-induced steatohepatitis." Ann Intern Med 124 (1996):  855-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26894, 11153, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', 'Loomus GN, Aneja P, Bota RA "A case of peliosis hepatis in association with tamoxifen therapy." Am J Clin Pathol 80 (1983):  881-3|Agrawal BL, Zelkowitz L "Bone ''flare,'' hypercalcemia, and jaundice after tamoxifen therapy ." Arch Intern Med 141 (1981):  1240|Blackburn AM, Amiel SA, Millis RR, Rubens RD "Tamoxifen and liver damage." Br Med J (Clin Res Ed) 289 (1984):  288|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Van Hoof M, Rahier J, Horsmans Y "Tamoxifen-induced steatohepatitis." Ann Intern Med 124 (1996):  855-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26895, 11155, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', 'Loomus GN, Aneja P, Bota RA "A case of peliosis hepatis in association with tamoxifen therapy." Am J Clin Pathol 80 (1983):  881-3|Agrawal BL, Zelkowitz L "Bone ''flare,'' hypercalcemia, and jaundice after tamoxifen therapy ." Arch Intern Med 141 (1981):  1240|Blackburn AM, Amiel SA, Millis RR, Rubens RD "Tamoxifen and liver damage." Br Med J (Clin Res Ed) 289 (1984):  288|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Van Hoof M, Rahier J, Horsmans Y "Tamoxifen-induced steatohepatitis." Ann Intern Med 124 (1996):  855-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26896, 27883, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', 'Loomus GN, Aneja P, Bota RA "A case of peliosis hepatis in association with tamoxifen therapy." Am J Clin Pathol 80 (1983):  881-3|Agrawal BL, Zelkowitz L "Bone ''flare,'' hypercalcemia, and jaundice after tamoxifen therapy ." Arch Intern Med 141 (1981):  1240|Blackburn AM, Amiel SA, Millis RR, Rubens RD "Tamoxifen and liver damage." Br Med J (Clin Res Ed) 289 (1984):  288|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Van Hoof M, Rahier J, Horsmans Y "Tamoxifen-induced steatohepatitis." Ann Intern Med 124 (1996):  855-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26897, 27884, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', 'Loomus GN, Aneja P, Bota RA "A case of peliosis hepatis in association with tamoxifen therapy." Am J Clin Pathol 80 (1983):  881-3|Agrawal BL, Zelkowitz L "Bone ''flare,'' hypercalcemia, and jaundice after tamoxifen therapy ." Arch Intern Med 141 (1981):  1240|Blackburn AM, Amiel SA, Millis RR, Rubens RD "Tamoxifen and liver damage." Br Med J (Clin Res Ed) 289 (1984):  288|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Van Hoof M, Rahier J, Horsmans Y "Tamoxifen-induced steatohepatitis." Ann Intern Med 124 (1996):  855-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26898, 27885, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', 'Loomus GN, Aneja P, Bota RA "A case of peliosis hepatis in association with tamoxifen therapy." Am J Clin Pathol 80 (1983):  881-3|Agrawal BL, Zelkowitz L "Bone ''flare,'' hypercalcemia, and jaundice after tamoxifen therapy ." Arch Intern Med 141 (1981):  1240|Blackburn AM, Amiel SA, Millis RR, Rubens RD "Tamoxifen and liver damage." Br Med J (Clin Res Ed) 289 (1984):  288|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Van Hoof M, Rahier J, Horsmans Y "Tamoxifen-induced steatohepatitis." Ann Intern Med 124 (1996):  855-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26899, 8949, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', 'Love RR, Surawicz TS, Williams EC "Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy." Arch Intern Med 152 (1992):  317-20|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Mike V, Currie VE, Gee TS "Fatal neutropenia associated with long-term tamoxifen therapy." Lancet 344 (1994):  541-2', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26900, 11153, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', 'Love RR, Surawicz TS, Williams EC "Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy." Arch Intern Med 152 (1992):  317-20|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Mike V, Currie VE, Gee TS "Fatal neutropenia associated with long-term tamoxifen therapy." Lancet 344 (1994):  541-2', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26901, 11155, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', 'Love RR, Surawicz TS, Williams EC "Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy." Arch Intern Med 152 (1992):  317-20|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Mike V, Currie VE, Gee TS "Fatal neutropenia associated with long-term tamoxifen therapy." Lancet 344 (1994):  541-2', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26902, 27883, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', 'Love RR, Surawicz TS, Williams EC "Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy." Arch Intern Med 152 (1992):  317-20|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Mike V, Currie VE, Gee TS "Fatal neutropenia associated with long-term tamoxifen therapy." Lancet 344 (1994):  541-2', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26903, 27884, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', 'Love RR, Surawicz TS, Williams EC "Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy." Arch Intern Med 152 (1992):  317-20|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Mike V, Currie VE, Gee TS "Fatal neutropenia associated with long-term tamoxifen therapy." Lancet 344 (1994):  541-2', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26904, 27885, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', 'Love RR, Surawicz TS, Williams EC "Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy." Arch Intern Med 152 (1992):  317-20|Ching CK, Smith PG, Long RG "Tamoxifen-associated hepatocellular damage and agranulocytosis ." Lancet 339 (1992):  940|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Mike V, Currie VE, Gee TS "Fatal neutropenia associated with long-term tamoxifen therapy." Lancet 344 (1994):  541-2', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26905, 8949, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', 'Griffiths MF "Tamoxifen retinopathy at low dosage." Am J Ophthalmol 104 (1987):  185-6|Bentley CR, Davies G, Aclimandos WA "Tamoxifen retinopathy: a rare but serious complication." BMJ 304 (1992):  495-6|Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G "Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients." Cancer 69 (1992):  2961-4|Pugesgaard T, Von Eyben FE "Bilateral optic neuritis evolved during tamoxifen treatment." Cancer 58 (1986):  383-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ "Screening for ocular toxicity in asymptomatic patients treated with tamoxifen." Am J Ophthalmol 117 (1994):  772-5|Mihm LM, Barton TL "Tamoxifen-induced ocular toxicity." Ann Pharmacother 28 (1994):  740-2|Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN "Use of tamoxifen for breast cancer: twenty-eight years later." J Clin Oncol 13 (1995):  513-29', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26906, 11153, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', 'Griffiths MF "Tamoxifen retinopathy at low dosage." Am J Ophthalmol 104 (1987):  185-6|Bentley CR, Davies G, Aclimandos WA "Tamoxifen retinopathy: a rare but serious complication." BMJ 304 (1992):  495-6|Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G "Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients." Cancer 69 (1992):  2961-4|Pugesgaard T, Von Eyben FE "Bilateral optic neuritis evolved during tamoxifen treatment." Cancer 58 (1986):  383-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ "Screening for ocular toxicity in asymptomatic patients treated with tamoxifen." Am J Ophthalmol 117 (1994):  772-5|Mihm LM, Barton TL "Tamoxifen-induced ocular toxicity." Ann Pharmacother 28 (1994):  740-2|Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN "Use of tamoxifen for breast cancer: twenty-eight years later." J Clin Oncol 13 (1995):  513-29', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26907, 11155, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', 'Griffiths MF "Tamoxifen retinopathy at low dosage." Am J Ophthalmol 104 (1987):  185-6|Bentley CR, Davies G, Aclimandos WA "Tamoxifen retinopathy: a rare but serious complication." BMJ 304 (1992):  495-6|Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G "Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients." Cancer 69 (1992):  2961-4|Pugesgaard T, Von Eyben FE "Bilateral optic neuritis evolved during tamoxifen treatment." Cancer 58 (1986):  383-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ "Screening for ocular toxicity in asymptomatic patients treated with tamoxifen." Am J Ophthalmol 117 (1994):  772-5|Mihm LM, Barton TL "Tamoxifen-induced ocular toxicity." Ann Pharmacother 28 (1994):  740-2|Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN "Use of tamoxifen for breast cancer: twenty-eight years later." J Clin Oncol 13 (1995):  513-29', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26908, 27883, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', 'Griffiths MF "Tamoxifen retinopathy at low dosage." Am J Ophthalmol 104 (1987):  185-6|Bentley CR, Davies G, Aclimandos WA "Tamoxifen retinopathy: a rare but serious complication." BMJ 304 (1992):  495-6|Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G "Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients." Cancer 69 (1992):  2961-4|Pugesgaard T, Von Eyben FE "Bilateral optic neuritis evolved during tamoxifen treatment." Cancer 58 (1986):  383-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ "Screening for ocular toxicity in asymptomatic patients treated with tamoxifen." Am J Ophthalmol 117 (1994):  772-5|Mihm LM, Barton TL "Tamoxifen-induced ocular toxicity." Ann Pharmacother 28 (1994):  740-2|Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN "Use of tamoxifen for breast cancer: twenty-eight years later." J Clin Oncol 13 (1995):  513-29', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26909, 27884, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', 'Griffiths MF "Tamoxifen retinopathy at low dosage." Am J Ophthalmol 104 (1987):  185-6|Bentley CR, Davies G, Aclimandos WA "Tamoxifen retinopathy: a rare but serious complication." BMJ 304 (1992):  495-6|Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G "Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients." Cancer 69 (1992):  2961-4|Pugesgaard T, Von Eyben FE "Bilateral optic neuritis evolved during tamoxifen treatment." Cancer 58 (1986):  383-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ "Screening for ocular toxicity in asymptomatic patients treated with tamoxifen." Am J Ophthalmol 117 (1994):  772-5|Mihm LM, Barton TL "Tamoxifen-induced ocular toxicity." Ann Pharmacother 28 (1994):  740-2|Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN "Use of tamoxifen for breast cancer: twenty-eight years later." J Clin Oncol 13 (1995):  513-29', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26910, 27885, 'Tamoxifen', 'Vision Disorders', 'Corneal changes, cataracts, and retinopathy have been reported during tamoxifen therapy.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to visual disturbances.', '2', 'Griffiths MF "Tamoxifen retinopathy at low dosage." Am J Ophthalmol 104 (1987):  185-6|Bentley CR, Davies G, Aclimandos WA "Tamoxifen retinopathy: a rare but serious complication." BMJ 304 (1992):  495-6|Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G "Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients." Cancer 69 (1992):  2961-4|Pugesgaard T, Von Eyben FE "Bilateral optic neuritis evolved during tamoxifen treatment." Cancer 58 (1986):  383-6|"Product Information. Nolvadex (tamoxifen)." Astra-Zeneca Pharmaceuticals  (2001):|Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ "Screening for ocular toxicity in asymptomatic patients treated with tamoxifen." Am J Ophthalmol 117 (1994):  772-5|Mihm LM, Barton TL "Tamoxifen-induced ocular toxicity." Ann Pharmacother 28 (1994):  740-2|Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN "Use of tamoxifen for breast cancer: twenty-eight years later." J Clin Oncol 13 (1995):  513-29', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26911, 4949, 'Sunitinib', 'Liver Diseases', 'The use of sunitinib has been associated with hepatotoxicity, including hepatic failure and in some cases with fatal outcomes.  Patients with hepatic impairment (total bilirubin > upper limit of normal (ULN) or Child-Pugh A, B and C) should be closely monitored during therapy with sunitinib.  Safety in patients with ALT or AST >2.5  ULN or, if due to liver metastases, >5.0  ULN has not been established.  Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended during treatment and increase frequency of monitoring is required for patients with preexisting or existing hepatic impairment.  Obtain periodic liver function testing and withhold for Grade 3 or 4 drug-related hepatic adverse events.  Discontinued if symptoms of pancreatitis or hepatic failure are present.  Do not restart sunitinib if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.', '3', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26912, 27741, 'Sunitinib', 'Liver Diseases', 'The use of sunitinib has been associated with hepatotoxicity, including hepatic failure and in some cases with fatal outcomes.  Patients with hepatic impairment (total bilirubin > upper limit of normal (ULN) or Child-Pugh A, B and C) should be closely monitored during therapy with sunitinib.  Safety in patients with ALT or AST >2.5  ULN or, if due to liver metastases, >5.0  ULN has not been established.  Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended during treatment and increase frequency of monitoring is required for patients with preexisting or existing hepatic impairment.  Obtain periodic liver function testing and withhold for Grade 3 or 4 drug-related hepatic adverse events.  Discontinued if symptoms of pancreatitis or hepatic failure are present.  Do not restart sunitinib if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.', '3', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26913, 27742, 'Sunitinib', 'Liver Diseases', 'The use of sunitinib has been associated with hepatotoxicity, including hepatic failure and in some cases with fatal outcomes.  Patients with hepatic impairment (total bilirubin > upper limit of normal (ULN) or Child-Pugh A, B and C) should be closely monitored during therapy with sunitinib.  Safety in patients with ALT or AST >2.5  ULN or, if due to liver metastases, >5.0  ULN has not been established.  Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended during treatment and increase frequency of monitoring is required for patients with preexisting or existing hepatic impairment.  Obtain periodic liver function testing and withhold for Grade 3 or 4 drug-related hepatic adverse events.  Discontinued if symptoms of pancreatitis or hepatic failure are present.  Do not restart sunitinib if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.', '3', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26914, 27743, 'Sunitinib', 'Liver Diseases', 'The use of sunitinib has been associated with hepatotoxicity, including hepatic failure and in some cases with fatal outcomes.  Patients with hepatic impairment (total bilirubin > upper limit of normal (ULN) or Child-Pugh A, B and C) should be closely monitored during therapy with sunitinib.  Safety in patients with ALT or AST >2.5  ULN or, if due to liver metastases, >5.0  ULN has not been established.  Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended during treatment and increase frequency of monitoring is required for patients with preexisting or existing hepatic impairment.  Obtain periodic liver function testing and withhold for Grade 3 or 4 drug-related hepatic adverse events.  Discontinued if symptoms of pancreatitis or hepatic failure are present.  Do not restart sunitinib if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.', '3', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26915, 4949, 'Sunitinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26916, 27741, 'Sunitinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26917, 27742, 'Sunitinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26918, 27743, 'Sunitinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26919, 4949, 'Sunitinib', 'Adrenal Insufficiency', 'Caution should be exercised when prescribing sunitinib in patients that elicit a stress response due to the hormonal and metabolic changes resulting from an injury, trauma, or a severe infection.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26920, 27741, 'Sunitinib', 'Adrenal Insufficiency', 'Caution should be exercised when prescribing sunitinib in patients that elicit a stress response due to the hormonal and metabolic changes resulting from an injury, trauma, or a severe infection.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26921, 27742, 'Sunitinib', 'Adrenal Insufficiency', 'Caution should be exercised when prescribing sunitinib in patients that elicit a stress response due to the hormonal and metabolic changes resulting from an injury, trauma, or a severe infection.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26922, 27743, 'Sunitinib', 'Adrenal Insufficiency', 'Caution should be exercised when prescribing sunitinib in patients that elicit a stress response due to the hormonal and metabolic changes resulting from an injury, trauma, or a severe infection.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26923, 4949, 'Sunitinib', 'Cardiovascular Diseases', 'The use of sunitinib has been associated with adverse cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal.  Because of these risks, physicians are advised to weigh this risk against the potential benefits of the drug when prescribing this drug to patients with cardiovascular dysfunction.  These patients should be carefully monitored and baseline and periodic evaluations of cardiovascular function should be considered while these patients are receiving sunitinib, especial caution is recommended in patients who are at risk for, or who have a history of cardiovascular events.  In patients without cardiac risk factors, a baseline evaluation of ejection fraction should be considered.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26924, 27741, 'Sunitinib', 'Cardiovascular Diseases', 'The use of sunitinib has been associated with adverse cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal.  Because of these risks, physicians are advised to weigh this risk against the potential benefits of the drug when prescribing this drug to patients with cardiovascular dysfunction.  These patients should be carefully monitored and baseline and periodic evaluations of cardiovascular function should be considered while these patients are receiving sunitinib, especial caution is recommended in patients who are at risk for, or who have a history of cardiovascular events.  In patients without cardiac risk factors, a baseline evaluation of ejection fraction should be considered.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26925, 27742, 'Sunitinib', 'Cardiovascular Diseases', 'The use of sunitinib has been associated with adverse cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal.  Because of these risks, physicians are advised to weigh this risk against the potential benefits of the drug when prescribing this drug to patients with cardiovascular dysfunction.  These patients should be carefully monitored and baseline and periodic evaluations of cardiovascular function should be considered while these patients are receiving sunitinib, especial caution is recommended in patients who are at risk for, or who have a history of cardiovascular events.  In patients without cardiac risk factors, a baseline evaluation of ejection fraction should be considered.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26926, 27743, 'Sunitinib', 'Cardiovascular Diseases', 'The use of sunitinib has been associated with adverse cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal.  Because of these risks, physicians are advised to weigh this risk against the potential benefits of the drug when prescribing this drug to patients with cardiovascular dysfunction.  These patients should be carefully monitored and baseline and periodic evaluations of cardiovascular function should be considered while these patients are receiving sunitinib, especial caution is recommended in patients who are at risk for, or who have a history of cardiovascular events.  In patients without cardiac risk factors, a baseline evaluation of ejection fraction should be considered.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26927, 4949, 'Sunitinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of sunitinib.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving this agent.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of this agent for dermatologic or soft tissue toxicity associated with severe or life-threatening complications.  If a diagnosis of Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected treatment with sunitinib must not be re-started.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26928, 27741, 'Sunitinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of sunitinib.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving this agent.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of this agent for dermatologic or soft tissue toxicity associated with severe or life-threatening complications.  If a diagnosis of Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected treatment with sunitinib must not be re-started.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26929, 27742, 'Sunitinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of sunitinib.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving this agent.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of this agent for dermatologic or soft tissue toxicity associated with severe or life-threatening complications.  If a diagnosis of Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected treatment with sunitinib must not be re-started.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26930, 27743, 'Sunitinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of sunitinib.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving this agent.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of this agent for dermatologic or soft tissue toxicity associated with severe or life-threatening complications.  If a diagnosis of Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected treatment with sunitinib must not be re-started.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26931, 4949, 'Sunitinib', 'Hemorrhage', 'The use of sunitinib has been associated with hemorrhagic events, some of which have been fatal.  Caution should be exercised in patients with or predisposed to bleeding complications.  Clinical assessment of these patients should include serial complete blood counts and physical examinations.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26932, 27741, 'Sunitinib', 'Hemorrhage', 'The use of sunitinib has been associated with hemorrhagic events, some of which have been fatal.  Caution should be exercised in patients with or predisposed to bleeding complications.  Clinical assessment of these patients should include serial complete blood counts and physical examinations.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26933, 27742, 'Sunitinib', 'Hemorrhage', 'The use of sunitinib has been associated with hemorrhagic events, some of which have been fatal.  Caution should be exercised in patients with or predisposed to bleeding complications.  Clinical assessment of these patients should include serial complete blood counts and physical examinations.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26934, 27743, 'Sunitinib', 'Hemorrhage', 'The use of sunitinib has been associated with hemorrhagic events, some of which have been fatal.  Caution should be exercised in patients with or predisposed to bleeding complications.  Clinical assessment of these patients should include serial complete blood counts and physical examinations.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26935, 4949, 'Sunitinib', 'Hypertension', 'The use of sunitinib has been associated with hypertension and it should be used with caution in patients with elevated blood pressure.  Therapy with sunitinib should be withheld in case of severe hypertension and appropriate measures should be taken to correct the blood pressure to acceptable readings.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26936, 27741, 'Sunitinib', 'Hypertension', 'The use of sunitinib has been associated with hypertension and it should be used with caution in patients with elevated blood pressure.  Therapy with sunitinib should be withheld in case of severe hypertension and appropriate measures should be taken to correct the blood pressure to acceptable readings.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26937, 27742, 'Sunitinib', 'Hypertension', 'The use of sunitinib has been associated with hypertension and it should be used with caution in patients with elevated blood pressure.  Therapy with sunitinib should be withheld in case of severe hypertension and appropriate measures should be taken to correct the blood pressure to acceptable readings.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26938, 27743, 'Sunitinib', 'Hypertension', 'The use of sunitinib has been associated with hypertension and it should be used with caution in patients with elevated blood pressure.  Therapy with sunitinib should be withheld in case of severe hypertension and appropriate measures should be taken to correct the blood pressure to acceptable readings.  Close monitoring of blood pressure is recommended.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26939, 4949, 'Sunitinib', 'Hypoglycemia', 'The use of sunitinib has been associated with symptomatic hypoglycemia, resulting in loss of consciousness or hospitalization.  Patients with diabetes mellitus should be monitored more closely during and after discontinuation of treatment with sunitinib, and their antidiabetic regimen should be adjusted accordingly.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26940, 27741, 'Sunitinib', 'Hypoglycemia', 'The use of sunitinib has been associated with symptomatic hypoglycemia, resulting in loss of consciousness or hospitalization.  Patients with diabetes mellitus should be monitored more closely during and after discontinuation of treatment with sunitinib, and their antidiabetic regimen should be adjusted accordingly.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26941, 27742, 'Sunitinib', 'Hypoglycemia', 'The use of sunitinib has been associated with symptomatic hypoglycemia, resulting in loss of consciousness or hospitalization.  Patients with diabetes mellitus should be monitored more closely during and after discontinuation of treatment with sunitinib, and their antidiabetic regimen should be adjusted accordingly.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26942, 27743, 'Sunitinib', 'Hypoglycemia', 'The use of sunitinib has been associated with symptomatic hypoglycemia, resulting in loss of consciousness or hospitalization.  Patients with diabetes mellitus should be monitored more closely during and after discontinuation of treatment with sunitinib, and their antidiabetic regimen should be adjusted accordingly.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26943, 4949, 'Sunitinib', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking sunitinib.  Patients with risk factors, such as those taking bisphosphonate medications or that have a dental disease could be at an increased risk of developing ONJ.  Close monitoring should be exercise when prescribing sunitinib to these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26944, 27741, 'Sunitinib', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking sunitinib.  Patients with risk factors, such as those taking bisphosphonate medications or that have a dental disease could be at an increased risk of developing ONJ.  Close monitoring should be exercise when prescribing sunitinib to these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26945, 27742, 'Sunitinib', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking sunitinib.  Patients with risk factors, such as those taking bisphosphonate medications or that have a dental disease could be at an increased risk of developing ONJ.  Close monitoring should be exercise when prescribing sunitinib to these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26946, 27743, 'Sunitinib', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking sunitinib.  Patients with risk factors, such as those taking bisphosphonate medications or that have a dental disease could be at an increased risk of developing ONJ.  Close monitoring should be exercise when prescribing sunitinib to these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26947, 4949, 'Sunitinib', 'Proteinuria', 'Therapy with sunitinib should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  Patients with nephrotic syndrome or repeat episodes of urine protein >=3 grams despite dose reductions should be instructed to withhold the dose of sunitinib and take appropriate actions according to clinical standards.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26948, 27741, 'Sunitinib', 'Proteinuria', 'Therapy with sunitinib should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  Patients with nephrotic syndrome or repeat episodes of urine protein >=3 grams despite dose reductions should be instructed to withhold the dose of sunitinib and take appropriate actions according to clinical standards.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26949, 27742, 'Sunitinib', 'Proteinuria', 'Therapy with sunitinib should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  Patients with nephrotic syndrome or repeat episodes of urine protein >=3 grams despite dose reductions should be instructed to withhold the dose of sunitinib and take appropriate actions according to clinical standards.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26950, 27743, 'Sunitinib', 'Proteinuria', 'Therapy with sunitinib should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  Patients with nephrotic syndrome or repeat episodes of urine protein >=3 grams despite dose reductions should be instructed to withhold the dose of sunitinib and take appropriate actions according to clinical standards.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26951, 4949, 'Sunitinib', 'Long QT Syndrome', 'Sunitinib can cause QT prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  This agent should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected before initiating therapy with this agent.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26952, 27741, 'Sunitinib', 'Long QT Syndrome', 'Sunitinib can cause QT prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  This agent should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected before initiating therapy with this agent.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26953, 27742, 'Sunitinib', 'Long QT Syndrome', 'Sunitinib can cause QT prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  This agent should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected before initiating therapy with this agent.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26954, 27743, 'Sunitinib', 'Long QT Syndrome', 'Sunitinib can cause QT prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  This agent should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected before initiating therapy with this agent.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26955, 4949, 'Sunitinib', 'Thyroid Diseases', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients taking sunitinib.  Therapy with sunitinib should be administered cautiously to patients with thyroid dysfunction.  Baseline laboratory measurement of thyroid function is recommended and if appropriate, treatment per standard medical practice should be given prior to initiation of therapy.  Clinical monitoring of thyroid function is recommended during therapy.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26956, 27741, 'Sunitinib', 'Thyroid Diseases', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients taking sunitinib.  Therapy with sunitinib should be administered cautiously to patients with thyroid dysfunction.  Baseline laboratory measurement of thyroid function is recommended and if appropriate, treatment per standard medical practice should be given prior to initiation of therapy.  Clinical monitoring of thyroid function is recommended during therapy.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26957, 27742, 'Sunitinib', 'Thyroid Diseases', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients taking sunitinib.  Therapy with sunitinib should be administered cautiously to patients with thyroid dysfunction.  Baseline laboratory measurement of thyroid function is recommended and if appropriate, treatment per standard medical practice should be given prior to initiation of therapy.  Clinical monitoring of thyroid function is recommended during therapy.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26958, 27743, 'Sunitinib', 'Thyroid Diseases', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients taking sunitinib.  Therapy with sunitinib should be administered cautiously to patients with thyroid dysfunction.  Baseline laboratory measurement of thyroid function is recommended and if appropriate, treatment per standard medical practice should be given prior to initiation of therapy.  Clinical monitoring of thyroid function is recommended during therapy.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26959, 4949, 'Sunitinib', 'Kidney Diseases', 'No dosage adjustment of sunitinib is necessary in patients with renal impairment.  However, when sunitinib therapy was given to patients with end-stage renal disease (ESRD) or on hemodialysis, the systemic exposure was 47% lower in subjects with ESRD on hemodialysis compared to subjects with normal renal function.  Therefore, the subsequent doses may be increased gradually up to 2 fold based on safety and tolerability.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26960, 27741, 'Sunitinib', 'Kidney Diseases', 'No dosage adjustment of sunitinib is necessary in patients with renal impairment.  However, when sunitinib therapy was given to patients with end-stage renal disease (ESRD) or on hemodialysis, the systemic exposure was 47% lower in subjects with ESRD on hemodialysis compared to subjects with normal renal function.  Therefore, the subsequent doses may be increased gradually up to 2 fold based on safety and tolerability.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26961, 27742, 'Sunitinib', 'Kidney Diseases', 'No dosage adjustment of sunitinib is necessary in patients with renal impairment.  However, when sunitinib therapy was given to patients with end-stage renal disease (ESRD) or on hemodialysis, the systemic exposure was 47% lower in subjects with ESRD on hemodialysis compared to subjects with normal renal function.  Therefore, the subsequent doses may be increased gradually up to 2 fold based on safety and tolerability.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26962, 27743, 'Sunitinib', 'Kidney Diseases', 'No dosage adjustment of sunitinib is necessary in patients with renal impairment.  However, when sunitinib therapy was given to patients with end-stage renal disease (ESRD) or on hemodialysis, the systemic exposure was 47% lower in subjects with ESRD on hemodialysis compared to subjects with normal renal function.  Therefore, the subsequent doses may be increased gradually up to 2 fold based on safety and tolerability.', '2', '"Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26963, 0, 'Suvorexant', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26964, 0, 'Suvorexant', 'Kidney Failure, Chronic', 'Some anxiolytic, sedative and hypnotic drugs have not been studied in patients with severe renal impairment and should not be used on these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26965, 0, 'Suvorexant', 'Lung Diseases', 'Suvorexant has respiratory depressant effects and should be used with caution in patients with compromised respiratory function.  Suvorexant has not been studied in patients with severe sleep apnea and severe COPD and should not be used in these patients.', '3', '"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26966, 0, 'Suvorexant', 'Narcolepsy', 'The use of suvorexant is contraindicated in patient with narcolepsy.', '3', '"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26967, 0, 'Suvorexant', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26968, 0, 'Suvorexant', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26969, 16929, 'Tedizolid', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26970, 27970, 'Tedizolid', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26971, 30009, 'Tedizolid', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26972, 16929, 'Tedizolid', 'Neutropenia', 'The antibacterial activity of tedizolid may be reduced in the absence of granulocytes.  In the mouse thigh infection model of Staphylococcus aureus, bacterial stasis was achieved in non-granulocytopenic mice at a human-equivalent dose of approximately 100 mg/day, whereas a human-equivalent dose of approximately 2000 mg/day was required in granulocytopenic mice with neutrophil count less than 100 cells/mL.  The safety and efficacy of tedizolid in patients with neutropenia (neutrophil counts <1000 cells/mm3) have not been adequately evaluated.  Alternative antibiotics should be considered in neutropenic patients who require treatment for acute bacterial skin and skin structure infections.', '3', '"Product Information. Sivextro (tedizolid)." Cubist Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26973, 27970, 'Tedizolid', 'Neutropenia', 'The antibacterial activity of tedizolid may be reduced in the absence of granulocytes.  In the mouse thigh infection model of Staphylococcus aureus, bacterial stasis was achieved in non-granulocytopenic mice at a human-equivalent dose of approximately 100 mg/day, whereas a human-equivalent dose of approximately 2000 mg/day was required in granulocytopenic mice with neutrophil count less than 100 cells/mL.  The safety and efficacy of tedizolid in patients with neutropenia (neutrophil counts <1000 cells/mm3) have not been adequately evaluated.  Alternative antibiotics should be considered in neutropenic patients who require treatment for acute bacterial skin and skin structure infections.', '3', '"Product Information. Sivextro (tedizolid)." Cubist Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26974, 30009, 'Tedizolid', 'Neutropenia', 'The antibacterial activity of tedizolid may be reduced in the absence of granulocytes.  In the mouse thigh infection model of Staphylococcus aureus, bacterial stasis was achieved in non-granulocytopenic mice at a human-equivalent dose of approximately 100 mg/day, whereas a human-equivalent dose of approximately 2000 mg/day was required in granulocytopenic mice with neutrophil count less than 100 cells/mL.  The safety and efficacy of tedizolid in patients with neutropenia (neutrophil counts <1000 cells/mm3) have not been adequately evaluated.  Alternative antibiotics should be considered in neutropenic patients who require treatment for acute bacterial skin and skin structure infections.', '3', '"Product Information. Sivextro (tedizolid)." Cubist Pharmaceuticals Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26975, 3617, 'Belladonna', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26976, 3617, 'Belladonna', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', 'Bantz EW, Dolen WK, Chadwick EW, Nelson HS "Chronic chlorpheniramine therapy: subsensitivity, drug metabolism, and compliance." Ann Allergy 59 (1987):  341-6|Simons FE, Frith EM, Simons KJ "The pharmacokinetics and antihistaminic effects of brompheniramine." J Allergy Clin Immunol 70 (1982):  458-64|Blamoutier J "Comparative trial of two antihistamines, mequitazine and brompheniramine." Curr Med Res Opin 5 (1978):  366-70|"Azatadine (optimine)--a new antihistamine." Med Lett Drugs Ther 19 (1977):  77-9|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|Mevorach D "Adverse effects of atropine sulfate autoinjection." Ann Pharmacother 26 (1992):  564|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26977, 3617, 'Belladonna', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|O''Connor PS, Mumma JV "Atropine toxicity." Am J Ophthalmol 99 (1985):  613-4|Clearkin LG "Angle closure glaucoma precipitated by atropine." Arch Intern Med 152 (1992):  880|Berdy GJ, Berdy SS, Odin LS, Hirst LW "Angle closure glaucoma precipitated by aerosolized atropine." Arch Intern Med 151 (1991):  1658-60|Pecora JL "Malignant glaucoma worsened by miotics in a postoperative angle- closure glaucoma patient." Ann Ophthalmol 11 (1979):  1412-4|Holland MG "Autonomic drugs in ophthalmology: some problems and promises. Section II: Anticholinergic drugs." Ann Ophthalmol 6 (1974):  661-4|Kanto J "New aspects in the use of atropine." Int J Clin Pharmacol Ther Toxicol 21 (1983):  92-4|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Goldstein JH "Effects of drugs on cornea, conjunctiva, and lids." Int Ophthalmol Clin 11 (1971):  13-34|"Product Information. Cogentin (benztropine)." Merck & Co., Inc  (2001):|"Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26978, 3617, 'Belladonna', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', 'Bantz EW, Dolen WK, Chadwick EW, Nelson HS "Chronic chlorpheniramine therapy: subsensitivity, drug metabolism, and compliance." Ann Allergy 59 (1987):  341-6|Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|Shutt LE, Bowes JB "Atropine and hyoscine." Anaesthesia 34 (1979):  476-90|O''Kelly SW, Spargo PM "Postoperative urinary retention in men." BMJ 302 (1991):  1403-4|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26979, 3617, 'Belladonna', 'Lung Diseases', 'The use of systemic anticholinergics is contraindicated in the treatment of lower respiratory tract symptoms including asthma.  Muscarinic receptor antagonists reduce bronchial secretions, which can result in decreased fluidity and increased thickening of secretions.  However, ipratropium does not produce these effects and can be used safely in treating asthma.', '3', 'Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26980, 3617, 'Belladonna', 'Myasthenia Gravis', 'Because antimuscarinic agents have anticholinergic effects, they are contraindicated in patients with myasthenia gravis.  Their use may be appropriate to reduce adverse muscarinic effects caused by an anticholinesterase agent.', '3', 'Shutt LE, Bowes JB "Atropine and hyoscine." Anaesthesia 34 (1979):  476-90|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Bentyl (dicyclomine)." Aventis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26981, 3617, 'Belladonna', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', 'Brown JW "Toxic megacolon associated with loperamide therapy." JAMA 241 (1979):  501-2|Walley T, Milson D "Loperamide related toxic megacolon in Clostridium difficile colitis." Postgrad Med J 66 (1990):  582|"Product Information. Imodium (loperamide)." Janssen Pharmaceuticals  (2001):|Marshall WF Jr, Rosenthal P, Merritt RJ "Atropine therapy and paralytic ileus in an infant." J Pediatr Gastroenterol Nutr 9 (1989):  532-4|"Lomotil for diarrhea in children." Med Lett Drugs Ther 17 (1975):  104|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26982, 3617, 'Belladonna', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|Lowenthal DT, Reidenberg MM "The heart rate response to atropine in uremic patients, obese subjects before and during fasting, and patients with other chronic illnesses." Proc Soc Exp Biol Med 139 (1972):  390-3|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|Lunde P "Ventricular fibrillation after intravenous atropine for treatment of sinus bradycardia." Acta Med Scand 199 (1976):  369-71|Cooper MJ, Abinader EG "Atropine-induced ventricular fibrillation: case report and review of the literature." Am Heart J 97 (1979):  225-8|Das G, Talmers FN, Weissler AM "New observations on the effects of atropine on the sinoatrial and atrioventricular nodes in man." Am J Cardiol 36 (1975):  281-5|Knoebel SB, McHenry PL, Phillips JF, Widlansky S "Atropine-induced cardioacceleration and myocardial blood flow in subjects with and without coronary artery disease." Am J Cardiol 33 (1974):  327-32|Bradshaw EG "Dysrhythmias associated with oral surgery." Anaesthesia 31 (1976):  13-7|Horgan J "Atropine and ventricular tachyarrhythmia." JAMA 223 (1973):  693|Zsigmond EK, Matsuki A, Sharafabadi C "Atropine and cardiac arrhythmia." N Engl J Med 288 (1973):  635|Massumi RA, Mason DT, Amsterdam EA, DeMaria A, Miller RR, Scheinman MM, Zelis R "Ventricular fibrillation and tachycardia after intravenous atropine for treatment of bradycardias." N Engl J Med 287 (1972):  336-8|Valentin N, Staffeldt H, Kyst A "Effect of i.v. atropine on cardiac rhythm, heart rate, blood pressure and airway secretion during isoflurane anaesthesia." Acta Anaesthesiol Scand 28 (1984):  621-4|Lazzari JO, Benchuga EG, Elizari MV, Rosenbaum MB "Ventricular fibrillation after intravenous atropine in a patient with atrioventricular block." Pacing Clin Electrophysiol 5 (1982):  196-200|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26983, 3617, 'Belladonna', 'Tachycardia', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with anticholinergics is rare.', '2', '"Product Information. Antivert (meclizine)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26984, 3617, 'Belladonna', 'Coronary Artery Disease', 'Antimuscarinic agents block vagal inhibition of the SA nodal pacemaker.  These agents should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with antimuscarinic drugs is rare.', '2', 'Lunde P "Ventricular fibrillation after intravenous atropine for treatment of sinus bradycardia." Acta Med Scand 199 (1976):  369-71|Knoebel SB, McHenry PL, Phillips JF, Widlansky S "Atropine-induced cardioacceleration and myocardial blood flow in subjects with and without coronary artery disease." Am J Cardiol 33 (1974):  327-32|Richman S "Adverse effect of atropine during myocardial infarction. Enchancement of ischemia following intravenously administered atropine." JAMA 228 (1974):  1414-6|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Bentyl (dicyclomine)." Aventis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26985, 3617, 'Belladonna', 'Stomach Ulcer', 'Antimuscarinic agents may cause a delay in gastric emptying and possibly antral stasis in patients with gastric ulcer.  Therapy with antimuscarinic agents should be administered cautiously to patients with gastric ulcer.', '2', 'Chernish SM, Brunelle RR, Rosenak BD, Ahmadzai S "Comparison of the effects of glucagon and atropine sulfate on gastric emptying." Am J Gastroenterol 70 (1978):  581-6|Mevorach D "Adverse effects of atropine sulfate autoinjection." Ann Pharmacother 26 (1992):  564|Cotton BR, Smith G "Single and combined effects of atropine and metoclopramide on the lower oesophageal sphincter pressure." Br J Anaesth 53 (1981):  869-74|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26986, 3617, 'Belladonna', 'Gastroesophageal Reflux', 'Antimuscarinic agents decrease gastric motility and relax the lower esophageal sphincter which promotes gastric retention and can aggravate reflux.  These drugs should be administered cautiously in patients with gastroesophageal reflux or hiatal hernia associated with reflux esophagitis.', '2', 'Chernish SM, Brunelle RR, Rosenak BD, Ahmadzai S "Comparison of the effects of glucagon and atropine sulfate on gastric emptying." Am J Gastroenterol 70 (1978):  581-6|Dow TG, Brock-Utne JG, Rubin J, Welman S, Dimopoulos GE, Moshal MG "The effect of atropine on the lower esophageal sphincter in late pregnancy." Obstet Gynecol 51 (1978):  426-30|Howells TH "The administration of metoclopramide with atropine." Anaesthesia 32 (1977):  677|Brock-Utne JG, Rubin J, Downing JW, Dimopoulos GE, Moshal MG, Naicker M "The administration of metoclopramide with atropine. A drug interaction effect on the gastro-oesophageal sphincter in man." Anaesthesia 31 (1976):  1186-90|Cotton BR, Smith G "Single and combined effects of atropine and metoclopramide on the lower oesophageal sphincter pressure." Br J Anaesth 53 (1981):  869-74|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26987, 3617, 'Belladonna', 'Colitis, Ulcerative', 'Antimuscarinic agents may suppress intestinal motility and produce paralytic ileus with resultant precipitation of toxic megacolon.  These drugs should be administered cautiously to patients with ulcerative colitis.', '2', 'Famewo CE "A re-evaluation of anticholergic premedication." Can Anaesth Soc J 24 (1977):  39-41|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bentyl (dicyclomine)." Aventis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26988, 3617, 'Belladonna', 'Liver Diseases', 'Atropine-like agents undergo significant hepatic metabolism.  Therapy with atropine-like agents should be administered cautiously to patients with liver disease.', '2', '"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26989, 3617, 'Belladonna', 'Renal Insufficiency', 'Atropine-like agents are primarily eliminated by the kidney.  Therapy with atropine-like agents should be administered cautiously to patients with renal disease.', '2', '"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26990, 3617, 'Belladonna', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|Valentin N, Staffeldt H, Kyst A "Effect of i.v. atropine on cardiac rhythm, heart rate, blood pressure and airway secretion during isoflurane anaesthesia." Acta Anaesthesiol Scand 28 (1984):  621-4|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):|"Product Information. Atropisol (atropine ophthalmic)." Ciba Vision Ophthalmics  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26991, 3617, 'Belladonna', 'Hyperthyroidism', 'In general, agents with anticholinergic activity may exacerbate hyperthyroidism.  Therapy with anticholinergics should be administered cautiously in patients with hyperthyroidism.  Thyroid levels should be monitored if usage is prolonged.', '1', '"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26992, 3617, 'Belladonna', 'Diarrhea', 'Diarrhea may be a symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy.  Antimuscarinic agents may further aggravate the diarrhea.  Therefore, these drugs should be administered cautiously in patients with diarrhea.', '1', '"Lomotil for diarrhea in children." Med Lett Drugs Ther 17 (1975):  104|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26993, 3617, 'Belladonna', 'Fever', 'Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.', '1', 'Stadnyk AN, Glezos JD "Drug-induced heat stroke." Can Med Assoc J 128 (1983):  957-9|Sarnquist F, Larson CP Jr "Drug-induced heat stroke." Anesthesiology 39 (1973):  348-50|Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986):  571|Forester D "Fatal drug-induced heat stroke." JACEP 7 (1978):  243-4|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Cogentin (benztropine)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26994, 0, 'Teduglutide', 'Pancreatic Diseases', 'Cholecystitis, cholangitis, cholelithiasis, and pancreatitis have been reported in clinical studies with teduglutide.  For identification of the onset or worsening of gallbladder/biliary/pancreatic disease, patients should undergo laboratory assessment of bilirubin, alkaline phosphatase, lipase and amylase within 6 months prior to starting teduglutide, and at least every 6 months while on treatment; or more frequently if needed.  If clinically meaningful changes are seen, further evaluation including imaging of the gallbladder, biliary tract and/or pancreas is recommended; and the need for continued teduglutide treatment should be reassessed.', '2', '"Product Information. Gattex (teduglutide)." NPS Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26995, 0, 'Teduglutide', 'Heart Failure', 'Fluid overload and congestive heart failure have been observed in clinical trials with teduglutide.  This was probably related to enhanced fluid absorption associated with the medication.  If fluid overload occurs, parenteral support should be adjusted and treatment should be reassessed, especially in patients with underlying cardiovascular disease.  If significant cardiac deterioration develops while on teduglutide, the need to continue treatment should be reassessed.', '2', '"Product Information. Gattex (teduglutide)." NPS Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26996, 0, 'Teduglutide', 'Intestinal Obstruction', 'Intestinal obstruction has been reported in clinical trials with teduglutide.  In patients who develop intestinal or stomal obstruction, treatment with teduglutide should be temporarily discontinued while the patient is clinically managed.  Treatment may be restarted when the obstructive episode resolves, if clinically indicated.  Caution is advised in patients with risk factors for intestinal obstruction.', '2', '"Product Information. Gattex (teduglutide)." NPS Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26997, 0, 'Teduglutide', 'Liver Failure', 'Teduglutide pharmacokinetics has not been assessed in patients with severe hepatic impairment.  Caution and monitoring is advised.  Patients with moderate hepatic impairment showed lower Cmax and AUC when compared to healthy matched control subjects after a single subcutaneous dose of teduglutide.  However, no dose adjustment is necessary for patients with mild and moderate liver impairment.', '2', '"Product Information. Gattex (teduglutide)." NPS Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26998, 0, 'Teduglutide', 'Neoplasms', 'Based on the pharmacologic activity and findings in animals, teduglutide has the potential to cause hyperplastic changes including neoplasia.  In patients at increased risk for malignancy, the clinical decision to use teduglutide should be considered only if the benefits outweigh the risks.  In patients with active gastrointestinal malignancy (GI tract, hepatobiliary, pancreatic), therapy should be discontinued.  Patients with colorectal polyps, should have these removed within 6 months prior to starting treatment with teduglutide.  In patients with active non- gastrointestinal malignancy, the clinical decision to continue therapy should be made based on risk- benefit considerations.', '2', '"Product Information. Gattex (teduglutide)." NPS Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26999, 0, 'Teduglutide', 'Kidney Diseases', 'Teduglutide is primarily cleared by the kidney and caution is advised when using in patients with moderate to severe renal impairment.  The manufacturers recommend to reduced the dose by 50% in patients with moderate and severe renal impairment (creatinine clearance less than 50 mL/min), and end-stage renal disease.', '2', '"Product Information. Gattex (teduglutide)." NPS Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27000, 27986, 'Tegaserod', 'Intestinal Obstruction', 'The use of tegaserod is contraindicated in patients with a history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions.  Stimulation of gastrointestinal motility might be harmful in these conditions.', '3', '"Product Information. Zelnorm (tegaserod)." Novartis Pharmaceuticals  (2002):', 'DDInter', 0);